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CHAPTER 1
general introduction
8general introduction
Traditionally, systemic treatment in cancer comprised cytotoxic chemotherapeutic agents, which 
interact non-specifically with cellular DNA and/or tubulin resulting in growth arrest of all fast growing 
cells, and hormonal agents. Increased understanding of cancer cell biology led to the development of 
agents that specifically target regulatory and signaling pathways of tumor cells. The approval of 
imatinib, the first rationally designed tyrosine kinase inhibitor, for treatment of bcr-abl positive chronic 
myeloid leukemia in 2001 and shortly thereafter for treatment of gastrointestinal stroma cell tumor 
(GIST), was the start of a new era of targeting and treating tumors.
Targeted therapies including inhibitors of the vascular endothelial growth factor receptor (VEGFR), 
epidermal growth factor receptor (EGFR) and mammalian target of rapamycin (mTOR) pathway, have 
been developed and have found their way into the clinical practice of cancer treatment. However, with 
the expanding use of targeted therapies, the first enthusiasm has evolved to a more realistic attitude 
also appreciating the drawbacks and imperfections of targeted therapies. In this thesis possibilities to 
improve treatment outcome of targeting therapies are explored.
Although targeted therapies block and/or inhibit a specific target, these targets are unfortunately not 
exclusively present on tumor cells. Thereby, also targeted therapies exert side effects. Ideally, 
treatment outcome should be predictable very early after the start of therapy, thereby avoiding 
continuation of an ultimately ineffective and expensive treatment with associated toxicities. 
Furthermore, as opposed to the cytotoxic conventional chemotherapeutics, targeted therapies are 
mostly cytostatic, by inhibiting cell growth and proliferation. The currently used response evaluation 
criteria in solid tumors (RECIST) guidelines, which are based on measurement of tumor size are felt not 
to be the best way to evaluate the treatment effect of all targeted agents. Evaluation methods based 
on tumor metabolism, such as positron emission tomography (PET) scanning, might be more 
appropriate than the tumor-size based computer tomography (CT).
Chapter 2 describes the possibilities of early response monitoring with 18F-fluorodeoxyglucose (FDG) 
in patients with renal cell carcinoma, treated with the mTOR inhibitor temsirolimus. In chapter 3 early 
response monitoring with serial PET scanning is used to early identify those patients who benefit from 
the addition of temsirolimus to pegylated liposomal doxorubicin (PLD). Chapter 4 describes the 
possibilities to predict the effect of therapy by pharmacokinetical monitoring.
Although major advances have been made by the introduction of targeted therapies, such as imatinib 
in GIST and HER2 directed agents, many more patients need better outcomes of therapy and therefore 
opportunities to improve therapy outcome are continuously explored. In general, monotherapy with 
a targeted agent leads to prolongation of the progression free survival for several months. Combination 
therapy might improve treatment outcome by enhanced antitumor activity through clinical and 
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1biochemical synergism and reduction of resistance. Chapter 3, 5 and 6 describe three phase I studies 
where targeted drugs are combined with conventional chemotherapy in patients with various solid 
tumors.
Since combination therapy also might lead to enhanced toxicities, the search for novel systemic 
treatment strategies with ideally less toxicity and significant anti-tumor effect is ongoing. Chapter 7 
describes such a treatment strategy: targeting carbon anhydrase IX, an antigen almost exclusively 
expressed on renal cell carcinoma cells, with a radiolabeled antibody.
A large anti-tumor effect is not the only goal to strive for, because for patients with cancer not only the 
quantity of life, but also the quality of life may be even more important. Disease and therapy related 
symptoms could have a major impact on daily activities, preventing patients to take part of family and 
social life.
Chapter 8 and 9 address the management of such quality of life aspects of patients. Malignant ascites 
and pleural effusions lead to shortness of breath and fatigue, which negatively affect the quality of life. 
In order to reduce these symptoms we performed a study in patients with malignant ascites and 
pleural effusions with cediranib, a VEGFR tyrosine kinase inhibitor (TKI), aiming to diminish these fluid 
effusions (chapter 8).
Chapter 9 describes the results of a study in patients with diarrhea due to the treatment with VEGFR 
TKIs. Diarrhea is a frequently occurring side effect of VEGFR TKIs, which can only partly be relieved by 
symptomatic treatment since the cause of the diarrhea is unknown. We investigated possible patho- 
physiological mechanisms of the diarrhea to arrive at a more rational treatment for the treatment of 
this disabling symptom.
Not only questions addressing the optimal timing of start of treatment, the monitoring of the effect of 
treatment and the management of adverse events have to be answered. It is just as important to 
answer the question whether and when to stop treatment. Generally, systemic therapy is given until 
progressive disease, as defined by the RECIST guidelines. It is, however, questionable whether 
progressive disease as defined by RECIST, means absolute resistance to treatment. The range of clinical 
sequelae observed after stopping VEGFR TKIs underlines the relevance of this issue. Most patients will 
have an indolent course with slowly progressing tumors, but in approximately 10% of all RCC patients 
accelerated tumor growth is described directly after discontinuation of therapy. To gain more insight 
in the biological mechanisms occurring in tumors directly after discontinuation of VEGFR TKI therapy, 
we performed a study in metastatic RCC patients using FDG-PET/CT and functional MRI. The results are 
described in chapter 10.
Finally, the results of the studies are summarized and suggestions for future research are given in chapter 11.
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aBstract
INTRODUCTION
Temsirolimus is an mTOR inhibitor and approved for first line treatment in poor-risk metastatic renal 
cell carcinoma (mRCC). In mRCC patients treated with temsirolimus after failure of at least one vascular 
endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI), 18F-fluorodeoxyglucose 
(FDG) positron emission tomography (PET)/CT was performed for early response monitoring. 
Furthermore, progression free survival (PFS) and overall survival (OS) were assessed.
PATIENTS AND METHODS
Adult patients with progressive mRCC after treatment with at least one VEGFR TKI were treated with 
weekly temsirolimus 25 mg intravenously until progressive disease or intolerable toxicities. FDG-PET/
CT was performed at baseline and two and six weeks after start of temsirolimus; standardized uptake 
values (SUV), metabolic volume and total lesion glycolysis (TLG, SUV x metabolic volume) were 
calculated. RECIST evaluation with CT scan was performed every six weeks.
RESULTS
Twenty-three patients were evaluated. We could not identify an FDG-PET parameter, which was 
predictive for either the response according to RECIST after six weeks, PFS or OS. The median PFS and 
OS were 7.6 months (range 1.4-22.8) and 15.7 months (range 2.6- NR), respectively. The PFS in our 
study compares favorably to historical controls in literature of mTOR inhibitors in second or higher line 
of therapy.
CONCLUSION
Early response imaging with FDG-PET/CT in temsirolimus-treated mRCC patients is not predictive for 
early response or for (progression free) survival. Remarkably, we found a long PFS in these patients, 
indicating that temsirolimus may be one of the therapeutic options in mRCC patients after failure of a 
VEGFR TKI.
13
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introduction
Temsirolimus is a selective inhibitor of the mammalian target of rapamycin (mTOR), a central enzyme 
in the PI3K/AKT pathway. Inhibition of mTOR culminates in cell cycle arrest by blocking progression 
from the G1 phase to the S phase, thereby down regulating cell growth and proliferation. In addition, 
temsirolimus also regulates the transcription of hypoxia inducible factor (HIF) and thereby the 
HIF-induced vascular endothelial growth factor production. In the Netherlands, temsirolimus is only 
approved for first-line treatment of patients with poor risk metastatic renal cell carcinoma (mRCC)(1). 
In 2014, the large phase III INTORSECT trial failed to show a progression free survival (PFS) advantage 
of second-line temsirolimus compared to sorafenib(2). However, everolimus, an oral mTOR inhibitor, 
did show activity in second-line as compared to placebo and was approved for second or third line 
treatment of mRCC after failure of vascular endothelial growth factor receptor tyrosine kinase inhibitor 
(VEGFR TKI) treatment(3, 4). There has been no head-to-head comparison of temsirolimus and 
everolimus in first or higher lines in patients with renal cell carcinoma.
Currently, the effect of treatment is evaluated by measuring tumor size with computed tomography 
(CT) scans using response evaluation criteria in solid tumors (RECIST) guidelines(5). However, since 
targeted agents are rather cytostatic as compared to the cytotoxic chemotherapy, the size-based 
RECIST evaluation leads to an underestimation of the effect. For these reasons, evaluation methods 
based on tumor metabolism might be more appropriate(6) than monitoring tumor volume. There is an 
increasing interest in positron emission tomography (PET) for use in the diagnosis, staging and 
treatment evaluation of cancer. Depending on the tracer, metabolic pathways of interest can be 
selectively measured. 
18
F-fluorodeoxyglucose (FDG), the most widely used tracer, accumulates 
intracellular as a result of enhanced glycolysis and has been associated with growth rate and 
malignancy characteristics of the tumor.
The main objective of this phase II study was to investigate whether molecular imaging with FDG-PET/
CT could be used for early response monitoring in mRCC patients treated with temsirolimus. 
Furthermore, as a secondary endpoint, we investigated whether temsirolimus after treatment with at 
least one VEGFR TKI could give a meaningful PFS and overall survival (OS) in mRCC patients.
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patients and methods
PATIENTS
Eligible patients were adults with histologically confirmed, advanced (stage IV or recurrent disease) 
RCC who had received at least one prior VEGFR TKI, had an ECOG status of 0 or 1, a life expectancy of 
at least eight weeks, at least one measurable lesion with the longest diameter ≥ 20-mm when 
measured by spiral CT (5-mm slice thickness contiguous) and adequate bone marrow, renal and 
hepatic function. Key exclusion criteria were untreated central nervous system metastasis, prior 
treatment with an mTOR inhibitor, surgery and/or radiation therapy within four weeks of randomi-
sation and poorly controlled diabetes mellitus.
STUDY DESIGN
In this open-label, single-centre phase II trial of temsirolimus, we planned to include twenty patients. 
Patients were treated with weekly temsirolimus 25 mg intravenously until progressive disease or 
intolerable toxicities. Response evaluation was performed every six weeks according to RECIST version 
1.1 using CT scans. PFS was defined as the time measured from the day of first administration of 
temsirolimus to first progression or death, whichever came first. OS was defined as the time measured 
from the day of first administration until death of any cause. This study was approved by the medical 
ethical committee of our institute and was conducted in accordance with the Principles of Good 
Clinical Practice and the Declaration of Helsinki. All patients provided written informed consent.
FDG-PET/CT
FDG-PET/CT was performed at baseline, after the second and the sixth temsirolimus infusion. Patient 
preparation and PET/CT acquisition and processing parameters were in strict accordance to the Dutch 
(NEDPAS) and European Association of Nuclear Medicine (EANM) standardization guidelines(7, 8). 
Images of the Biograph Duo scanner were reconstructed using the 2 iterations/8 subsets (2i/8s) 
OSEM-2D reconstruction algorithm, smoothed with a 5-mm full width at half maximum (FWHM) 
Gaussian filter.
According to RECIST, up to five target lesions per patient were identified and for quantitative 
assessment of these lesions regions of interest (ROI) were obtained semi-automatically. FDG accumu-
lation for each voxel within the ROI was registered in MBq. This was corrected for the injected dose, 
patient’s body weight and time elapsed between the injection and scanning to obtain the standardized 
uptake value (SUV). Volumes of interest (VOIs) were delineated using 50% and 70% isocontour 
thresholds based on a fixed percentage of the maximum activity within the lesion. As such, the 
maximum SUV, SUV50 and SUV70 within the VOI could be determined. The total lesion glycolysis (TLG) 
per patient was calculated by summing the products of the mean SUV within the VOI and the volume 
of that VOI. A volume weighted SUV (vwSUV) per patient was calculated by dividing the TLG by the 
total volume of lesions in that patient. The fractional change (∆) in the vwSUV per patient and TLG 
15
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between FDG-PET/CT at baseline, after two weeks and after six weeks was calculated and expressed 
as a percentage.
STATISTICAL METHODS
Patients were evaluable for early response monitoring if at least two FDG-PET/CTs (baseline and one 
other time point) and a CT scan after six weeks were performed. Patients were replaced if not evaluable 
for early response monitoring. Spearman’s correlation coefficient was used to assess the fractional 
change in vwSUV and TLG from three different time points on the one hand and results from CT 
assessment after six weeks according to RECIST 1.1, PFS and OS on the other hand. The predictive 
value of changes in tumor metabolism was assessed with Cox proportional regression- and Kaplan 
Meier analysis. The level of significance was set at 0.05 based on two-sided tests.
results
PATIENTS
Between January 2010 and July 2013, 23 patients (20 male, median age 64 years) were included in this 
study (table 1). All patients had undergone surgery for their primary tumor and all were previously 
treated with one or two VEGFR TKIs. Four patients had also been treated with interferon, one with 
interleukin-2 and three patients had participated in a phase I study with radioimmunotherapy(9). 
According to the Heng criteria(10), based on laboratory values measured at the start of treatment with 
temsirolimus, one patient (number nine) had a poor risk mRCC, whereas the others had an intermediate 
risk mRCC.
FDG-PET/CT
Of the 23 patients included in the study, three patients had to be replaced according to protocol. One 
patient had no FDG avid lesions, one patient did not have any FDG-PET/CTs due to logistical problems 
and one patient was not RECIST-evaluated because of rapid clinical deterioration due to an ischemic 
cerebral vascular accident. In 18 patients all three FDG-PET/CTs were performed according to protocol; 
in two patients the third FDG-PET/CT was not performed due to the patients’ clinical condition at that 
moment (pneumonia and fever of unknown origin). In total, 70 metastatic lesions were evaluated by 
PET/CT. The median SUV at baseline was 7.1 (range 1.1-20.7), after two doses 4.7 (range 0.8-19.3) and 
after six doses 4.5 (range 0.9-18.4). Baseline SUV did not correlate with response on CT after six weeks, 
or with the growth rate pre-baseline (figure 1). Cox proportional regression analysis did not show any 
relation between the fractional decrease in TLG or in vwSUV at any time and response at CT after six 
weeks, or with PFS or OS.
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ANTITUMOR ACTIVITY
Tumor response of the target lesions of all patients after six weeks of temsirolimus is shown in figure 1. 
According to RECIST 1.1 all patients had stable disease. The median growth rate decreased from 
+25.0% (0-140%) in the months before baseline to -1.9% (-21.7 – 15.2%) after six weeks of temsirolimus, 
although large differences were observed amongst patients. The median PFS of all 23 included patients 
was 7.6 months (range 1.4-22.8), with five patients having a PFS longer than a year. The median overall 
survival was 15.7 months with two patients still alive after 5.5 and 3.5 years of follow up.
Characteristi cs No.
Total number of pati ents 23
Sex Male 20
Female 3
Age (years) Median
Range
64
44-79
ECOG PS 0 10
1 13
Histology Clear cell 19
Papillary type 1 1
Papillary type 2 1
Papillary type 1 and 2 1
Clear cell with rhabdoid 
dediff erenti ati on
1
TNM Stage I 5
II 3
III 7
IV 8
No. of prior systemic 
treatment regimens
1 15
2 5
3 2
4 1
Table 2.1 Pati ent characteristi cs
17
temsirolimus in renal cell cancer: response evaluation with fdg-pet/ct
2
discussion
This phase II study investigated if FDG-PET/CT could be used for early response monitoring in patients 
treated with temsirolimus after failure of VEGFR TKI treatment. Various SUV-derived values were 
calculated from three PET/CT scans per patient. However, we could not identify a single parameter, 
which was related to RECIST evaluation after six weeks, or to the PFS or OS. Therefore, we can conclude 
that FDG-PET/CT in this context is clinically not meaningful. In part this can be attributed to the fact 
that all patients experienced stable disease at the six-weeks evaluation, which hindered the statistics 
considerably.
Figure 2.1 The tumor growth rate from three months pre-baseline to six weeks post-baseline
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In 23 patients, of whom fifteen were treated in second line, five in third line, two in fourth line and one 
patient in fifth line, the median PFS was 7.6 months (range 1.4-22.8). The median OS was 15.7 months 
(range 2.6- not reached). The PFS in our study compares favorably to historical controls in literature 
treated with mTOR inhibitors in second or higher line of therapy (see table 2 for an overview of studies 
reporting therapy outcome of temsirolimus and/or everolimus after failure of a VEGFR TKI in renal cell 
carcinoma patients).
This study had some limitations. First of all, the number of patients is relatively low to draw firm 
conclusions. With all patients having stable disease at first evaluation, the number of events was low. 
When we set up this study in 2009, the only possibility for second line treatment of mRCC patients was 
everolimus and with this study we provided an extra line of treatment for patients. However, during 
the course of the study, more (oral) treatment options became available and as a consequence patient 
recruitment became very difficult. Moreover, increasing knowledge about mTOR inhibitors in general 
showed that a volume response is not widely seen. As such, it is difficult to define a role for early 
response imaging. At last, while we used FDG as widely available tracer, the proliferation marker FLT 
could possibly has given more insight given the nature of the study drug.
Although in our study all patients had stable disease according to RECIST 1.1 after six weeks of 
treatment, we found a significant decrease in the tumor growth rate (TGR) of tumors per patient in the 
six weeks after start of therapy as compared to the three months pre-baseline (figure 1). Various 
studies have reported on the use of TGR as opposed to or in addition of RECIST measurements of 
tumor volume(11-14). Since the TGR incorporates the time between the imaging examinations, it 
allows a quantitative and dynamic evaluation of the tumor response. TGR have been shown to be an 
independent predictor of PFS in metastatic renal cell cancer(11). Although the TGR is not yet 
established as a method for tumor evaluation, the decrease in TGR during temsirolimus therapy, is a 
strong indication of its clinical effect in this setting.
In conclusion, in our study in mRCC patients treated with temsirolimus after failure of at least one 
VEGFR TKI, early response imaging with FDG-PET/CT had no value as early predictor for outcome of 
therapy and survival. Remarkably, we observed a PFS of 7.6 months, which is considerably longer than 
the PFS observed in two large phase III studies and various retrospective studies.
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aBstract
INTRODUCTION
Pegylated liposomal doxorubicin (PLD) is active in breast, endometrial and ovarian cancer. Preclinical 
data suggest that the combination of PLD with a mammalian target of rapamycin (mTOR) inhibitor has 
an additive effect. The safety and recommended phase two dose (RPTD) of temsirolimus in combination 
with PLD were assessed. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT was 
performed for early response monitoring.
PATIENTS AND METHODS
Nineteen patients with advanced breast, endometrial and ovarian cancer were treated with increasing 
doses of temsirolimus (10,15 or 20 mg once weekly) and PLD (30 or 40 mg/m2 once every four weeks). 
PLD was initiated two weeks after start of temsirolimus. FDG-PET/CT was performed at baseline, after 
two and six weeks. Standardized uptake values (SUV), metabolic volume and total lesion glycolysis 
(TLG, SUV x metabolic volume) were calculated.
RESULTS
The RPTD was 15 mg temsirolimus and 40 mg/m2 PLD. Dose-limiting toxicities (DLT) were thrombo-
cytopenia grade 3 with nose bleeding and skin toxicity grade 3. Most frequent treatment-related 
toxicities were nausea, fatigue, mucositis, and skin toxicity. Changes in TLG after two weeks predicted 
partial response (PR) after ten weeks (p=0.037). A rise in SUV between the second and sixth week 
predicted progression (PD) (p= 0.034) and was associated with worse progression free survival (PFS) 
(HR 1.068; p = 0.013).
CONCLUSION
The RPTD was established at 15 mg temsirolimus weekly and PLD 40 mg/m2 once every four weeks 
and the combination was safe. Early response evaluation with FDG-PET/CT may predict subsequent 
radiological PR and PD.
This trial is registered under number NCT0098263.
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introduction
Temsirolimus is a selective inhibitor of the mammalian target of rapamycin (mTOR), a central enzyme 
in the PI3K/AKT pathway. Activation of this pathway has been associated with many important 
oncological processes such as cell proliferation and survival. Inhibition of mTOR leads to blockage of 
the G1 to S phase transition of the cell cycle. In addition to directly inhibiting tumor cell growth, 
temsirolimus also regulates the transcription of hypoxia inducible factor (HIF) and thereby the 
HIF-induced vascular endothelial growth factor production. Weekly infusions of 25 mg temsirolimus 
have shown antitumor activity in renal(1), lung(2), breast(3, 4), ovarian(5, 6) and endometrial 
cancer(7). Preclinical studies suggest that mTOR inhibitors can have additive antitumoral and anti-an-
giogenic effects to chemotherapy, e.g. doxorubicin(8, 9, 10). In addition, activation of AKT has been 
associated with resistance to chemotherapy and hormone therapy in preclinical cancer models(11), 
which can be reversed by adding an mTOR inhibitor(12). Pegylated liposomal doxorubicin (PLD) is a 
doxorubicin formulation encapsulated in long-circulating pegylated liposomes, which are small enough 
to pass through leaky tumor vasculature, resulting in their accumulation in the tumor’s interstitial 
space. PLD 50 mg/m2 once every four weeks has shown activity in patients with breast, endometrial 
and ovarian cancers(13-16). Consequently, the combination of temsirolimus and PLD might be 
effective in metastatic breast, endometrial and ovarian cancer.
Currently, treatment responses are evaluated by CT scans using response evaluation criteria in solid 
tumors (RECIST) guidelines(17), which are based on measurement of tumor size. However, the use of 
RECIST in the evaluation of targeted therapies is under debate, since they lead to necrosis and 
cavitation with only minimal decrease or even a slight increase in tumor size. Thus, the effect of 
targeted therapy is often underestimated by using the size-based RECIST evaluation. Furthermore, it 
takes time for volumetric changes of tumors to occur, whereas early response prediction could 
contribute to better personalized medicine. Evaluation methods based on tumor metabolism or 
vascularisation might be more appropriate(18). For these reasons, there is an increasing interest in the 
role of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in evaluating (early) 
treatment response.
The principle objectives of this phase Ib study were to determine the maximum tolerated dose (MTD) 
and recommended phase two dose (RPTD) of the combination of temsirolimus and PLD. Secondary 
objectives were to assess the safety and toxicity, pharmacokinetics (PK) and antitumor activity of the 
combination. Furthermore, by means of repeated FDG-PET/CT to assess the effect on tumor 
metabolism, we aimed to early identify those patients who benefit from the addition of temsirolimus 
to PLD.
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patients and methods
PATIENTS
Eligible patients had histologically proven advanced breast, endometrial or ovarian cancers and were 
refractory to standard therapies, ≥ 18 years, had an ECOG status of 0 or 1, a life expectancy of at least 
twelve weeks and adequate bone marrow, kidney and liver function. Exclusion criteria included a left 
ventricular ejection fraction < 50%, prior cumulative dose >450 mg/m2 doxorubicin or >600 mg/m2 
epirubicin, previous treatment with mTOR inhibitors and clinically symptomatic brain metastases.
STUDY DESIGN
In this single centre study predefined dose levels (DL) were evaluated in a standard 3 + 3 dose escalation 
design. The dose levels were chosen in a way that the approved PLD dose in combination therapy 
(40 mg/m2) was quickly reached (see table 1). Dose limiting toxicities (DLTs) were determined during 
the first four weeks of combination therapy and were defined as grade 4 neutropenia lasting ≥ seven 
days, febrile neutropenia, grade 4 trombocytopenia or thrombocytopenic bleeding requiring 
transfusion, every toxicity giving rise to > fourteen days delay of the second cycle or any grade 3 or 4 
non-hematological toxicity except nausea, vomiting, diarrhea and hyperglycemia, which were rapidly 
controlled by appropriate measures. These toxicities must have been declared related to treatment by 
the investigator. The MTD was defined as the highest dose at which one or no DLT had been observed 
among six patients.
Dose levels Dose
temsirolimus 
(mg)
Dose PLD
(mg/m2)
No. of
pati ents 
included
No. of DLTs Comments
1 10 30 5 0
2 10 40 3 0
3 15 40 3 0
4 20 40 9 2 Thrombocytopenia gr.3 
with bleeding
Skin toxicity gr.3
5 25 40 0
6 25 50 0
Table 3.1 Dose limiti ng toxiciti es
PLD = Pegylated liposomal doxorubicin DLT = Dose-limiti ng toxicity
Figure 3.1 Treatment and imaging schedule
PLD
Temsirolimus
Diagnosti c CT
FDG-PET/CT
1 2 3 4 5 6 7 11 wks
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This study was approved by the medical ethical committee and was conducted in accordance with the 
Principles of Good Clinical Practice and the Declaration of Helsinki. All patients provided written 
informed consent.
TREATMENT
After prophylactic tavegil 2 mg iv, temsirolimus was administered intravenously over 30 minutes. After 
a two-week run in period to perform pharmacokinetic and pharmacodynamic measurements, PLD iv 
was added once every four weeks (see figure 1). Pharmacokinetic and pharmacodynamic results will 
be published separately. Treatment continued until progressive disease, unacceptable toxicity or 
patients’ wish. Patients could receive a maximum number of nine cycles of PLD, but were allowed to 
continue on temsirolimus monotherapy thereafter.
EVALUATION OF PATIENTS
Adverse events were graded according to common terminology criteria for adverse events (CTCAE) 
version 3.0(19) and recorded during weekly visits. We performed monitoring of hematology, blood 
chemistry and physical examinations every two weeks. To assess the left ventricular ejection fraction 
a multigated radionuclide angiography (MUGA scan) was performed at baseline, after four weeks and 
after every third cycle of PLD. Response evaluation was performed every two cycles according to 
RECIST version 1.1 using computed tomography (CT) scans. A partial response (PR) had to be confirmed 
by radiologic assessment eight weeks later.
Dose levels Dose
temsirolimus 
(mg)
Dose PLD
(mg/m2)
No. of
pati ents 
included
No. of DLTs Comments
1 10 30 5 0
2 10 40 3 0
3 15 40 3 0
4 20 40 9 2 Thrombocytopenia gr.3 
with bleeding
Skin toxicity gr.3
5 25 40 0
6 25 50 0
Table 3.1 Dose limiti ng toxiciti es
PLD = Pegylated liposomal doxorubicin DLT = Dose-limiti ng toxicity
Figure 3.1 Treatment and imaging schedule
PLD
Temsirolimus
Diagnosti c CT
FDG-PET/CT
1 2 3 4 5 6 7 11 wks
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18F-FDG-PET/CT
FDG-PET/CTs were performed at baseline, after two weeks of single agent temsirolimus, just before the 
first administration of PLD, and after six weeks, just before start of the second cycle (figure 1). Patient 
preparation and PET/CT acquisition and processing parameters were in strict accordance to the Dutch 
(NEDPAS) and European Association of Nuclear Medicine (EANM) standardization guidelines(20, 21). 
Up to five target lesions per patient were identified and for quantitative assessment of these lesions 
regions of interest (ROI) around the whole tumor were obtained semi-automatically. FDG accumulation 
for each voxel within the ROI was registered in MBq/ml. This was corrected for the injected dose of FDG, 
patient’s body weight and time elapsed between the injection and scanning to obtain the standardized 
uptake value (SUV). Volumes of interest (VOIs) were delineated using 50% and 70% isocontour 
thresholds based on a fixed percentage of the maximum activity within the lesion. As such, the 
maximum SUV, SUV50 and SUV70 within the VOI could be determined. The total lesion glycolysis (TLG) 
per patient was calculated by summing the products of the mean SUV within the VOI and the volume 
of that VOI. The fractional change (∆) in the mean SUV per patient and TLG between FDG-PET/CT at 
baseline, after two weeks and after six weeks was calculated and expressed in percentage.
 
STATISTICAL METHODS
Spearman’s correlation coefficient and Mann Whitney test were used to assess the fractional change 
in SUV and TLG from three different time points on the one hand and results from CT assessment 
according to RECIST 1.1 after ten weeks on the other hand. Univariate analysis was performed to test 
the relationship between changes in tumor metabolism, RECIST measurements and PFS using the Cox 
regression analysis. Covariates tested were the fractional change in SUV, SUV50, SUV70, TLG, TLG50, 
TLG70, RECIST results and PFS and patient characteristics: age, tumor type and ECOG performance 
status. Candidate variables with p ≤ 0.1 were selected for the multivariate analysis. The fractional 
change in measurements between FDG-PET/CT at baseline, after two weeks and after six weeks was 
stratified by the median value and was compared using the Log Rank test. All statistical analysis were 
performed using SPSS 20.0 software (SPSS, Chicago, IL, USA). The level of significance was set at 0.05 
based on two-sided tests.
results
PATIENT CHARACTERISTICS
Table 2 shows the characteristics of the twenty heavily pre-treated patients who were included in the 
study. Eleven patients with ovarian, five with endometrial and four with breast cancer were included. 
A total of nineteen patients started therapy, as one patient appeared to have an ileus at baseline and 
was replaced. Four other patients (two in DL1 and two in DL4) had early PD within the DLT period and 
were replaced as per protocol.
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DOSE-LIMITING TOXICITIES AND MTD
Four dose levels were investigated, ranging from 10-20 mg temsirolimus and 20-40 mg/m2 of PLD (see 
table 1). There were no DLTs on DL1-3. On DL4 (temsirolimus 20 mg and PLD 40 mg/m2 ) two out of six 
evaluable patients experienced a DLT. The first patient had a grade 3 thrombocytopenia with nose 
bleeding for which she was transfused on day 8 of the first cycle. Before platelet recovery, her condition 
deteriorated fast due to progressive disease and she was not able to restart treatment. The second 
patient had grade 3 skin toxicity on day 15 of the first cycle, despite of appropriate ointments.
According to the protocol, due to DLTs at DL4, we should have expanded DL3 (temsirolimus 15 mg and 
PLD 40 mg/m2 ) to six patients to determine the MTD. Unfortunately, at that time PLD was no longer 
available due to production problems. Consequently, the MTD could not be established. Because no 
DLT was observed in DL3, we recommend to explore this dose further in phase II studies.
OVERALL SAFETY AND TOLERABILITY
Table 3 summarizes all toxicities (related and unrelated) occurring with a frequency of > 30% or CTCAE 
grade ≥3 during therapy. The most common adverse events were anemia (95%), nausea (89%), and 
fatigue (84%). Skin toxicity was reported in a total of 84% of patients, occurring as dry skin (68%), rash 
(53%) and hand-foot-syndrome (HFS)(53%). Hematological toxicities were infrequently observed, 
except for grade 1 anemia in 95% of patients. Five patients reported an ileus (four with ovarian cancer, 
one with endometrial cancer), all of which were deemed unrelated to therapy. In twelve patients a rise 
Characteristi cs No.
Total number of pati ents 20
Age (years) Median
Range
57
21-70
ECOG PS 0 12
1 8
Primary organ site Ovary 11
Endometrium   5
Breast 4
Number of prior systemic 
treatment regimens
1 9
2 5
3 2
> 3 4
Prior radiotherapy 10
Table 3.2 Pati ent characteristi cs
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in NT-pro BNP (a biomarker for cardiac insufficiency) was observed during therapy. In eleven patients 
this was not accompanied by clinical symptoms of left ventricular dysfunction or changes in the 
electrocardiogram and was therefore considered as clinically not significant. One breast cancer patient 
had a grade 3 increase in NT-pro BNP and an asymptomatic decline of the left ventricular ejection 
fraction (LVEF). Although the decline in LVEF could have been caused by a retrosternal metastasis close 
to the heart, a relationship to PLD could not be excluded. Therefore, therapy was discontinued. 
Permanent dose reductions of PLD in seven patients (two on DL2, two on DL3 and three on DL4) and 
of temsirolimus in three patients (one on DL3 and two on DL4) were necessary, due to grade 2 and 3 
skin toxicity and grade 3 mucositis. One patient experienced a severe allergic reaction to temsirolimus 
in the third cycle and consequently this was withdrawn.
ANTITUMOR ACTIVITY
According to RECIST v.1.1, three patients (two with ovarian and one with endometrial cancer) had 
confirmed and durable partial responses of 10.1, 12.7 and 13.7 months, respectively. Ten patients had 
stable disease, of whom eight patients (two with ovarian, three with endometrial and three with 
breast cancer) had a prolonged stable disease (>16 weeks) with a median duration of 6.4 months. At 
the first evaluation four patients were progressive. Of the nineteen patients who started therapy, two 
patients were not evaluable according to RECIST because of the fact that a second CT scan was not 
performed due to early deterioration of clinical condition.
FDG-PET/CT
Of the twenty patients, only one patient had no FDG avid lesions. Three patients had just one FDG-PET/
CT due to very early PD and were excluded from analysis. In three other patients only two FDG-PET/
CTs were performed due to early PD; these were included in the analysis. (see table 4) Median SUV of 
all lesions at baseline was 9.2 (range 3.4 to 27.6), after two weeks 6.8 (range 1.6 to 17.0) and after six 
weeks 6.4 (range 2.2 to 17.1). The median ∆SUV of all lesions from baseline to two weeks later was 
-20.8% (range -67.0 to 33.7%), from baseline to six weeks later -38.2% (range -62.2 to 25.6%) and from 
two weeks on therapy to six weeks -8.1% (range -44.0 to 45.9%). Figure 2 shows a typical example of 
a patient with breast cancer and subcutaneous metastasis with a metabolic response on therapy.
The three patients with a PR according to RECIST 1.1 after ten weeks of treatment had a significant 
larger fractional decrease in TLG50 after two infusions of temsirolimus than patients who showed 
stable or progressive disease (-60.3 versus -19.5%; p= 0.037). There was a trend for the same result for 
TLG70 (-79.1 versus -23.8%, p=0.051). On the other hand, patients who showed PD after ten weeks 
had a mean increase in SUV from week 2 to week 6 of 14%, whereas patients without PD had a mean 
decrease of 15.8% (p=0.034). The Cox proportional regression analysis showed that the degree of 
change in SUV from the second to the sixth week was associated with PFS (HR 1.068; 95% CI 1.014 - 
1.124; p=0.013). None of the other PET parameters was significantly associated with PFS. Of the 
general patient characteristics tested, only ECOG performance status was a candidate for multivariate 
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testing (p= 0.108). In the multivariate analysis the relationship between ECOG and PFS did not sustain 
(p= 0.77), however the degree of change in SUV from the second to the sixth week was an independent 
predictor for survival (p=0.05).
Kaplan Meier analysis of the relationship between PFS and ∆SUV from two weeks on therapy to six 
weeks (dichotomized by the median ∆SUV) showed a significant difference in PFS (8.1 months for the 
group lower than the median versus 3.7 months for the group higher than the median; log rank 
p=0.009) between the two groups (see figure 3).
discussion
This phase Ib study investigated the safety and toxicity of the combination of temsirolimus, an mTOR 
inhibitor, and PLD. The recommended phase II dose is temsirolimus 15 mg once a week and PLD 40 mg/
m2 once every four weeks. Patients who were treated on the first three dose levels had no significant 
toxicities during the first cycle. During treatment with temsirolimus 15 mg and PLD 40 mg/m2, we 
observed a limited number of possibly related grade 3 toxicities (mucositis, hypokalemia and elevated 
NT-pro BNP, all occurring once) and no grade 4 toxicities (table 3). Due to the fact that production of PLD 
Figure 3.2 Successive FDG-PET/CT fi gures of a pati ent with breast cancer and 
 subcutaneous nodules with a clear decrease in FDG uptake in ti me
Figure 3.3 Kaplan Meier plot of the relati onship between the fracti onal change 
 in SUV and the progression free survival (PFS)
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was stopped in November 2011, the study had to be terminated before formally establishing MTD.
Picus et al. performed a phase I study with temsirolimus and PLD in patients with resistant solid 
malignancies(22) in which they enrolled 22 patients. The MTD and RPTD in this trial were temsirolimus 
25 mg every week and PLD 25 mg/m2 every four weeks. Another study in advanced soft tissue and 
bone sarcoma patients established a RPTD of 20 mg/m2 temsirolimus weekly and 30 mg/m2 liposomal 
doxorubicin every four weeks(23). In our study, the dose levels were defined in a way that the dose of 
PLD was increased first, so that we would reach a rational dose of PLD sooner. Secondly, the dose of 
temsirolimus was increased. Therefore, we found a slightly different recommended phase II dose with 
a higher PLD dose and a somewhat lower temsirolimus dose than in these two studies. However, our 
dose is consistent with other combination studies with PLD, which also found doses of 30-40 mg/m2 
to be the best tolerable(24-27).
This combination was safe and well tolerated, with predictable and manageable adverse effects. Since 
both temsirolimus and PLD are known to cause skin problems and mucositis, we expected extra 
toxicity in this area as compared to monotherapy. In our study, the incidence of skin related adverse 
Figure 3.2 Successive FDG-PET/CT fi gures of a pati ent with breast cancer and 
 subcutaneous nodules with a clear decrease in FDG uptake in ti me
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events, such as dry skin (68%) and rash (53%), and mucositis was in accordance with the observed 
incidence at a dose of single agent PLD (50 mg/m2) and easily manageable with ointments and dose 
reductions. However, although comparisons across trials should be made with caution, it seemed that 
the combination of temsirolimus and PLD resulted in more patients with HFS as compared to studies 
with monotherapy PLD 40 mg/m2 every four weeks (53 versus 18-28% (28-30)). In our study this led 
to dose reductions of PLD in four patients, but no patients had to discontinue therapy due to HFS.
In our study we performed serial FDG-PET/CT and observed that early response evaluation with 
FDG-PET/CT seemed clinically feasible. Results of FDG-PET/CTs after two weeks of temsirolimus 
predicted which patients will have partial response on CT scan after ten weeks of therapy, whereas 
FDG-PET/CT results after six weeks predicted later radiological PD. For patients who experience 
toxicities of therapy, it is very valuable when they know very early during treatment if the therapy will 
eventually pay off in terms of a beneficial antitumor effect. Toxicities are easier to bear when patients 
know early that the tumor is shrinking, or that the treatment will extend their live as long as they are 
able to handle the therapy A FDG-PET result predicting partial response already after two weeks of 
therapy, might thus have a relevant positive effect on the quality of life of patients. Conversely, early 
prediction of progressive disease avoids continuation of an ultimately ineffective and expensive 
treatment with associated toxicities and enables an earlier start of a treatment alternative with 
possible favorable anti-tumor effects. This is of utmost importance for the quality of care and life of 
patients.
SUV is a widely used semi-quantitative parameter for glucose metabolism in tumors and has been 
shown to be correlated with PFS and overall survival in different tumor types. However, SUV only 
incompletely captures the tumor response to therapy, because it does not incorporate total tumor 
metabolic activity but rather reflects metabolic activity per gram of tissue(31). To overcome this 
suboptimal evaluation of metabolic response measurement of total lesion glycolysis (TLG) was 
introduced(32).
In this study, patients with breast, endometrial and ovarian cancer could be included, because PLD has 
proven to be an effective treatment modality in all these three tumor types(14-16). To correct for 
potential differences in response to treatment and thus in change of metabolism as assessed by 
FDG-PET, tumor type was incorporated as a covariate in the univariate analysis. For analysis of the PET 
data, the low number of patients and the fact that four different dose levels were assessed also hinders 
the interpretation of results. Despite these limitations, however, significant results were found, which 
instigates further research in a larger, more homogeneous patient population.
39
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In conclusion, treatment with the combination of temsirolimus and PLD in patients with breast, 
endometrial and ovarian cancer, is safe and manageable. The RPTD is 15 mg temsirolimus every week 
and PLD 40 mg/m2 once every four weeks. Furthermore, the degree of therapy-induced changes in 
tumor glucose metabolism is predictive for patient outcome in this population. These data warrants 
further studies with the combination therapy and FDG-PET/CT evaluation.
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aBstract
INTRODUCTION
Pegylated liposomal doxorubicin (PLD) is used to treat patients with breast and gynecological cancers. 
In order to optimize treatment with PLD, we assessed the prognostic and predictive factors for efficacy 
of PLD.
PATIENTS AND METHODS
Seventeen patients treated with PLD 30 or 40 mg/m2 underwent pharmacokinetic sampling during the 
first cycle of treatment. PLD exposure was calculated. An univariate analysis was performed with the 
variables: hand-foot syndrome, mucositis, rash, neutropenia, age, tumor type, number of previous 
therapies, ECOG performance status and progression free survival (PFS). Candidate variables with p ≤ 
0.1 were selected for the multivariate analysis.
RESULTS
Based on the results of the multivariate analysis, the PLD exposure (log AUC) was higher in patients 
who experienced rash (p=0.002) and mucositis (p=0.001) compared to those who did not have these 
adverse events. The development of hand-foot syndrome was significantly related to a lower risk of 
disease progression (HR 0.1; 95% CI 0.02-0.64). Patients with an ECOG status of 0 had a longer PFS 
than the patients with an ECOG status of 1 (HR 5.4; 95% CI 1.3-22.8). Moreover PLD exposure (log AUC) 
was also positively related to PFS (HR 0.001; 95% CI 0.00-0.42).
CONCLUSIONS
The extent of the exposure to PLD was correlated with more adverse events and longer PFS. This has 
important clinical implications, since dose reductions or interruptions might thus negatively affect 
treatment outcomes. More attention should be paid to preventive and supportive measures of adverse 
events of PLD to keep the exposure to PLD as high as possible.
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introduction
Pegylated liposomal doxorubicin (PLD, Caelyx®) is proven to be effective in patients with breast, 
endometrial and ovarian cancers in a schedule of 50mg/m2 every four weeks(1-4). In lower doses (20 
mg/m2) it is used in patients with Kaposi sarcoma(5). Side effects often occur and include hand-foot 
syndrome, mucositis and rash. Previous studies have shown that myelosuppression, mostly leuco- and 
neutropenia, is generally mild and clinically insignificant, in contrast to the myelosuppression seen 
with conventional doxorubicin(6). Mucositis and myelosuppression are reported more frequently at 
higher doses, whereas hand-foot syndrome seems to be dependent of dose-density(6-9). The 
occurrence of side effects frequently leads to dose and interval modifications, resulting in a decreased 
amount of drug administered. However, Amantea et al. described a significant relationship between 
lesion response in patients with Kaposi sarcoma and both the average daily maximum doxorubicin 
concentration and dose intensity(10). Mouse models also have shown that higher doses and shorter 
dose intervals have increased therapeutic efficacy compared to lower doses or longer dose intervals(8, 
11). Dose reductions or interruptions might thus negatively affect treatment outcome.
PLD is a special formulation of doxorubicin hydrochloride (HCl), an anthracycline antibiotic. It is 
encapsulated in a delivery system of long circulating liposomes with surface-bound hydrophilic polyet-
hylene glycol (PEG). This formulation known as pegylation, protects the liposomes from detection by 
the mononuclear phagocyte system(12). The liposomes are small enough to pass through vasculature 
with increased permeability, such as in tumors with increased neoangiogenese and skin, resulting in 
accumulation in the tumor’s interstitial space. In comparison to conventional doxorubicin, PLD exhibits 
a relatively slow plasma clearance and has a small volume of distribution. At lower doses (10-20 mg/
m2) PLD shows linear pharmacokinetics, while at higher doses non-linear pharmacokinetics are 
suggested, best described by a two compartment non-linear model with zero order input and 
Michaelis-Menten elimination(13).
In order to optimize treatment with PLD, it is important to know the factors that are correlated to 
treatment benefit and the development of toxicity. This might help to select those patients who need 
an adjusted dose on forehand or who should be treated with an alternative treatment regimen. In our 
centre we performed a phase Ib study with PLD in combination with temsirolimus, an mTOR inhibitor, 
in patients with breast, endometrial and ovarian cancers (NCT0098263)(14). The primary objective of 
this study was to find the maximum tolerable dose of the combination. Additionally the pharmacoki-
netics of PLD were assessed. We used these data to assess the predictive factors for efficacy of PLD.
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PATIENTS
Patients were treated in a single-centre phase I study which assessed the maximum tolerated dose of 
the combination of temsirolimus and PLD. Eligible patients had histological proven advanced breast, 
endometrial or ovarian cancers and were refractory to standard therapies, ≥ 18 years, had an ECOG 
status of 0 or 1, a life expectancy of at least twelve weeks and a neutrophil count of ≥ 1500/µL, platelets 
≥ 100,000/µL, hemoglobin ≥ 8.0 g/dL, glomerular filtration rate ≥ 60 mL/min, alanine aminotrans-
ferase (ALT) and aspartate aminotransferase (AST) levels <2,5 x upper limit of normal (ULN), total 
bilirubin ≤ ULN, fasting level of total cholesterol < 350 mg/dL and triglyceride level of < 400 mg/L. 
Exclusion criteria included a left ventricular ejection fraction < 50%, prior cumulative dose >450 mg/
m2 doxorubicin or >600 mg/m2 epirubicin, previous treatment with mTOR inhibitors and clinically 
symptomatic brain metastases. This study was approved by the medical ethical committee and was 
conducted in accordance with the Principles of Good Clinical Practice and the Declaration of Helsinki. 
All patients provided written informed consent.
STUDY DESIGN AND TREATMENT PLAN
Four different dose levels were evaluated per patient cohort, with increasing doses for both PLD and 
temsirolimus. Therapy was started with weekly infusions with temsirolimus monotherapy, administered 
intravenously (iv) over 30 minutes. After a two-week run in period, PLD iv was added once every four 
weeks. PLD was administered over 90 minutes in the first cycle and over 60 minutes in the consecutive 
cycles. Patients were pre-treated with clemastine 2mg iv to prevent hypersensitivity reactions from 
temsirolimus. On the days when both drugs were co-administered, temsirolimus was given first. In case of 
severe toxicity dose reductions were allowed as pre-defined in the study protocol. Adverse events were 
graded according to common terminology criteria for adverse events (CTCAE) version 3.0(15) and recorded 
during weekly visits. Hand-foot syndrome was defined as dermatitis, skin changes (e.g. peeling, blisters, 
bleeding, edema) or pain localized on the hands and/or feet. Rash was defined as macular, popular or 
vesicular eruption or erythema with or without associated symptoms (e.g. pruritus and desquamation). 
Hematology, blood chemistry and physical examinations were assessed every two weeks. Response 
evaluation was performed every eight weeks according to response evaluation criteria for solid tumors 
(RECIST) version 1.1(16) using computed tomography (CT) scans. Progression free survival (PFS) was 
defined as the time measured from the day of inclusion in the study until first observation of progression 
or death, whichever occurred first. After the end of treatment we followed patients for toxicity until death, 
the start of a new line of therapy or until all toxicities were resolved, whichever came first.
PHARMACOKINETIC SAMPLING
Blood samples for pharmacokinetic (PK) analysis were obtained during the first cycle of PLD. Samples 
were collected before the start of the infusion, 1, 2, 24 and 72-96 hours after the end of PLD infusion 
and thereafter every week before the following doses of temsirolimus were administered.
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All blood samples were collected in heparinized tubes, and cells were directly separated by centrifu-
gation. The plasma supernatant was kept at -70°C until the day of analysis.
A high-performance liquid chromatographic assay with fluorescence detection was developed for the 
determination of doxorubicin and its active metabolite doxorubicinol in human plasma based on two 
previously described bioanalytical methods(17, 18). Quantitative extraction of doxorubicin and 
doxorubicinol was achieved by sample pretreatment with a depegylation step of 250 µL plasma with 
25 µL 6% triton for ten minutes. Thereafter protein-precipitation was performed by adding 250µL of 
methanol:zinc sulphate [89%] (1:1). Doxorubicin and doxorubicinol were separated isocratically on a 
Waters Atlantis T3 C18 analytical column (15 x 4.6 mm, i.d. 5µm). The mobile phase consisted of 
acetonitrile:sodiumacetatebuffer [0.68% pH4] (25:75 v/v). The related compound daunorubicin was 
used as internal standard. The column effluent was monitored fluorimetrically at an excitation 
wavelength of 480 nm and an emission wavelength of 560 nm, with a band width of 40 nm. Two 
separate calibration lines were constructed for the low and high concentration. In the low calibration 
line both doxorubicin and doxorubicinol were linear over a range of 50 – 1000 ng/mL. In the high 
calibration range both doxorubicin and doxorubicinol were linear over a range of 500-50,000 ng/mL. 
The lowest limit of quantification was determined to be 50 ng/mL for both compounds. The within day 
and between day accuracy and precision for doxorubicin were 87.5 - 102.3% and 1.0 – 8.9%, respec-
tively. The within day and between day accuracy and precision for doxorubicinol were 87.6 - 99.6% and 
0.6 - 12.9%, respectively PLD exposures were calculated using a non-compartmental trapezoidal 
approach (Phoenix® WinNonlin® v6.3). The area under concentration-time curve from time zero to 
infinity (AUCinf) was calculated using the linear trapezoidal rule from time zero to the time corres-
ponding to last sampling point (Clast) and extrapolation to infinity, based on the last observed concen-
tration, which is legitimate if the extrapolation is less than 20 percent.
STATISTICAL ANALYSIS
An independent t-test was used to assess the possible influence of different dose levels of temsirolimus 
and the PLD exposure (log AUC). For the analysis of toxicity, we selected those toxicities that occurred 
most and were considered clinically relevant: hand-foot syndrome, mucositis, rash and neutropenia. 
Dichotomous end points (yes or no) for toxicity present during therapy with PLD were used. Toxicities 
were corrected for baseline conditions and toxicities that developed during the first two weeks with 
mono-therapy temsirolimus, to exclude the adverse events that were unrelated to the use of PLD. An 
independent t-test was used to determine the relation between PLD, temsirolimus and sirolimus 
exposure (log AUC) and the occurrence of the different toxicities. Univariate analysis was performed to 
test the relationship between PFS and clinical and demographic variables using the Cox regression 
analysis. Covariates tested were the presence of toxicities, the natural logarithm of the AUC of PLD and 
patients characteristics: age, tumor type, number of previous therapies and ECOG performance status. 
To rule out any effect of the co-administration of temsirolimus, the natural logarithm of temsirolimus 
and its metabolite sirolimus were also taken into account. Candidate variables with p ≤ 0.1 were 
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selected for the multivariate analysis. There were no missing data. All statistical analysis were performed 
using SPSS 20.0 software (SPSS, Chicago, IL, USA). The level of significance was set at 0.05 based on 
two-sided tests. Since this is an exploratory study, no correction for multiple testing was done.
results
PATIENTS
A total of twenty patients entered the study. Seventeen patients started therapy with PLD, as three 
patients had early progressive disease and didn’t receive any PLD. Patient characteristics of these 
seventeen patients are shown in table 1. Nine patients with ovarian, four with endometrial and four 
with breast cancer were included. Four patients were treated with PLD 30 mg/m2 in combination with 
temsirolimus 10 mg, whereas the other thirteen patients were treated with PLD 40 mg/m2 of which 
three in combination with 10 mg temsirolimus, three in combination with 15 mg temsirolimus and 
seven in combination with 20 mg temsirolimus. The median number of cycles of treatment with PLD 
was six, with a range of one to fourteen. In three patients a dose delay of one week of PLD occurred 
during therapy, due to hand-foot syndrome (n=2, in cycle 4) and rash (n=1, in cycle 2). These patients 
resumed treatment with a dose reduction of 75% PLD according to the protocol. Besides these three 
patients, four others needed a dose reduction of PLD to 75% of the original dose due to toxicity. This 
was due to hand-foot syndrome in one patient, rash in two patients and mucositis in one patient. Dose 
reductions occurred in cycle 2 (n=1), cycle 4 (n=2) and in cycle 7 (n=1).
Characteristi cs No.
Total number of pati ents 17
Age (years) Median
Range
61
21-70
ECOG status 0 10
1 7
Primary organ site Ovary 9
Endometrium 4
Breast 4
No. of prior systemic 
treatment regimens
1 6
2 5
3 2
> 3 4
Table 4.1 Pati ent characteristi cs
Figure 4.1 Time-concentrati on profi le of doxorubicin
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PHARMACOKINETICS
PK samples of PLD were obtained from all seventeen treated patients. Concentration-time profiles of 
PLD are shown in figure 1. Pharmacokinetic parameters of PLD, grouped by different doses of 
temsirolimus, are shown in table 2. The AUC of PLD was not affected by the co-administration of 
different dose levels of temsirolimus. In our samples, we were not able to quantify doxorubicinol, the 
active metabolite of PLD, which is in line with earlier data presented on the pharmacokinetics of PLD.
PHARMACODYNAMICS
The PLD exposure (log AUC) was higher in patients who experienced rash (p=0.002) and mucositis 
(p=0.001) compared to patients who did not have these adverse events. There was no relation 
between PLD exposure and the occurrence of hand-foot syndrome and neutropenia. Moreover, there 
was no relation between the temsirolimus and sirolimus exposure and the occurrence of toxicities.
The median PFS of the overall group of seventeen patients was 5.0 months (range 0.7-13.5 months). 
The PFS for patients with gynecological cancers was 5.8 months (0.7-13.5 months), and for the patients 
with breast cancer it was 4.4 months (2.7-7.5 months). This was not statistically significantly different 
(p= 0.42). Univariate analysis for the complete group of seventeen patients showed that the presence 
of hand-foot syndrome, mucositis, rash and the PLD exposure were significantly related to the PFS. 
These variables were thus used in the multivariate analysis. The results of the uni- and multivariate 
analysis are shown in table 3. The development of hand-foot syndrome was significantly related to a 
lower risk of disease progression (HR 0.1; 95% CI 0.02-0.64). Patients with an ECOG status of 0 had a 
longer PFS than the patients with an ECOG status of 1 (HR 5.4; 95% CI 1.3-22.8). Moreover PLD 
exposure (log AUC) was also positively related to PFS (HR 0.001; 95% CI 0.00-0.42). In the univariate 
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analysis, rash and mucositis were related to the PFS, but in the multivariate analysis this relationship 
did not sustain. Univariate analysis for the separate groups divided by tumor type didn’t show any 
relation of the covariates with PFS. However, uni- and multivariate analysis in the group of the 
Dose PLD 
(mg/m2)
Dose 
temsirolimus 
(mg)
No of pts AUC 0-inf 
doxorubicin 
(mg*h/L)
Cmax (mg/L) T1/2 (h)
30 10 4 2434.9
(1604.9-3342.7)
21.3
(19.7-22.8)
76.5
(59.9-97.1)
40 10 3 3499.6
(2918.9-3902.2)
31.5
(29.6-35.5)
70.7
(52.6-93.4)
40 15 3 3879.1
(2828.2-5766.8)
35.1
(29.8-46.4)
77.6
(63.4-86.7)
40 20 7 3414.6
(1370.8-5670.2)
28.9
(23.0-33.1)
75.3
(46.3-105.0)
Table 4.2 Pharmacokineti cs of doxorubicin in combinati on with temsirolimus 
 grouped by dose level
AUC 0-inf = Area under concentrati on-ti me curve from ti me zero to infi nity  Cmax  = Peak plasma concentrati on  T1/2 = Terminal half-life
Data are presented as geometric means (with ranges).
N with Δ 
CTC>1
Univariate analysis Multi variate 
analysis
p HR (95% CI) p
Hand-foot 
syndrome
10 0.04 0.10 (0.02-0.64) 0.02
Rash 10 0.05 1.23 0.82
Mucositi s 14 0.00 0.00 0.94
Neutropenia 4 0.66
Age 0.67
ECOG 0.10 5.39 (1.28-22.78) 0.02
Tumor type 0.85
PLD exposure 0.01 0.01 (0.00-0.42) 0.02
Temsirolimus 
exposure
0.95
Sirolimus exposure 0.97
Table 4.3 Relati on with progression free survival: results of uni- and multi variate analysis
N with Δ CTC>1 = number of pati ents with the occurrence of toxiciti es or worsening with more than one grade according to CTC AE criteria, 
during therapy with PLD  HR  = Hazard rati o  CI = Confi dence interval  ECOG = Eastern Cooperati ve Oncology Group
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gynecological cancers (endometrial and ovarian cancer) showed the same results as in the complete 
group of patients, with PLD exposure (HR 0.003; 95% CI0.0-0.28), the occurrence of hand-foot 
syndrome (HR 0.112; 95% CI 0.18-0.71) and ECOG performance status (HR 6.6; 95% CI 1.20-35.8) being 
significantly related to PFS.
discussion
PLD is a doxorubicin formulation encapsulated in long-circulating pegylated liposomes, with a 
distinctive toxicity profile. PLD accumulates not only in tumors, but also in other tissues with a large 
capillary bed and slow circulation, such as skin and probably mucosa. Frequently occurring toxicities 
such as mucositis, rash and hand-foot syndrome may be dose limiting and necessitate dose adjustments 
or interruptions. In order to optimize therapy for patients treated with PLD, we assessed the relati-
onship between PLD exposure (log AUC) and the toxicity and efficacy. We showed that rash and 
mucositis occur more frequently in patients with higher PLD exposure levels. Moreover, we showed 
that PFS was related to PLD exposure. Also, patients who experienced hand-foot syndrome and 
patients with a better clinical condition had a prolonged PFS.
In order to be able to compare the pharmacokinetic parameters of PLD in this study with data from 
other studies, we performed a Medline search for studies describing AUCs of PLD. Because the PK of 
PLD is potentially non-linear above doses of 20 mg/m2, only studies using the same doses of PLD (30 
and 40 mg/m2) and the same agent (Caelyx®) were included. However, only two studies were found 
using Caelyx 30 mg/m2. Briasoulis et al. reported mean AUCs of doxorubicin of 1323 mg*h/l and 1400 
mg*h/L in four and two patients respectively(19). Gabizon et al. reported a mean doxorubicin AUC/mg 
dose of thirteen patients treated with 30 mg/m2 of 49 mg*h/L(20). One study in which three patients 
with Kaposi sarcoma were treated with 40 mg/m2 PLD reported a mean doxorubicin AUC of 642 
mg*h/L(21). In comparison to these data, the AUCs we found were clearly higher (2434.9 mg*h/L for 
30 mg/m2 and 3536.6 mg*h/L for 40 mg/m2). However, even when we compare our results vis-à-vis 
with AUCs reported at higher doses of PLD (50-60 mg/m2), the values we found are clearly higher(9, 
11, 20, 22, 23). This might be explained by the distinct methods used to depegylate the PLD in our 
plasma samples and thereby potentially recover more doxorubicin resulting in a higher AUC. In our 
method we used 6% instead of 3% Triton for depegylation to increase the recovery to approximately 
100%(17). A potential bioanalytical explanation for the higher levels of doxorubicin found , was 
excluded by cross-validating out assay to the assay used at Johns Hopkins. It seems unlikely that the 
addition of temsirolimus in this study led to an interaction with PLD PK. Both agents are metabolized 
by CYP3A4 which could have influenced the exposure to PLD. However, the exposure to PLD in our 
study did not change significantly over different dose ranges of temsirolimus (see table 2). Moreover, 
Thornton et al. also performed a study with the combination of temsirolimus and PLD in which they 
describe the PK of temsirolimus(24), which was not altered by the addition of PLD.
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We found a clear relation between PLD exposure and PFS in our study. To the best of our knowledge 
we are the first to describe this relationship. Amantea et al. did perform a PK study in patients with 
Kaposi sarcoma and described that the higher the Cmax of PLD, the higher the chance of a partial 
response(10). The relationship between pharmacokinetic and pharmacodynamic parameters of PLD 
has been studied more often. We found that patients who did suffer from rash and mucositis had a 
significant higher PLD exposure than patients who did not experience these events. Lyass et al. did not 
find a correlation between the AUC of PLD and common toxicities such as leucocyte nadir, stomatitis 
and hand-foot syndrome in patients with metastatic breast cancer. However, they did find a correlation 
between the dose of PLD and Cmax on the one hand and leucocyte nadir count and stomatitis on the 
other hand. Hand-foot syndrome was correlated with t1/2 (Spearman’s rho 0.56; p=0.0083)(9). Xu et 
al. also studied patients with metastatic breast cancer in China and found a correlation between PLD 
exposure and neutropenia (Spearman’s rho 0.36; p= 0.016) and nausea (Spearman’s rho 0.3; p=0.045). 
Vomiting, keratosis follicularis and pigmentation were not correlated with any PK parameter. In this 
study HFS and mucositis were not assessed(23). A study, which assessed the possible relationship 
between PK parameters of free doxorubicin and toxicity was negative(24).
In this study, patients with breast, endometrial and ovarian cancer could be included, because PLD has 
proven to be an effective treatment modality in these tumor types(1-4). Moreover, PK studies have 
been performed in different tumor types(10, 25, 26) and showed similar results for the pharmaco-
kinetic parameters. Thus the heterogeneity in this study population will not affect the outcomes. To 
correct for potential differences, tumor type was incorporated as a covariate in the univariate analysis.
In our study, patients who developed a hand-foot syndrome had a prolonged progression free survival 
than patients without this adverse event. In the multivariate analysis, hand-foot syndrome was an 
independent predictor of PFS. Hand-foot syndrome was also found to be a biomarker for efficacy 
during treatment with sunitinib in Chinese patients with renal cell carcinoma(27). Other biomarkers 
for efficacy have been identified, such as moderate neutropenia in breast cancer patients treated with 
CMF(28) and skin toxicity during treatment with epidermal growth factor receptor inhibitors(29). 
However, this is not a justification for “treatment until toxicity”, since the quality of life of patients at 
this stage of disease should be guarded. Further studies should assess the possibilities to use the 
development of hand-foot syndrome as a biomarker of survival.
In conclusion, our study showed that the occurrence of mucositis and rash is associated with a higher 
exposure to PLD. Furthermore, the occurrence of hand-foot syndrome, a better clinical performance 
before start of therapy and a higher exposure to PLD all lead independently to a prolonged PFS. This 
has important implications for clinical practice: one should prevent dose reductions of PLD in case of 
toxicities as this will lead to a shorter PFS. More attention should be paid to preventive and supportive 
measures in order to keep exposure to PLD as high as possible.
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aBstract
INTRODUCTION
The vascular endothelial growth factor receptor (VEGFR) pathway plays a pivotal role in solid 
malignancies and is probably involved in chemotherapy resistance. Pazopanib, inhibitor of, among 
other receptors, VEGFR1–3, has activity as single agent and is attractive to enhance anti-tumor activity 
of chemotherapy. We conducted a dose-finding and pharmacokinetic (PK)/ pharmacodynamics study 
of pazopanib combined with two different schedules of ifosfamide.
PATIENTS AND METHODS
In a 3 + 3 + 3 design, patients with advanced solid tumors received escalating doses of oral pazopanib 
combined with ifosfamide either given three days continuously or given 3-h bolus infusion daily for 
three days (9 g/m2 per cycle, every three weeks). Pharmacokinetic data of ifosfamide and pazopanib 
were obtained. Plasma levels of placental-derived growth factor (PlGF), vascular endothelial growth 
factor-A (VEGF-A), soluble VEGFR2 (sVEGFR2) and circulating endothelial cells were monitored as 
biomarkers.
RESULTS
Sixty-one patients were included. Pazopanib with continuous ifosfamide infusion appeared to be safe 
up to 1000 mg per day, while combination with bolus infusion ifosfamide turned out to be too toxic 
based on a variety of adverse events. Ifosfamide- dependent decline in pazopanib exposure was 
observed. Increases in PlGF and VEGF-A with concurrent decline in sVEGFR2 levels, consistent with 
pazopanib-mediated VEGFR2 inhibition, were observed after addition of ifosfamide.
CONCLUSION
Continuous as opposed to bolus infusion ifosfamide can safely be combined with pazopanib. Ifosfamide 
co-administration results in lower exposure to pazopanib, not hindering biological effects of pazopanib. 
Recommended dose of pazopanib for further studies combined with three days continuous ifosfamide 
(9 g/m2 per cycle, every three weeks) is 800 mg daily.
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introduction
Given the heterogeneity of cancer, it is conceivable that combinations of anti-tumor agents render the 
best outcomes for patients with advanced solid malignancies. The combination of conventional 
cytotoxic therapy with inhibition of the vascular endothelial growth factor receptor (VEGFR) pathway 
is attractive for several reasons. The VEGFR inhibition reduces the interstitial pressure of tumors 
rendering higher intratumoral levels of concomitantly administered cytotoxic agents and enhances 
effects of several cytotoxic agents at the tumor cell level(1-3). In addition, most VEGFR-inhibiting 
agents have no overlapping toxicities with conventional cytotoxics.
Pazopanib is a tyrosine kinase inhibitor targeting the VEGFR1-3, the platelet-derived growth factor 
receptors α and β and c-kit(4). It received marketing approval for patients with metastatic renal cell 
carcinoma and for patients with advanced non-adipocytic soft tissue sarcomas(5, 6). The recommended 
dose of pazopanib is 800 mg once daily with fatigue, diarrhea, nausea, hypertension and elevated 
liver-enzymes as most common toxicities(6). Ifosfamide is standard of care for different tumor types 
including advanced soft tissue sarcomas, where a continuous and bolus infusion schedule have shown 
equivalent activity. Myelosuppression, febrile neutropenia (FN) and encephalopathy are the most 
relevant toxicities(7). Given the potential of the combination of pazopanib and ifosfamide, we 
performed a phase I study to determine the recommended dose of pazopanib combined with 
ifosfamide in two different schedules.
patient and methods
PATIENT SELECTION
Patients with advanced or metastatic solid tumors for whom ifosfamide-based therapy was considered 
appropriate or for whom no standard therapy was available were eligible. Other inclusion criteria 
included: ECOG performance status <2, evaluable or measurable disease (RECIST 1.1)(8), age 18 years, 
adequate bone marrow, liver, and renal function, and systolic blood pressure (BP) <160 mm Hg and 
diastolic BP <90 mm Hg (two antihypertensive drugs allowed). Main exclusion criteria were: history of 
cardiovascular disease other than hypertension and signs/symptoms of central nervous system 
metastases. The study was approved by the institutional review boards and conducted in accordance 
with the principles embodied in the Declaration of Helsinki. Written informed consent was obtained 
from each participant prior to enrollment.
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STUDY DESIGN
Daily oral pazopanib was evaluated in combination with a fixed dose of ifosfamide 9 g/m2 per cycle, 
either given as three days continuous intravenous infusion (CIV) or as three hours bolus intravenous 
infusion (BIV) for three consecutive days, both at three-weekly intervals. Pazopanib was escalated in 
serial cohorts at a dose of 400, 800 and 1000 mg daily. If the maximal tolerated dose (MTD) would be 
exceeded at 400 mg then an extra cohort exploring pazopanib at 200 mg daily was added.
The 3 + 3 + 3 design, a novel model recently proposed aiming to reduce falsely halting dose escalation 
in combination phase I trials, was applied in the original protocol(9). If a dose-limiting toxicity (DLT) 
was observed in one patient, three additional patients were recruited at that dose level, with dose 
escalation proceeding if no further DLT occurred at that dose level. If DLT was observed in two out of 
six, three additional patients were enrolled. If a DLT occurred in two out of three, >two out of six or 
>two out of nine patients in a cohort, MTD had been exceeded. The MTD was defined as the highest 
dose level with a DLT incidence of <33%.
In order to be exposed to steady-state concentrations of pazopanib and to determine the effects of 
ifosfamide administration on pazopanib pharmacokinetics (PK), patients in the dose-escalation phase 
started on pazopanib seven days prior to the first cycle of ifosfamide. At the MTD, six additional 
patients were treated in an expansion cohort to get better insight into the safety profile, to confirm the 
MTD, and to further study the PK interaction. For the latter, pazopanib was started seven days after the 
first ifosfamide cycle in the patients in the expansion phase, which enabled an intra-patient comparison 
of ifosfamide PK with or without the presence of pazopanib (see figure 1).
Using the Common Terminology Criteria for adverse events, version 3.0, DLT during the first treatment 
cycle (in the dose expansion phase during the first two treatment cycles) was defined as: grade 4 
neutropenia ≥ 7 days, FN, grade 4 thrombocytopenia, creatinine clearance 50 ml/min, grade 3–4 
proteinuria or any drug-related grade 3 or 4 non-hematological toxicity. Hypertension was considered 
a DLT in case of symptomatic hypertension; persistent (>24 h) and asymptomatic systolic BP >170 mm 
Hg and/or diastolic BP >100 mm Hg; systolic BP 160-170 and/or diastolic BP 90-100 that could not be 
controlled within two weeks; or an increase of diastolic BP >20 mm Hg, which despite antihypertensive 
medication was not adequately controlled within two weeks. A dose delay or interruption exceeding 
two weeks was classified as DLT. If neutropenia comprised the predominant DLT at a certain dose level, 
that and subsequent levels were explored in combination with granulocyte cell stimulating factor 
(pegfilgrastim 6 mg once per cycle).
Patients were treated for a maximum of six ifosfamide cycles. Patients experiencing clinical benefit 
from the combination of pazopanib and ifosfamide were allowed to continue treatment thereafter 
with pazopanib until disease progression or unacceptable toxicity.
Figure 5.1 Study design
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PK SAMPLING AND ANALYSIS
Concentrations of ifosfamide and its most important metabolites, 2-dechloroethyl-ifosfamide, 
3-dechloroethyl-ifosfamide and 4-hydroxy-ifosfamide were quantitated as previously reported in 
eleven –sixteen samples per ifosfamide cycle(10). For the analysis of pazopanib, fifteen samples per 
patient were drawn and quantified as previously reported(11).
STATISTICAL DATA ANALYSIS
Plasma concentrations of ifosfamide and its metabolites were plotted as a function of time. Area 
under the curve (AUC) was calculated by the trapezoidal method. Non- compartmental PK analysis 
including half-life (T½, h) was calculated using the software package WinNonlin version 6.1. Total body 
clearance of ifosfamide was calculated by dividing the administered dose by the AUC of ifosfamide. 
Statistical analysis were made using the software package SPSS (v20). Correlation of the changes in 
AUC or clearance and half-life was evaluated by a two-sided paired t-test for subjects in the expansion 
cohorts.
Median plasma pazopanib concentration-time profiles were generated for subjects in the dose 
escalation cohorts. The area under the plasma pazopanib concentration–time curve from 0 to 24 h 
(AUC (0–24)) was calculated using nominal blood sample collection times after administration of 
pazopanib on day 21 cycle 1 (pazopanib alone) and day 3 cycle 2 (pazopanib plus ifosfamide) for 
subjects in the expansion cohorts.
Figure 5.1 Study design
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BIOMARKER ANALYSIS
Biomarker samples were collected in all patients at baseline and prior to cycle 2 day 1. During the 
escalation phase, an additional sample was drawn prior to day 1 cycle 1 and during the expansion prior 
to the first pazopanib dose. Circulating endothelial cell (CEC) enumeration was determined with a 
flow-cytometry-based method(12). Plasma concentrations of VEGF-A, soluble VEGFR2 (sVEGFR2) and 
placental-derived growth factor (PlGF) were determined using ELISA (R&D Systems, Minneapolis, MN, 
USA) according to the manufacturers’ instructions.
results
DOSE ESCALATION, MTD AND DOSE INTENSITY
In total, 61 patients were enrolled (see table 1), 29 in the CIV schedule and 32 on the BIV schedule. In 
all, 15 out of 61 patients were not evaluable for determination of DLT of the combination and were 
replaced. The most common reason was early progression (n = 5). Two other patients were registered 
but did not receive a dose of study drug at all. Three patients appeared not to tolerate the single agent 
treatment they received before the second agent was added. As the aim of this study was to identify 
the MTD of the combination of pazopanib and ifosfamide, it was decided to replace these patients. 
Five others were not evaluable due to a diversity of reasons including withdrawal of consent (not 
based on toxicity), and an allergic reaction to mesna, which was prophylactically administered with 
ifosfamide.
In the CIV arm, no DLTs were observed in the three evaluable patients at the first dose level, whereas 
one DLT (FN) was observed at a dose level with 800 mg pazopanib (six evaluable patients). At the 
highest pre-defined dose level of 1000 mg pazopanib two DLTs occurred (FN and encephalopathy) in 
nine patients. During expansion phase (n = 6) at this dose level, no additional DLTs were observed. At 
the MTD in the CIV arm, the dose intensity of ifosfamide and pazopanib was 92% and 93%, respec-
tively, with a median number of ifosfamide cycles of four.
In the first two patients treated with 400 mg pazopanib in the BIV arm, an episode of FN was 
encountered. Adding G-CSF to the 400 mg pazopanib dose level three DLTs were observed in nine 
patients (grade 3 encephalopathy, grade 3 proteinuria and grade 3 pneumonia during neutropenia). 
The dose of pazopanib was de-escalated to 200 mg and supported with G-CSF. In two out of the first 
nine evaluable patients DLTs occurred (one case each of grade 3 encephalopathy and FN). The 
subsequent dose expansion in another six patients resulted in three more DLTs (pneumonia during 
neutropenia and grade 5 cardiac arrest in one patient, renal toxicity and grade 3 fatigue).
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TOXICITY
In addition to hematological toxicity, the main grades 3–4 toxicities during combination therapy were 
fatigue and hypophosphatemia, irrespective of treatment schedule. Grade 3/4 vomiting was more 
pronounced in the BIV-treated patients, whereas all grades of hypertension and grade 3/4 neutropenia 
occurred more often in the CIV group (see table 2).
Characteristi cs No.
Age (years) Median
Range
56
18-76
WHO 0 23 (38)
1 38 (62)
Tumor type Sarcoma (incl GIST) 19
Melanoma 6
Urothelial carcinoma 6
Ovarian carcinoma 5
Carcinoma of unknown 
primary
5
Prostate 4
Gastric carcinoma 3
Esophageal carcinoma 3
Miscellaneous 10
Previous non-hormonal 
systemic anti cancer 
treatment
0 12
1 29
2 11
3 3
4 4
5 1
Table 5.1 Pati ent characteristi cs
GIST = Gastro-intesti nal stromal tumor  WHO = World Health Organizati on
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CIV (n= 26) BIV (n= 27)
First cycle
AEs
AEs at all 
combinati on 
cycles
First cycle
AEs
AEs at all 
combinati on 
cycles
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Anemia 1 21 5 26 0 23 4 27
Thrombocytopenia 1 7 3 13 3 14 5 17
Neutropenia 23 24 25 25 13 16 15 19
Fati gue 2 24 6 25 2 20 5 23
Nausea 1 24 2 25 2 22 2 23
Vomiti ng 0 15 0 21 5 20 6 21
Mucositi s 0 8 0 11 0 4 0 8
Anorexia 0 17 0 22 1 15 4 18
Consti pati on 0 17 0 19 0 13 0 15
Diarrhea 0 10 0 15 1 7 1 11
Hypertension 1 10 2 13 1 3 2 4
Encephalopathy 1 10 1 14 2 9 3 14
ALAT 0 13 0 19 0 11 1 12
ASAT 0 14 1 19 0 12 0 16
Hypophosphatemia 2 11 5 13 1 12 5 17
Proteinuria 1 11 1 12 0 9 0 15
Table 5.2 Most frequent adverse events during the fi rst and during all combinati on cycles
ALAT = Alanine aminotransaminase  ASAT = Aspartate aminotransferase  CIV = Conti nuous intravenous infusion  
BIV = Bolus intravenous infusion  AEs = Adverse events
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PHARMACOKINETICS
Pazopanib had no impact on plasma half-life, AUC or clearance, of ifosfamide or any of its metabolites. 
Figures 2 and 3 depicts the ifosfamide concentrations with and without concomitant administration of 
pazopanib. In contrast, pazopanib concentrations declined by ~35% within 72 h during concomitant 
ifosfamide infusion in patients in the dose escalation phase during CIV (see figure 4). There seems to 
be a time-dependent effect, resulting in comparable median plasma pazopanib concentrations at the 
end of ifosfamide infusion across dose-levels of pazopanib (figure 4).
PK analysis in patients treated in the dose expansion phase revealed that the mean AUC (0–24) of 
pazopanib was reduced by ~27% upon co-administration of ifosfamide as compared with the AUC of 
pazopanib single agent (see figure 5).
CIV (n= 26) BIV (n= 27)
First cycle
AEs
AEs at all 
combinati on 
cycles
First cycle
AEs
AEs at all 
combinati on 
cycles
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Grd 
3/4
All 
grds
Anemia 1 21 5 26 0 23 4 27
Thrombocytopenia 1 7 3 13 3 14 5 17
Neutropenia 23 24 25 25 13 16 15 19
Fati gue 2 24 6 25 2 20 5 23
Nausea 1 24 2 25 2 22 2 23
Vomiti ng 0 15 0 21 5 20 6 21
Mucositi s 0 8 0 11 0 4 0 8
Anorexia 0 17 0 22 1 15 4 18
Consti pati on 0 17 0 19 0 13 0 15
Diarrhea 0 10 0 15 1 7 1 11
Hypertension 1 10 2 13 1 3 2 4
Encephalopathy 1 10 1 14 2 9 3 14
ALAT 0 13 0 19 0 11 1 12
ASAT 0 14 1 19 0 12 0 16
Hypophosphatemia 2 11 5 13 1 12 5 17
Proteinuria 1 11 1 12 0 9 0 15
Table 5.2 Most frequent adverse events during the fi rst and during all combinati on cycles
ALAT = Alanine aminotransaminase  ASAT = Aspartate aminotransferase  CIV = Conti nuous intravenous infusion  
BIV = Bolus intravenous infusion  AEs = Adverse events
Figure 5.2 Mean concentrati ons (plus SD) of ifosfamide administered alone 
 (closed symbols: bars up) or in combinati on with pazopanib 
 (open symbols: bars down) during the 3-days conti nuous infusions
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Figure 5.3 Mean concentrati ons (plus SD) of ifosfamide administered alone 
 (closed symbols, bars up) or in combinati on with pazopanib 
 (open symbols, bars down) during three consecuti ve bolus infusion days
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Figure 5.4 Median plasma pazopanib concentrati on ti me profi le 
 (dose escalati on, in pati ents with conti nuously given ifosfamide)
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BIOMARKER ANALYSIS
During the treatment with pazopanib, there was a dose-dependent increase in PlGF and VEGF-A with 
a concurrent decline in sVEGFR2 (see table 3). Importantly, this phenomenon remained intact after the 
addition of ifosfamide. No consistent pattern was seen by enumeration of CEC (data not shown).
ANTI-TUMOR ACTIVITY
Of 45 patients evaluable for response, ten partial responses were observed: four in the CIV-treated 
patients (two patients with synovial sarcoma, one each with ovarian and prostate cancer) and six 
patients in the BIV schedule (urothelial cancer (n = 2), one each with sarcoma not otherwise specified, 
mesothelioma, ovarian cancer and an cancer of unknown primary). Prolonged disease stabilization 
defined as stable disease for at least three months was noted in nine and five patients in the CIV and 
BIV group, respectively.
Figure 5.5 Pazopanib area-under-curve (AUC) administered as single agent (day 21, cycle 1) 
 versus combined administrati on with conti nuous ifosfamide (day 3, cycle 2) 
 in the dose expansion phase
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discussion
In this study, we explored safety and tolerability of the combination of pazopanib and ifosfamide, and 
its possible dependence on the ifosfamide infusion schedule. Pazopanib in combination with 
BIV-administered ifosfamide turned out to be intolerable. In contrast, if ifosfamide is continuously 
administered over three days, pazopanib could be escalated to dose levels exceeding the registered 
single agent dose of 800 mg daily. The inclusion of a dose higher than the registered single agent dose 
was done, since in a previous study a drug-drug interaction between ifosfamide and sunitinib resulted 
in a decreased exposure to sunitinib(10). This observation was confirmed in the current study, showing 
a PK interaction between pazopanib and ifosfamide.
Our study clearly underlines that the administration schedule of one of the drugs of a combination can 
have a major impact on the tolerability of the combination. One of the reasons that could account for 
the observed differences in tolerability between the two schedules of ifosfamide might be a 
Ifosfamide 
schedule
Biomarker Pazopanib 
dose
Baseline Aft er 7 days 
pazopanib but 
prior to ﬁ rst 
ifosfamide
Prior to second 
ifosfamide
CIV PIGF 400 1 1.75 1.35
800 1 6.87 8.46
1000 1 7.13 4.39
VEGF-A 400 1 1.08 0.54
800 1 5.26 5.72
1000 1 3.85 2.73
sVEGFR2 400 1 0.89 0.88
800 1 0.77 0.70
1000 1 0.76 0.69
BIV PIGF 200 1 1.81 1.75
400 1 2.40 3.24
VEGF-A 200 1 1.72 3.12
400 1 1.96 2.20
sVEGFR2 200 1 0.89 0.81
400 1 0.79 0.77
Table 5.3 Biomarkers in the dose escalati on cohorts (baseline normalized to 1)
CIV = Conti nuous intravenous infusion  BIV = Bolus intravenous infusion  PIGF = Placental derived growth factor  
VEGF-A = Vascular endothelial growth factor-A  sVEGFR2 = Soluble VEGFR2
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schedule-dependent drug-drug interaction. Previously, pazopanib has demonstrated PK interactions 
with conventional chemotherapy, resulting in higher exposure to paclitaxel or the combination of 
paclitaxel and carboplatin(13-15). In contrast, combining pazopanib with full-dose gemcitabine was 
feasible up to 800 mg pazopanib and no PK interaction was found(16). Currently, extensive PK analysis 
did not show an impact of pazopanib on serum levels of ifosfamide or its metabolites.
In contrast, pazopanib exposure was clearly lowered by concurrent infusion of ifosfamide. This effect 
of ifosfamide on pazopanib levels yielded in similar pazopanib concentrations at the end of the 
ifosfamide infusion, regardless of the dose of pazopanib given. A potential underlying mechanism 
might be ifosfamide’s inductive effects on CYP3A(17) for which pazopanib, in addition to being a weak 
inhibitor, is also a substrate(18). If the induction of CYP3A by ifosfamide is indeed the cause of the 
decreased pazopanib exposure, this could imply that other drugs able to induce CYP3A should be 
avoided during pazopanib therapy but this warrants further exploration.
Yet, this PK interaction does not explain the striking difference in tolerability between the CIV and BIV 
schedule. In a study in patients with soft tissue sarcoma, BIV and CIV administrations of ifosfamide 
were compared demonstrating CIV to be slightly less toxic in terms of a lower rate of treatment discon-
tinuation due to toxicity and a lower incidence of grade 3–4 dyspnoe and infection. However, CIV 
induced a higher incidence of grade 3–4 anemia and grade 2–3 nausea than BIV ifosfamide(7). The 
higher incidences of grade 3–4 neutropenia in the CIV schedule (88%; 23 out of 26 patients) compared 
with the BIV (48%; 13 out of 27 patients) observed in this study were in contrast with the study by 
Lorigan et al in which comparable incidences in CIV- and BIV-treated patients for grade 3–4 neutropenia 
incidence (62.7% vs 60.0%) were found(7). This strongly suggests that the potentiating effect of 
pazopanib on the occurrence of neutropenia depends on the chosen infusion schedule. Auto- 
induction of ifosfamide is 52% higher during bolus infusion as compared with continuous infusion(19) 
and as a result higher concentrations of ifosfamide are generated. Accordingly, the AUC 0–72 of 
ifosfamide in our trial was indeed higher during bolus infusions as compared with the continuous 
infusion (3149 μg*h/ml vs 2234 μg*h/ml, respectively).
Three cytokines known to reflect biological effects from VEGFR-TKIs showed alterations in PlGF, 
VEGF-A and sVEGFR levels following exposure to pazopanib consistent with inhibition of VEGFR2 
activity(20). Ifosfamide did not nullify these pazopanib-induced biological effects, so ifosfamide does 
not hinder pazopanib to exert biological effects despite its lowering effects on pazopanib-levels.
This study shows that the upper boundary of safe dosing is, at least, 1000 mg per day pazopanib with 
CIV ifosfamide 9 g/m2. Like the single-agent pazopanib dose-finding study, the tolerable dose is higher 
than the currently approved dose, chosen on the basis of PK parameters and analyses of biological 
activity . On the basis of the facts that the exposure to pazopanib during ifosfamide is comparable in 
patients using 1000 mg per day and 800 mg per day after 48 h (figure 4) and that the 
Ifosfamide 
schedule
Biomarker Pazopanib 
dose
Baseline Aft er 7 days 
pazopanib but 
prior to ﬁ rst 
ifosfamide
Prior to second 
ifosfamide
CIV PIGF 400 1 1.75 1.35
800 1 6.87 8.46
1000 1 7.13 4.39
VEGF-A 400 1 1.08 0.54
800 1 5.26 5.72
1000 1 3.85 2.73
sVEGFR2 400 1 0.89 0.88
800 1 0.77 0.70
1000 1 0.76 0.69
BIV PIGF 200 1 1.81 1.75
400 1 2.40 3.24
VEGF-A 200 1 1.72 3.12
400 1 1.96 2.20
sVEGFR2 200 1 0.89 0.81
400 1 0.79 0.77
Table 5.3 Biomarkers in the dose escalati on cohorts (baseline normalized to 1)
CIV = Conti nuous intravenous infusion  BIV = Bolus intravenous infusion  PIGF = Placental derived growth factor  
VEGF-A = Vascular endothelial growth factor-A  sVEGFR2 = Soluble VEGFR2
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pharmacodynamic parameters showed that the short period of lower pazopanib levels using 800 mg 
compared with 1000 mg pazopanib did not have any effects on the pazopanib-induced biological 
effects, both in line with findings from the phase I trial on pazopanib monotherapy(11), we recommend 
as dose for further studies 800 mg pazopanib and CIV ifosfamide 9 g m2.
Importantly, this is the first phase I study to apply the 3 + 3 + 3 design. This pre-planned design for 
combination phase I trials aims to eliminate chances of falsely halting dose escalation, based on a high 
a priori chance of developing a DLT of one of the drug(9). In the CIV arm, two out of the first six 
patients at the 1000 mg pazopanib dose level experienced a DLT. According to the conventional 3 + 3 
design, this would have been interpreted as toxicity exceeding MTD. However, no DLTs were 
encountered in the other nine patients enrolled in this dose level. This strongly underscores the clinical 
applicability of this 3 + 3 + 3 approach in establishing the tolerability of drug combinations.
In conclusion, this study has clearly demonstrated that tolerability of pazopanib and ifosfamide is 
dependent on the infusion schedule. An evident explanation for the observed differences is not readily 
available. Furthermore, ifosfamide appeared to lower pazopanib levels, but despite the lower levels of 
pazopanib, it still exerted biological activity. In addition, this study stresses the importance of the 3 + 
3 + 3 design for exploring drug combinations in phase I studies when one of the agents is known to 
induce high rates of toxicity. Last, based upon our data the dose recommended for pazopanib when 
combined with CIV ifosfamide 9 g/m2 is 800 mg, while a combination with bolus ifosfamide is not 
feasible. Further studies on the combination of pazopanib and ifosfamide are currently being designed.
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TO THE EDITOR
Carrato et al.(1) recently published their results of a randomized phase III trial of fluorouracil (5-FU), 
leucovorin (LV) and irinotecan (FOLFIRI) plus either sunitinib or placebo in patients with metastatic 
colorectal cancer (mCRC). Intravenous FOLFIRI was administered every two weeks as irinotecan 180 
mg/m2, LV 200 mg/m2 immediately followed by 5-FU 400 mg/m2 bolus and 5-FU 2400 mg/m2 as a 
46-hour infusion. The dosage of oral sunitinib was 37,5 mg/day in a four weeks on/two weeks off 
schedule. The study failed to demonstrate superiority for FOLFIRI plus sunitinib and showed an 
increased incidence of grade ≥ 3 adverse events for this combination when compared to FOLFIRI plus 
placebo (neutropenia (68 vs 30%), diarrhea (16 vs 8%), thrombocytopenia (11 vs 1%), anemia, 
stomatitis, fatigue, hand-footsyndrome and febrile neutropenia). Furthermore, more deaths as a 
result of toxicity (n=12 versus n=4) and significantly more dose delays, dose reductions and treatment 
discontinuations occurred in the sunitinib arm.
We performed a phase I study in a standard 3 + 3 trial design with capecitabine, irinotecan (CAPIRI) 
and sunitinib in patients with mCRC as second line treatment (NCT00777478). Both capecitabine and 
irinotecan were administered at a reduced starting dose (capecitabine 850 mg/m2 on day 1-14 and 
irinotecan 200 mg/m2 on day 1, every three weeks) due to the expected additive toxicities of the 
combination with sunitinib. This study was approved by the medical ethical committee and was 
conducted in accordance with the Principles of Good Clinical Practice and the Declaration of Helsinki. 
All patients provided written informed consent.
We treated four patients at dose level 1, with sunitinib given at 25 mg/day continuously, and observed 
two dose limiting toxicities (DLTs): a grade 3 neutropenia lasting more than seven days and a delay of 
more than fourteen days of the second cycle because of neutropenia and thrombocytopenia. 
According to protocol we subsequently treated the following patients at a lower dose level with 
sunitinib 12,5 mg/day continuously. Both patients at this dose level experienced neutropenia grade 3, 
which led to dose delays of irinotecan and dose interruptions of sunitinib and capecitabine. In one of 
these two patients, sunitinib was definitively withdrawn after cycle 4 and thereafter this patient did 
not experience any hematological toxicities anymore, even when the dose of irinotecan was escalated. 
Because any clinical benefit was not expected with lower doses of sunitinib with already reduced 
doses of capecitabine and irinotecan, the study was discontinued and we concluded that a combination 
of CAPIRI with sunitinib was not feasible.
FOLFIRI, in comparison to CAPIRI, is associated with less adverse events as has been shown in a phase 
III trial, in which patients were randomized between treatment with FOLFIRI and CAPIRI(2). Grade 3 to 
4 nausea, vomiting, diarrhea and dehydration occurred significantly more frequently in the CAPIRI 
arm, and neutropenia occurred more frequently in the FOLFIRI arm (43 vs 32%). Although these data 
show that CAPIRI is associated with a higher incidence of toxic events, it is considered as a feasible 
regimen. The CAIRO study included the largest patient cohort that received the same CAPIRI regimen 
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(capecitabine 1000 mg/m2 and irinotecan 250 mg/m2) as first line treatment (n=402)(3). The most 
frequently occurring grade ≥3 adverse event in this study was diarrhea (26%). Neutropenia was 
observed in only 7% of the patients, whereas anemia and thrombocytopenia occurred both in 1% of 
patients. This study showed CAPIRI to be a feasible regimen which does not require the inconvenience 
of using ambulatory infusion devices and more frequent patient visits as is the case with FOLFIRI(3, 4). 
In general practice, both CAPIRI and FOLFIRI can thus be used. In the light of the high incidence of 
mostly hematological toxicities that occur when adding sunitinib to either regimen, it is important to 
notice that the incidence of hematological toxicities does not differ between CAPIRI and FOLFIRI.
In the study of Carrato et al. sunitinib 37,5 mg/day was dosed in the four weeks on/two weeks off 
schedule, whereas we started with 25 mg/day continuously. Thereby, the total dosage of sunitinib in 
our study during six weeks was higher, which may have contributed to the observed toxicity. Taken 
together, these data show that sunitinib cannot be combined with CAPIRI or FOLFIRI regimens.
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aBstract
INTRODUCTION
Despite recent advances in treatment of metastatic clear cell renal cell carcinoma (ccRCC), the search 
for alternative treatment modalities continues. A phase II radioimmunotherapy (RIT) trial with 
177lutetium (177Lu)-girentuximab was initiated to evaluate the efficacy of this RIT approach in patients 
with metastatic ccRCC.
PATIENTS AND METHODS
In this non-randomized phase II trial, patients with progressive metastatic ccRCC who met the inclusion 
criteria received RIT with 2405 MBq/m2 177Lu-labeled girentuximab, if targeting of the antibody was 
observed after a diagnostic injection with 111indium (111In)-labeled girentuximab. Patients were 
eligible for another treatment cycle if they had at least stable disease (SD) on evaluation after three 
months according to RECIST v.1.1 and did not have prolonged grade 4 hematological toxicity. 
Retreatment was at 75% of the previous activity dose with a maximum of three treatment cycles in 
total.
RESULTS
In this study, fourteen patients received at least one infusion with 177Lu-girentuximab. After the first 
treatment cycle, eight (57%) patients had SD, one (7%) patient had partial regression (PR), whereas 
progressive disease (PD) was seen in the other five (36%) patients. The treatment was generally well 
tolerated, but resulted in grade 3-4 hematological toxicity in all, but one, patients. Of the nine patients 
with SD/PR after the first cycle, three patients were not eligible for retreatment due to prolonged 
hematological toxicity. After the second treatment cycle, continued SD was observed in five out of six 
patients. All five suffered from prolonged thrombocytopenia and were therefore not eligible for the 
third cycle.
CONCLUSION
RIT with 177Lu-girentuximab resulted in disease stabilization in nine out of fourteen patients with 
progressive ccRCC, but myelotoxicity prevented retreatment in some patients.
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introduction
Despite advances in the treatment of metastatic clear cell renal cell carcinoma (ccRCC) with antibodies 
targeting the vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor 
(VEGFR) tyrosine kinase inhibitors (VEGFR TKIs) and mammalian target of rapamycin (mTOR) inhibitors 
in the past decade(1-10), there is still an unmet need for improved treatment options of this disease. 
The search for novel systemic treatment strategies with less toxicity and significant anti-tumor effect 
has led to therapeutic regimes using radiolabeled antibodies specifically targeting tumor-associated 
antigens expressed on tumor cells. For ccRCC, which accounts for approximately 85 percent of the 
malignant renal tumors, the radiolabeled chimeric monoclonal antibody girentuximab is extensively 
investigated for both radioimmunodetection and radioimmunotherapy (RIT)(11-20). Girentuximab 
specifically targets carbonic anhydrase IX (CAIX), a tumor-associated antigen ubiquitously expressed in 
primary ccRCC and its metastases but not found in the normal kidney(21-23). Because of the specific 
targeting of girentuximab to CAIX-expressing lesions, this antibody is a potent carrier for tumor 
targeted delivery of β-emitting radionuclides(24). Two independent phase I radioimmunotherapy (RIT) 
trials have been carried out using yttrium-90 (90Y) or lutetium-177 (177Lu) labeled girentuximab in 
patients with metastatic ccRCC(12, 25). These trials were designed to assess the maximum tolerated 
dose (MTD), dosimetry, pharmacokinetics, and incidence of human anti-chimeric antibody (HACA) 
formation. While the results of the 90Y-girentuximab trial are not yet available, 177Lu-girentuximab RIT 
proved to be safe and well tolerable at activity dose levels as high as 2405 MBq/m2. Moreover, 17 of 
23 (74%) patients with advanced ccRCC demonstrated stable disease three months after the first 
infusion with 177Lu-girentuximab(12). Because of these encouraging results, a phase II trial at MTD 
was initiated. Here we report the results of this RIT study in patients with advanced ccRCC.
patients and methods
Adult patients with histopathologically proven metastatic ccRCC with evidence of progressive disease 
(>15% growth) or new RECIST v.1.1 evaluable lesions, with a maximum diameter of five centimeters, 
were eligible for participation. Additional inclusion criteria were a Karnofsky performance score > 70, 
white blood cell (WBC) count > 3.5 x 109/l, thrombocyte count >150 x 109/l, hemoglobin > 6 mmol/l, 
total bilirubin ≤ 2 x upper limit of normal (ULN), aspartate aminotransferase (ASAT), alanine aminot-
ransferase (ALAT ) ≤ 3 x ULN (≤5 x ULN if liver metastases present), MDRD > 40 ml/min and a negative 
pregnancy test for women of child bearing potential.
Previous treatment with external beam radiation, immunotherapy, anti-VEGF antibodies and VEGFR 
TKIs or mTOR inhibitors was allowed, when more than four weeks prior to study entry. Exclusion 
criteria were untreated hypercalcemia, cardiac disease (New York Heart Association classification III or 
IV), a life expectancy shorter than four months. In addition, patients with a history or clinical evidence 
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of central nervous system (CNS) metastases were excluded, unless patients were previously treated 
and had no evidence of active CNS metastases for ≥ 3 months prior to enrollment, and had no 
requirement for steroids or enzyme inducing anticonvulsants in the last fourteen days. Inclusion and 
exclusion criteria are listed in more detail in table 1.
The study was registered on the clinicaltrials.gov website (NCT02002312) and was approved by the 
Medical Review Ethics Committee of the Region Arnhem-Nijmegen. All subjects provided written 
informed consent.
STUDY DESIGN
The primary end point of this non randomized phase II trial study was to determine the therapeutic 
efficacy of 177Lu-girentuximab in patients with progressive metastatic ccRCC. Response was defined as at 
least stable disease (SD) on evaluation after three months according to the Response Evaluation Criteria 
in Solid Tumors (RECIST) v.1.1. Secondary objectives of this study were to assess the progression-free 
survival (PFS) and overall survival (OS) and to explore the toxicity of the 177Lu-girentuximab treatment. 
PFS was defined as the time measured from the day of first administration of 177Lu-girentuximab to first 
progression (either radiological or clinical) or death, whichever occurred first. OS was defined as the time 
from the first injection with 177Lu-girentuximab to the date of death from any cause.
STUDY PROCEDURES
Preparation of the radiolabeled antibody was performed as described earlier[17]. In brief, girentuximab 
was conjugated with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA, Macrocyclics, 
Dallas, TX, USA) and labeled with either 185 MBq 111In (Mallinckrodt Medical, Petten, The Netherlands) 
for the diagnostic infusion, or with 2405 MBq/m2 of 177Lu (ITG, Gärching, Germany) for the therapeutic 
infusion. Radiochemical purity exceeded 95% in all cases as confirmed by instant thin layer 
chromatography.
After screening, all eligible patients received an infusion with 185 MBq/10 mg 111In-DOTA-girentuximab 
to enable diagnostic imaging. Whole body planar and Single-Photon Emission Computed Tomography 
(SPECT/CT) images were acquired two hours, two to four and five to seven days after injection of the 
111In-labeled antibody to determine targeting of the radiolabeled monoclonal antibody. If at least one 
evaluable metastatic lesion was visualized with 111In-girentuximab, 177Lu-DOTA-girentuximab (2405 
MBq/m2, 10 mg) was administered nine to ten days after infusion of 111In-DOTA-girentuximab. Patients 
were eligible for a maximum of three treatment cycles if they did not show progressive disease (PD), 
did not have grade 4 hematological toxicities for more than one week and met the inclusion criteria 
prior to each cycle. Additionally, if rapid clearance of the antibody from the circulation and high liver, 
spleen and bone marrow uptake was detected on whole body planar images on day 2–4, indicating 
HACA formation, patients were excluded from further RIT cycles. Retreatment followed twelve to 
fourteen weeks after the previous therapeutic infusion at 75% of the previous activity dose (1805 
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MBq/ m2 for RIT cycle 2). Patients were monitored for twelve weeks for hematologic toxicity. 
CT scanning to evaluate response according to the RECIST v.1.1 criteria was performed at baseline and 
twelve weeks after infusion of 77Lu-DOTA-girentuximab.
1.1 Inclusion criteria
• Pati ents with proven advanced and progressive RCC of the clear cell type
• Presence of evaluable lesions all < 5 cm, according to RECIST v.1.1, 
• Karnofsky Performance status: > 70 
• Laboratory values:
 - White blood cells > 3.5 x 109/l
 - Platelet count > 150 x 109/l
 - Hemoglobin > 6 mmol/l 
 - Total bilirubin < 2 x ULN 
 - ASAT, ALAT < 3 x ULN (< 5 x ULN if liver metastases present)
 - MDRD ≥ 40 ml/min
• Negati ve pregnancy test for women of child¬bearing potenti al (urine or serum)
• Age over 18 years 
• Writt en informed consent
1.2 Exclusion criteria
• Known or suspected CNS metastases including leptomeningeal metastases. History or clinical 
evidence of  CNS metastases (unless they are previously-treated CNS metastases and pati ents 
meet all three of the following criteria: are asymptomati c, have had no evidence of acti ve CNS 
metastases for ≥3 months prior to enrollment, and have had no requirement for steroids or 
enzyme inducing anti convulsants in the last 14 days)
• Untreated hypercalcemia
• Chemotherapy, external beam radiati on, immunotherapy or angiogenesis inhibitors or mTOR 
inhibitors within four weeks prior to study. Limited fi eld external beam radiotherapy to prevent 
pathological fractures is allowed , when unirradiated, evaluable lesions elsewhere are present
• Cardiac disease with New York Heart Associati on classifi cati on of III or IV 
• Pati ents who are pregnant, nursing or of reproducti ve potenti al and are not practi cing an 
eff ecti ve method of contracepti on
• Any unrelated illness, e.g. acti ve infecti on, infl ammati on, medical conditi on or laboratory 
abnormaliti es, which in the judgment of the investi gator will signifi cantly aff ect pati ents’ 
clinical status 
• Life expectancy shorter than four months
Table 7.1 Inclusion and exclusion criteria
RCC = Renal cell carcinoma  RECIST = Response Evaluati on Criteria in Solid Tumors  ULN = Upper limit of normal  
ASAT = Aspartate aminotransferase  ALAT = Alanine aminotransferase  MDRD = Modifi cati on of diet in renal disease, 
formula to esti mate Glomerular Filtrati on Rate  CNS = Central nervous system  mTOR = Mammalian target of rapamycin
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STATISTICAL ANALYSIS
A Simon two-stage minimax design was used to calculate the number of patients needed to reach the 
desirable response rate. The desirable response rate was set at 0.65, with α = 0.05 and β = 0.10. 
Response was defined as at least stable disease (SD) on evaluation after three months according to 
RECIST v.1.1. If a response rate of >0.25 was seen after the first treatment cycle in the first six patients, 
in total fourteen patients had to be included in this study.
results
In 2013, after inclusion of the first six patients, interim analysis indicated that three of the six patients 
had stable disease three months after the first treatment with 177Lu-girentuximab. Therefore, 
recruitment was continued and terminated after a total of fourteen evaluable patients were included.
In total, sixteen adult patients with metastatic ccRCC were enrolled between August 2011 and April 
2014. Two patients were excluded from the study, because known ccRCC lesions did not show any 
targeting at diagnostic imaging five to seven days post injection of 111In-girentuximab. In the other 
fourteen patients (nine men and five women; median age: 68 year; range: 56–75 years) accumulation 
of 111In-girentuximab was observed in at least one of the suspect lesions (see figure 1). Patient charac-
teristics are listed in table 2. Thirteen out of fourteen patients had a favorable prognosis and one 
patient had an intermediate prognosis according to the Memorial Sloan-Kettering Cancer Center 
(MSKCC) prognostic scoring system[26]. Three patients had received prior systemic treatment with 
VEGFR TKIs or Interferon-α (INF-α) and five patients received local therapies (either metastasectomy 
or external beam radiotherapy).
EFFICACY
Tumor response of the target lesions of all patients after the first cycle of RIT is shown in figure 2. The 
mean growth rate of the target lesions decreased from 14% to 5%, although large differences were 
observed between patients. Nine out of fourteen patients (64%) showed response (SD or PR) after the 
first treatment cycle (table 2). Six out of these nine patients were eligible for a second therapeutic 
infusion, whereas the other three patients had to be excluded from further treatment due to prolonged 
myelotoxicity. After the second RIT, durable responses were observed in five patients and disease 
progression was observed in one patient. The five patients with prolonged clinical benefit after the 
second RIT were not eligible for a third RIT due to slow recovery of myelotoxicity.
Patient #2 died of the consequences of a bleeding in a previously undetected cerebral metastases one 
week before response evaluation was planned. Because this patient had recovered from hemato-
logical toxicity, at the moment of the bleeding, it was concluded that this event was unrelated to the 
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study drug. In patient #6, CT imaging of the chest and abdomen showed stabilization of the target 
lesions, however, a new bone lesion in the right shoulder was detected with 111In-girentuximab scinti-
graphy at the start of the second RIT cycle (see figure 3). Conventional radiological studies confirmed 
this observation and the patient was therefore ineligible for additional 177Lu-girentuximab infusions. 
Patient #10 was retrospectively diagnosed with PD early during the second RIT cycle: a bone metastases 
that became symptomatic during the second cycle of RIT was noted upon re-evaluation of 
111In-girentuximab imaging after the first RIT cycle. Although data from this patient were not used for 
response evaluation after RIT 2, they were included in the toxicity analysis.
For all patients, the available PFS and OS intervals are listed in table 2. The median PFS for all patients 
in this study was 8.1 months. Because the numbers are small and follow-up of several patients is 
ongoing, no additional statistical analyses were performed.
Clear targeti ng of 111In-girentuximab was observed in multi ple lung lesions and consequently this 
pati ent was eligible for infusion with 177Lu-girentuximab
Figure 7.1 Diagnosti c SPECT/CT images of pati ent #4 during the fi rst RIT cycle
86
Tumor growth of the target lesions aft er RIT1 and 2 per pati ent according to RECIST criteria v.1.1
The dott ed lines in pati ents 3, 6, 7, 8, 11 and 14 represent the tumor growth of the target lesions aft er exclusion from additi onal RIT treatment cycles.
Figure 7.2 Eff ect of 177Lu-girentuximab RIT on growth rate of target lesions
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TOXICITY
All patients experienced grade 3-4 thrombocytopenia in the first RIT cycle, with the exception of 
patient #5 (grade 2) and #10 (grade 1). The nadir of the platelet count was at median of five weeks post 
injection of 177Lu-girentuximab (see figure 4). Generally, patients recovered from grade 3 or higher 
thrombocytopenia in two to three weeks. In total, three patients developed a severe thrombo-
cytopenia requiring at least one thrombocyte infusion. In ten out of fourteen patients the thrombocytes 
were above 150 x 109/L at the end of the first cycle of RIT, however none of the patients reached their 
pre-RIT thrombocyte levels. In the seven patients receiving a second therapeutic injection, the 
hematological toxicity was milder than after the first RIT cycle, however, slow recovery from 
myelotoxicity precluded a third treatment cycle in five patients. Transient grade 3-4 leucocytopenia 
was observed in nine patients, with the nadir at a median of six weeks after the therapeutic injection 
(figure 4). Four patients developed grade 4 neutropenia, of which three patients required 
Despite stabilizati on of disease in the chest and abdomen aft er RIT 1 in pati ent #7, a new bone 
lesion in the right shoulder detected with 111In-girentuximab scinti graphy at the start of the second 
RIT cycle indicated progressive disease. Magneti c Resonance Imaging (MRI) of the right shoulder 
confi rmed this observati on. Therefore the pati ent was excluded from the study.
Figure 7.3 111In-girentuximab imaging at the start of RIT 1 and RIT 2 
 and MRI image of right shoulder during RIT 2
pre RIT 1 pre RIT 2
MRI
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Figure 7.4 Leuco- and thrombocyte counts during RIT 1 and RIT 2
Thrombo- and leucocyte counts are presented as mean ± standard error of the mean (s.e.m.).
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hospitalization due to febrile neutropenia. Apart from the myelotoxicity, treatment with 
177Lu-girentuximab was generally well tolerated, as thirteen patients experienced mild (grade 1-2) 
adverse events, such as fatigue, anorexia, vomiting, nausea and diarrhea. Only two cases of grade 3 
adverse events were observed: fatigue (n=1) and anorexia (n=1). No allergic reactions due to the 
girentuximab infusions were observed.
Of the six patients who were treated with VEGFR TKIs afterwards, three patients could not be optimally 
dosed due to myelotoxicity. Patient #1 was treated with sunitinib 50 mg in a 4/2 scheme and 
experienced grade 4 thrombocytopenia, which was complicated by a subarachnoidal bleeding. The 
dose had to be reduced to 25 mg in a 2/1 scheme in order to keep the thrombocytes above 50 x 109/L. 
This patient had progressive disease after six months of treatment and did not restart any other 
therapy. Patient #10 experienced grade 3 thrombocytopenia and leucocytopenia after starting 
sunitinib 50 mg in a 4/2 scheme. Later, he was treated with sunitinib 37.5 mg in a 3/1 scheme and 
experienced grade 1 myelotoxicity without complications for six months. Patient #16 recently started 
treatment with sunitinib 37.5 mg continuously, but because of a rapidly developing thrombocytopenia, 
the dose was reduced to 25 mg continuously.
discussion
177Lu-girentuximab RIT resulted in stabilization of previously progressive disease in nine out of 
fourteen patients with advanced ccRCC. The mean growth rate of the target lesions decreased after 
the first cycle of RIT (figure 2), although this result has to be viewed with caution as the overall results 
are clearly influenced by several outliers. RIT with 177Lu-girentuximab resulted in few side effects, 
although reversible grade 3-4 hematological toxicity was observed in all but one patients (table 2), 
which seems to be more profound than in the phase I trial(12). In the seven patients treated with two 
RIT cycles, successive injections with 177Lu-girentuximab at 75% of the previous activity dose did not 
result in higher toxicity levels. Because of the high incidence of grade 3-4 hematological toxicity, in 
future studies the currently used dose of 2405 MBq/m2 may have to be adjusted to allow all patients 
to complete the three treatment cycles in case of disease stabilization.
The results of the current study are encouraging, however, how girentuximab-based RIT should be 
implemented into clinical practice is not yet clear. At present, one of the biggest challenges is to 
identify patients who will benefit most from RIT. Previous studies indicate that RIT is mainly suitable 
for treatment of small volume disease or possibly as adjuvant treatment in selected cases(20, 26). 
Although our study was designed to evaluate the efficacy of 177Lu-girentuximab RIT in patients with 
metastatic ccRCC, it would also be worthwhile to test 177Lu-girentuximab RIT as adjuvant therapy in 
the future. In that case, the activity dose of 2405 MBq/m2 may should be lowered to prevent severe 
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myelotoxicity in an adjuvant setting and permit adequate treatment with TKIs in case of metastatic 
RCC after failure of the primary treatment.
Besides optimization of the timing of RIT in the management of ccRCC, personalized dosing based on 
dosimetric analysis of the data acquired during the pre-treatment 111In-girentuximab imaging is likely 
to improve 177Lu-girentuximab RIT. Previous studies have clearly shown the correlation between red 
bone marrow dose and hematological toxicity, and indicate that diagnostic data can be used to predict 
absorbed doses and myelotoxicity of girentuximab-mediated RIT(27, 28). This approach is of particular 
interest, as the trade-off between efficacy and toxicity can be tailored to the individual patient. In the 
near future, Positron Emission Tomography (PET) with zirconium-89 (89Zr) labeled girentuximab will 
be evaluated in ccRCC patients. Preclinical data indicate superior imaging characteristics compared to 
both the 111In-labeled and the radioiodinated anti-CAIX antibody(12, 29), and PET will allow more 
accurate quantification of activity doses in the relevant tissues. Our center is currently in the process 
of initiating a trial to evaluate the added value of 89Zr-girentuximab beyond clinical work-up in patients 
with good or intermediate prognosis metastatic ccRCC who are eligible for watchful waiting 
(NCT02228954). This trial is likely to improve our knowledge regarding identification of patients who 
benefit most from 177Lu-girentuximab infusions and will help towards patient-tailored dosing of RIT.
Last but not least, an important step to successfully implement girentuximab-based RIT is to determine 
the sequence of other treatment modalities such as VEGFR TKIs, the current standard of care in 
metastatic RCC. As we recently reported, treatment with VEGFR TKIs has a profound effect on the 
uptake of 111In-girentuximab in ccRCC lesions(30). Data from the latter study indicate that the tumor 
targeting of girentuximab-based RIT is severely hampered if given during VEFGR TKI treatment and 
that RIT should preferably be given either before VEGFR TKI treatment or after cessation of the VEFGR 
TKI treatment. Further studies are warranted to evaluate the duration of this VEFGR TKI-induced effect 
and could help to improve treatment strategies for metastatic ccRCC.
In conclusion, 177Lu-girentuximab RIT is promising in terms of clinical response in patients with 
progressive metastatic ccRCC and was generally well tolerated, although prolonged myelotoxicity 
prevented retreatment in some patients.
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aBstract
INTRODUCTION
Malignant ascites and pleural effusion are challenging clinical problems, with a major impact on 
quality of life. We conducted a randomized phase II trial to assess the palliative value of cediranib, an 
oral vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).
PATIENTS AND METHODS
After a baseline paracentesis or thoracentesis (on day 0), patients with symptomatic malignant ascites 
and/or pleural effusion were randomized between immediate treatment with cediranib (Immediate 
Cediranib) or delayed treatment with cediranib (Delayed Cediranib) on day 29, or after a new puncture 
was needed. The primary objective of the study was the puncture-free survival, defined as the time 
from study start (day 1) to the first need for paracentesis or thoracentesis, or time to death, whichever 
event occurred first.
RESULTS
Twelve patients were enrolled. The median puncture-free survival was 45 days (range 10 - 368) in the 
Immediate Cediranib patients and seven days (range 4 - 13) in the Delayed Cediranib patients 
(p=0.011). The change in puncture-free interval (the puncture-free survival after study start minus the 
puncture-free interval before study start) increased with a median of 31 days in the Immediate 
Cediranib patients and shortened with a median of three days in the Delayed Cediranib patients 
(p=0.015). The most common adverse events were fatigue and anorexia.
CONCLUSIONS
Cediranib increased the puncture free-survival and puncture free-interval with an acceptable toxicity 
profile. This is the first study in which an oral VEGFR TKI showed beneficial palliative effects in patients 
with malignant effusions.
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introduction
Malignant ascites and malignant pleural effusion are challenging clinical problems in cancer patients, 
which have a major impact on quality of life, especially when standard anti-cancer therapies are not 
available or no longer feasible. Ovarian- and gastrointestinal cancers are the most common causes of 
malignant ascites (1), while lung and breast cancer are the most common causes of malignant pleural 
effusion (2). In a survey among 209 patients with malignant ascites, 58% of patients had ascites-
related symptoms. The most frequently occurring symptoms were abdominal swelling, abdominal 
pain, nausea, anorexia, vomiting, fatigue, dyspnea and early saturation with eating (1). The main 
complaints of pleural effusion are dyspnea, cough, and chest pain(3). The prognosis of malignant 
ascites or pleural effusion is poor with a median survival of only 5.7 and 4 months, respectively (1, 3). 
Although paracentesis, diuretics and shunting are commonly used procedures as treatment for 
malignant ascites, the evidence for their efficacy is weak and no prospective randomized trials have 
been performed(4). For malignant pleural effusion thoracentesis, chemical and mechanical pleurodesis, 
pleural catheter drainage and pleuroperitoneal shunting are treatment options; however there is no 
universally accepted standard approach (3), and the results are often temporary. Repeated paracentesis 
or thoracentesis increases the risk of infection, perforation of abdominal organs or the lung, bleeding, 
and therefore the risk of hospitalization in a group of patients who are in the palliative phase of their 
disease. Therefore, there is a need for an effective palliative treatment that provides symptomatic 
relief from ascites and pleural effusions and that is associated with limited toxicity.
Preclinical and clinical studies have shown that malignant effusion is associated with high levels of 
vascular endothelial growth factor (VEGF) in serum/plasma as well as in malignant effusions (5-7). 
VEGF in malignant pleural effusion and ascites appears to be biologically active as demonstrated by its 
stimulating effect on endothelial cell proliferation (8).
Cediranib (AZD2171) is an oral VEGF receptor tyrosine kinase inhibitor (VEGFR TKI) with an inhibitory 
effect on all three VEGF receptors (VEGFR-1, 2 and -3) (9). Cediranib has been shown to have anti 
tumor activity as monotherapy in several cancers and the recommended dose is 45 mg once daily 
(10,11). Common adverse events include hypertension, fatigue, diarrhea and hoarseness (12).
We conducted a single center randomized phase II study of cediranib to determine the effect and 
safety of cediranib as palliative treatment of malignant ascites or pleural effusion.
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methods
PATIENTS
Eligible patients had symptomatic malignant ascites and/or pleural effusion, due to a histological 
proven solid malignancy which was refractory to standard anti-tumor therapy or for which no standard 
therapy existed. Patients were ≥18 years with a Karnofsky performance score of ≥ 50. Patients had 
adequate hematologic, renal and hepatic functions. Excluded were patients with a pleural or peritoneal 
tap, with a history of poorly controlled hypertension or with a resting blood pressure >150/100, with 
a prolonged QTc, or significant hemorrhage in the previous three months. Written informed consent 
was obtained before entering the study.
STUDY DESIGN
This was an open label, single center, randomized phase II study. Patients were randomized 1:1 
between “immediate treatment” with cediranib (Immediate Cediranib) on day 1, or “delayed 
treatment” with cediranib (Delayed Cediranib) on day 29, or after a subsequent puncture was required, 
whichever came first. All patients received best supportive care.
The primary objective of this study was to determine the effects of cediranib as palliative treatment of 
malignant ascites or pleural effusion, by assessment of the puncture-free survival, defined as the time 
from study start (day 1) to the first need for paracentesis or thoracentesis, or time to death, whichever 
event occurred first. The decision to perform a paracentesis or thoracentesis was taken on the basis of 
the symptoms of the patient and the amount of malignant effusion at that moment. The secondary 
objectives of this study were: 1. the change in puncture-free interval defined as the difference between 
the puncture free survival and the puncture free interval before start of the study (in days); 2. the 
puncture free survival after starting cediranib, defined as the time to first need for paracentesis or 
thoracentesis or time to death (whichever event occurred first) after starting cediranib (in days); 3. to 
assess the tolerability of cediranib in a palliative end-stage disease; and 4. to determine the overall 
survival (OS). This study was registered at ClinicalTrials.gov, number NCT01262612.
TREATMENT PLAN AND DOSE MODIFICATION
Patients were planned to start with the study at the time they needed a new paracentesis or thoracentesis 
due to increasing fluid accumulation and symptoms. The day that the patient underwent the paracentesis 
or thoracentesis was day 0 of the study. During every paracentesis or thoracentesis as much as possible 
effusion was removed. The starting dose of cediranib was 30 mg orally once daily. Special in this study 
was the possibility to decrease (to minimal 15 mg once daily) or re-increase the dose after a dose 
reduction for toxicity (to a maximum of 30 mg once daily) during the study to get an individualized 
optimal palliative treatment with cediranib. The maximum dose of cediranib was 30 mg and not 45 mg 
because of observed toxicities in other studies(12) and the pure palliative intention of the study. Patients 
were scheduled to continue cediranib as long as clinical benefit in relation to the malignant effusion was 
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experienced and side effects were acceptable, even when progressive disease was observed.
PATIENT EVALUATION AND FOLLOW-UP
Toxicity assessment, hematology, biochemistry and full physical examination and Karnofsky 
performance status were performed at baseline and weekly during the first two cycles of cediranib 
use, and thereafter once every eight weeks. VEGF was measured in plasma and in ascites or pleural 
effusion at screening visit and every time a puncture took place. Levels of VEGF were measured by a 
specific enzyme linked immunosorbent assay (ELISA) as previously described (13, 14). Tumor 
evaluations with computed tomography (CT) scans were performed at baseline, after one month and 
after every eight weeks. Response was evaluated according to the Response Evaluation Criteria of 
Solid Tumors (RECIST) version 1.1(15).
STATISTICAL ANALYSIS
We based our power calculation on the data of the catumaxomab phase II/III study as presented 
during the ASCO Annual Meeting in 2009 (16), where a median puncture-free survival of 44 days in the 
catumaxomab group was found compared to 11 days in the paracentesis only arm. Assuming a median 
puncture-free survival time of 44 days for the Immediate Cediranib patients and 11 days for the 
Delayed Cediranib patients, a total of sixteen patients per group was required to obtain a power of 
80% for an analysis of puncture free survival time using a two-sided alpha of 0.05. If the puncture-free 
survival in the Immediate Cediranib group was > 44 days, the treatment of ascites or pleural effusion 
with cediranib was assumed to be effective.
Kaplan-Meier survival curves were used to analyze the OS of the enrolled patients. The duration of OS 
was defined from the date of study start to the date of death. Differences in OS between the two 
groups were compared using the log-rank test. Analyses were done in SPSS version 20.0 and a P value 
of ≤0.05 was considered significant.
results
Between April 2010 and January 2012, twelve patients were enrolled in the study; six were randomized 
for immediate starting with cediranib and six for delayed starting (see figure 1). Patient characteristics are 
summarized in table 1. The study was discontinued prematurely after inclusion of twelve patients. Reasons 
to stop the study prematurely were: (1) a difficult accrual and (2) the decision to stop further development 
of cediranib by AstraZeneca due to the disappointing results of two large phase II-III trials (17,18). In the 
Delayed Cediranib group, five out of six patients started cediranib after their first paracentesis or 
thoracentesis (all before day 29). In one patient cediranib was not started due to an ileus. One patient in 
the Delayed Cediranib group only used cediranib for one day because of rapid clinical deterioration.
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Figure 8.1 CONSORT fl ow diagram
Assessed for eligibility n=12
Randomized n=12
Excluded n= 0 
Group: Delayed treatment with Cediranib n=6  
On day 0 ascites puncture or thoracentesis
If necessary ascites puncture or thoracentesis: n=6
On day 1 aft er puncture start cediranib 30 mg 
Received cediranib aft er fi rst puncture n=5  
Did not receive cediranib aft er fi rst puncture due to 
deteriorati on of conditi on n=1
Lost to follow-up: n=0
Disconti nued cediranib due to:
Deteriorati on with pleural eff usion n=1
Deteriorati on with pleural eff usion and ascites n=1
Deteriorati on n=3
Analysed: n=6
Group: Immediate treatment with Cediranib n=6 
On day 0 ascites puncture or thoracentesis
On day 1 start cediranib 30 mg n=6
If necessary ascites puncture or thoracentesis: n=2 
Lost to follow-up: n=0
Disconti nued cediranib due to:
Deteriorati on with ascites n=1
Deteriorati on n=3
Death due to deteriorati on n=2
Analysed: n=6
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If necessary ascites puncture or thoracentesis: n=6
On day 1 aft er puncture start cediranib 30 mg 
Received cediranib aft er fi rst puncture n=5  
Did not receive cediranib aft er fi rst puncture due to 
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Disconti nued cediranib due to:
Deteriorati on with pleural eff usion n=1
Deteriorati on with pleural eff usion and ascites n=1
Deteriorati on n=3
Analysed: n=6
Group: Immediate treatment with Cediranib n=6 
On day 0 ascites puncture or thoracentesis
On day 1 start cediranib 30 mg n=6
If necessary ascites puncture or thoracentesis: n=2 
Lost to follow-up: n=0
Disconti nued cediranib due to:
Deteriorati on with ascites n=1
Deteriorati on n=3
Death due to deteriorati on n=2
Analysed: n=6
Pati ent 
no.
Age 
(years)
Sex PS Tumor Prior 
lines 
chemo-
therapy
Ascites / 
pleural 
eﬀ usion*
Group: Immediate treatment with Cediranib
1 49 M 80 Mixed germ cell carcinoma of the testi s 5 Ascites
05 58 F 60 Papillary serous adenocarcinoma of the 
ovary            
3 Pleural eff usion
07 79 F 80 M. Paget of the mamma                              1 Ascites
08 49 M 50 Malignant mesothelioma 
of the tunica vaginalis                   
2 Ascites
11 58 F 60 Adenocarcinoma of the pancreas            2 Ascites
12 62 F 50 Papillary serous adenocarcinoma 
of the ovary                
2 Ascites
Group: Delayed treatment with Cediranib
02 56 M 70 Peritoniti s carcinomatosa with strong 
CEA expression of the colon          
2 Ascites
03 62 F 70 Extra ovary ovarian adenocarcinoma        5 Ascites
04 55 M 80 Sclerosing epitheloid fi brosarcoma 
of the foot          
1 Pleural eff usion
06 67 F 60 Papillary serous adenocarcinoma 
of the ovary          
1 Ascites 
09 63 M 80 Adenocarcinoma of the esophagus            2 Pleural eff usion
10 47 F 70 Adenocarcinoma of the mamma and 
serous papillary adenocarcinoma 
of the ovary
3 Pleural eff usion
Table 8.1 Pati ent characteristi cs
M = Male  F = Female  PS = Performance status
* = Pati ents with ascites and pleural eff usion are categorized in the group (ascites or pleural eff usion) troubling them most
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PUNCTURE-FREE SURVIVAL AND PUNCTURE-FREE INTERVAL
The two patient groups did not significantly differ in the puncture-free interval before start of the 
study or the amount of fluid removed before the study and on day 0 (see table 2). The primary 
objective of this study was the median puncture-free survival, which was longer in the Immediate 
Cediranib group (45 days) compared to the Delayed Cediranib group (7 days: p=0.011) (see figure 2). 
Furthermore, the change in puncture free-interval showed in the Immediate Cediranib patients a 
median improvement of 31 days, but in the Delayed Cediranib group a decline of three days (p=0.015) 
(table 2). The median puncture-free interval after starting cediranib was 45 days in the Immediate 
Cediranib group versus 14 days in the Delayed Cediranib group, this was not a significant difference 
(table 2). One patient with a chemorefractory germ cell tumor used the cediranib for more than one 
year and never needed an ascites puncture again. After six months the cediranib dose was reduced to 
20 mg because of fatigue, and four months later the dose was further decreased to 15 mg because of 
anorexia and fatigue, and patient continued cediranib treatment until two days before his death.
The puncture free survival defi ned as the ti me to fi rst need for paracentesis or thoracentesis or ti me 
to death, whichever event occurred fi rst aft er start of the study (in days) in the two study groups 
(Immediate treatment with Cediranib and Delayed treatment with Cediranib).
Figure 8.2 Puncture free survival
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VEGF IN PLASMA AND ASCITES OR PLEURAL EFFUSION
At baseline, the median plasma VEGF concentration was 1.45 ng/ml (range 0.96 - 2.46 ng/ml), the 
median VEGF concentration in pleural effusion was 14.87 ng/ml (range 1.4 - 24.43 ng/ml), and the 
median VEGF concentration in ascites was 28.09 ng/ml (range 9.86 - 51 ng/ml). We found no correlation 
between the VEGF concentration in plasma and ascites or pleural effusion at baseline and the primary 
and secondary endpoints as puncture-free survival, puncture-free interval, puncture-free interval 
after starting cediranib, or overall survival (data not shown).
SAFETY AND TOLERABILITY
Adverse events are shown in table 3. There were no treatment-related deaths. One patient in the 
Delayed Cediranib group was admitted to the hospital prior to the initiation of cediranib treatment 
and received red blood cell transfusion due to bleeding after paracentesis at baseline. Three patients 
were hospitalized because of an ileus due to disease progression. As expected the most common 
grades 3 and 4 toxic effects included fatigue and anorexia, which was in less than half of the cases 
related to cediranib use: most adverse events were strongly related to the underlying disease like 
anorexia, nausea, fatigue and weight loss.
All patients started with Cediranib at a dose of 30 mg. Dose reductions to 20 mg were performed in 
three patients, in two of them due to fatigue and in one because of mucositis and diarrhea. Two of 
these three patients needed a further dose reduction to 15 mg. Cediranib was temporarily discon-
tinued for reasons of radiotherapy, a combination of adverse events (a so called drug holiday) and 
hypertension.
TUMOR RESPONSE AND OVERALL SURVIVAL
Only three patients were in good enough clinical condition to perform a CT scan for evaluation of the 
tumor response, all three from the Immediate Cediranib group. We observed one partial response, 
one stable disease and one progressive disease. All three patients had an improvement in their 
puncture-free interval after starting cediranib. The patient with progressive disease lived for more 
than one year without the need for a new puncture. The median overall survival in the Immediate 
Cediranib group and the Delayed Cediranib group was 73 days (range 10-368) and 24 days (range 
19-36), respectively (p=0.087: table 2).
The puncture free survival defi ned as the ti me to fi rst need for paracentesis or thoracentesis or ti me 
to death, whichever event occurred fi rst aft er start of the study (in days) in the two study groups 
(Immediate treatment with Cediranib and Delayed treatment with Cediranib).
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discussion
To our knowledge, this is the first phase II study of an oral VEGF inhibitor for the palliative treatment 
of malignant ascites and/or pleural effusion. We showed that it was feasible to treat patients with 
symptomatic malignant ascites and/or pleural effusion with cediranib, and although the groups were 
very small, there is a strong suggestion of clinical benefit on ascites or pleural effusion during the use 
of cediranib. We found a significant and meaningful longer median puncture-free survival (primary 
objective) and an increased puncture-free interval in the Immediate Cediranib group (45 days) 
compared to the Delayed Cediranib group (7 days). Cediranib was well tolerated most of the time 
although dose reduction took place in 25% of the patients and short “drug holidays” were sometimes 
necessary.
Our results are in line with the outcomes of the phase II/III trial with catumaxomab for the treatment 
of malignant ascites in epithelial cancer (19). In this study, catumaxomab was administered after 
paracentesis as a six hour intraperitoneal infusion on days 0, 3, 7, and 10 and compared to paracentesis 
alone. In the catumaxomab arm, the puncture-free survival was significantly longer compared to the 
paracentesis only arm (46 days versus 11 days). Catumaxomab has recently been approved in Europe 
for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial 
tumors where standard therapy is not available or no longer feasible. Catumaxomab was also tested in 
a phase I/II study in patients with malignant pleural effusion(20). The investigators concluded that 
intrapleural catumaxomab was feasible in this group, but considering the substantial number of 
drop-outs and deaths in short proximity to study treatment, there was doubt if malignant pleural 
effusion was the right indication(20). In our study, we only had four patients with pleural effusion; 
after start with cediranib, two of them did not need a new thoracentesis. The results of another trial 
concerning a palliative treatment of malignant ascites by blocking VEGF with an intravenous infusion 
of aflibercept every two weeks were recently published (21,22). The recombinant fusion protein, 
aflibercept binds and neutralizes VEGF A, VEGF B, and placental growth factor(23). In the phase II 
placebo-controlled study, the drug showed clinical activity in patients with advanced ovarian cancer 
and recurrent symptomatic malignant ascites. The time to repeat paracentesis and paracentesis-free 
survival were significantly longer with aflibercept than with placebo (55.5 days versus 7.7 days), and 
there was a greater mean improvement from baseline in symptoms of ascites. However, in the 
treatment group, three out of 29 patients developed a fatal intestinal perforation versus one in the 
placebo group(22). Gastrointestinal perforation is also a well-known complication of anti-VEGF 
treatment with bevacizumab in ovarian carcinoma patients(24). No perforation events were observed 
in our study or in a phase II study with 46 ovarian carcinoma patients treated with cediranib(12).
Consistent with others, we found that the VEGF levels in ascites and pleural effusions were much 
higher than in matched plasma samples(5). We found no indication that the VEGF values at baseline 
could predict the course of the disease or the reaction on cediranib.
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A limitation of our study is the low number of patients participating. We had problems with including 
the 32 patients as was intended. Frequently, this was due to rapid disease progression before 
screening. Our difficulties with the study accrual are a reflection of the fragile patient population with 
malignant ascites or pleural effusion, and this is also seen in other studies(22).
Given the palliative setting and the poor prognosis of patients with malignant ascites or pleural 
effusion, cediranib may have the right profile to be an effective and tolerable palliative treatment, 
especially because of its oral administration and the short elimination half-life (9), which makes careful 
titration possible. In this study, we performed a puncture at the start of the study, but with the 
experience we already have with cediranib and other oral VEGF TKIs, we presume that a puncture 
before starting the medication is not necessary in the majority of patients. When cediranib is effective, 
it will reduce the malignant effusion rapidly in a non invasive manner. The effects of cediranib on 
malignant effusions are probably a class effect of all VEGF TKIs.
In conclusion, our data strongly suggest a palliative effect for an oral VEGFR TKI in the treatment of 
malignant ascites or pleural effusion. This palliative effect may even continue after formal tumor 
progression has been documented, and therefore no official tumor evaluation by RECIST criteria is 
warranted. Although confirmation of these results by a larger prospective placebo-controlled trial 
would be preferred, the feasibility in terms of patient accrual rate appears low. Our data suggest that 
an oral anti-VEGFR treatment may be considered in patients with malignant effusions.
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aBstract
INTRODUCTION
Diarrhea is a frequently occurring adverse event during treatment with vascular endothelial growth 
factor receptor tyrosine kinase inhibitors (VEGFR TKIs) and is mostly accompanied by abdominal 
cramps, flatulence and pyrosis. These complaints impair quality of life and lead to dose reductions and 
treatment interruptions. It is hypothesized that the diarrhea might be due to ischemia in bowel 
mucosa or inflammation, but the exact underlying pathophysiological mechanism of the diarrhea is 
still unknown. We aimed at exploring the mechanism for diarrhea in these patients by thorough 
endoscopic and histological assessment.
MATERIALS AND METHODS
Endoscopies of the upper and lower gastrointestinal(GI) tract in ten patients with metastatic renal cell 
carcinoma (mRCC) who developed diarrhea during treatment with VEGFR TKIs were performed.
RESULTS
Ten patients were included. The results showed endoscopically normal mucosa in the lower GI tract in 
seven patients without signs of ischemic colitis or inflammation. Gastroduodenoscopy revealed 
gastro-esophageal reflux disease, bulbitis and/or duodenitis with ulcers in eight patients. In three 
selected patients with bulbitis/duodenitis additional video capsule endoscopy was performed but 
revealed no additional intestinal abnormalities.
CONCLUSION
We observed frequent mucosal abnormalities in the upper GI tract in VEGFR TKI treated mRCC patients 
with diarrhea. Although these abnormalities provide insufficient explanation for the occurrence of 
diarrhea, we suggest to perform routine upper GI endoscopy in VEGFR TKI treated patients with GI 
complaints.
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introduction
Tyrosine kinase inhibitors (TKIs) of the vascular endothelial growth factor receptors (VEGFR), such as 
sunitinib, sorafenib and pazopanib, have improved survival in patients with metastatic RCC. These 
drugs showed to increase progression free survival and stabilization of the disease compared to 
interferon alpha(1, 2) or placebo(3, 4). VEGFR TKIs inhibit angiogenesis, cell proliferation and tumor 
cell invasion. In general, VEGFR TKIs are tolerated reasonably well, but diarrhea is a frequently reported 
side-effect(1, 3-7) which may persist for a prolonged period of time. In 53% of 375 patients treated 
with sunitinib diarrhea was observed and in 5% of cases it was severe, defined as grade 3 diarrhea 
according to the common terminology criteria for adverse events (CTCAE)(1). A phase III study with 
pazopanib reported similar percentages, 52% of patients having diarrhea which was severe diarrhea in 
4% (4).
Diarrhea negatively influences the quality of life due to flatulence, cramps, urge and fecal incontinence. 
Furthermore, diarrhea can necessitate dose reductions or interruptions, potentially leading to less 
effectiveness of treatment. Therefore, it is of utmost importance to understand, treat and if possible 
prevent VEGFR TKI- induced diarrhea.
Despite its frequent occurrence, the etiology and pathophysiological mechanisms that lead to diarrhea 
in patients treated with VEGFR TKIs have not been clarified yet. Several potential causes for diarrhea 
in these patients have been previously suggested. VEGFR TKIs do not exclusively inhibit the vasculature 
of tumors, but also have their effect on the blood supply of healthy organs. Cases have been published 
in which ischemic colitis and perforation have been reported after treatment with bevacizumab and 
VEGFR TKIs(8-12). Chronic low-grade ischemia can also occur and lead to chronic symptoms. We 
hypothesized that ischemic conditions in the bowel mucosa might lead to the diarrhea in patients 
treated with VEGFR TKIs. Second, it is known that angiogenesis is involved in the pathogenesis of 
inflammatory bowel diseases(13, 14). It may be that inflammation has a role in the pathogenesis of 
the diarrhea.
In order to explore possible causes of diarrhea in patients who developed diarrhea during treatment 
with a VEGFR TKI, including intestinal ischemia and mucosal inflammation, we performed an endoscopy 
of the upper and lower gastrointestinal (GI) tract.
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material and methods
Ten consecutive patients on VEGFR TKI treatment for metastatic RCC who developed diarrhea of any 
grade according to the common terminology criteria of adverse events (CTC AE)(15) were asked for 
participation in this study. Diarrhea was defined as the sudden deviation of normal bowel movements, 
with a higher frequency of bowel movements (at least three times a day), a larger quantity and feces 
containing more water than before. Patients with a known history of bowel diseases such as inflam-
matory bowel disease, lactose intolerance or celiac disease were excluded. Patients using laxatives on 
a regular basis were also excluded.
The medical ethical committee of our institute (nr 2011/151) approved this study. After providing 
written informed consent, a thorough history was taken, covering all aspects of diarrhea and 
accompanying GI complaints in relation to treatment with the VEGFR TKI. In all patients, both a sigmoi-
doscopy and gastroduodenoscopy were performed. At least two biopsies from stomach, duodenum 
and sigmoid each were taken on formalin and liquid nitrogen and stored on -20°C until analysis. In case 
of macroscopic abnormalities targeted additional biopsies were taken. A pathologist with expertise in 
GI diseases (IN) assessed all biopsies in a systematic way. In the context of the “ischemic” hypothesis, 
additional immunohistochemical stainings on stomach, duodenal and sigmoid biopsies for CD31 
(marker for endothelial cells), D2-40 (marker for lymphatic endothelial cells) and VEGFR2 (the receptor 
that mediates almost all of the known cellular responses to VEGF) were done. Stainings for cytomega-
lovirus (CMV) and helicobacter pylori were performed to rule out an infectious cause.
results
PATIENTS
Ten patients with metastatic clear cell RCC were enrolled between November 2011 and March 2013. 
Patient characteristics are described in table 1. Nine patients were treated before study entry with 
sunitinib for a median duration of 11 months. One patient was on treatment with cediranib 30 mg 
once daily in a phase I study since 62 months. The median duration of therapy before occurrence of 
the diarrhea was 5 months (range 1-14 months), including four patients complaining of diarrhea since 
the first cycle. Patients complained about frequent bowel movements, median 4 to 5 times a day, 
typically starting in the late afternoon or early after dinner and occurring within a short time interval 
e.g. two or three times in 30 minutes time (see table 2). Seven patients also reported nocturnal bowel 
movements necessitating passing stools at night. Five patients reported fecal incontinence. In eight 
patients, the diarrhea was accompanied with abdominal cramps and/or flatulence. Patients did not 
report undigested food, blood or mucus in the stools, nor did they describe the typical findings of 
steatorrhoe (pale, greasy, voluminous stools). Seven patients used loperamide chronically to control 
Pat. 
no.
TKI Dosage
(per day)
Age 
(year)
Sex BMI Months on 
treatment
Start of 
diarrhea 
(months on 
treatment)
Concomitant 
medicati on
1 suniti nib 37,5 mg 
CDD
63 M 26,4 12 7 amlodipine, loperamide
2 suniti nib 37,5 mg 
CDD
59 F 24,1 36 3 atenolol, levothyroxine, 
loperamide
3 suniti nib 50 mg 
4/2
47 M 26,4 17 7 amlodipine, atenolol, 
lisinopril, loperamide, 
omeprazole
4 suniti nib 37,5 mg 
CDD
58 M 23,9 11 7 amlodipine, 
levothyroxine, 
lisinopril, loperamide, 
pantoprazole
5 cediranib 30 mg 
CDD
66 M 25,0 62 14 amlodipine, doxycyclin, 
levothyroxine, 
loperamide
6 suniti nib 50mg 
4/2
61 M 27,4 7 1 amlodipine, ASA, 
hydrochlorothiazide
7 suniti nib 25 mg 
CDD
60 M 43,7 10 1 amlodipine, atenolol
8 suniti nib 37,5 mg 
CDD
65 M 28,1 10 7 ASA, furosemide, 
isosorbide mononitrate, 
lisinopril, loperamide, 
metf ormin, nebivolol, 
oxycodone, 
pantoprazole, 
simvastati n
9 suniti nib 37,5 mg 
4/2
61 M 28,1 26 1 ASA, atorvastati n, 
chlortalidone, 
clopidogrel, diazepam,  
isosorbide mononitrate, 
loperamide, 
losartan, metoprolol, 
pantoprazole
10 suniti nib 37,5 mg 
CDD
50 M 25,7 9 1 none
Table 9.1 Pati ent characteristi cs
Pt. no. = Pati ent number  TKI = Tyrosine kinase inhibitor  CDD = Conti nous daily dosing  4/2 = Four weeks on, two weeks off 
M = Male  F = Female  BMI = Body mass index  ASA = Acetylsalicylic acid
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their complaints. All patients changed their food and drinking habits in an attempt to diminish the 
complaints: milk products, fat and spicy food were banned from the menu, with variable results.
ENDOSCOPY: MACROSCOPIC FINDINGS
In half of the patients the sigmoidoscopy showed macroscopic abnormalities with swollen mucosa, a 
polyp in the rectum, impression from outside accompanied by an ulcer, teleangiectasias and diverti-
culosis all occurring once (see table 3). With gastroduodenoscopy macroscopic abnormalities were 
found in eight out of ten patients (table 3). Five patients had gastro esophageal reflux disease (GERD) 
and four patients had endoscopic signs of bulbitis/duodenitis with ulcers. In one patient with a long 
history of heartburns and a family history of reflux esophagitis, a carcinoma in situ of the esophagus 
was found, which was treated subsequently by endoscopic mucosal resection.
ENDOSCOPY: MICROSCOPIC FINDINGS
The microscopic findings of the biopsies in patients by sigmoidoscopy and gastroduodenoscopy are 
shown in table 3. Biopsies of the sigmoid showed abnormalities in three patients: a hyperplastic polyp, 
localization of RCC in the submucosa/lamina propria and aspecific abnormalities in architecture with 
focal bleeding. In three patients the staining for VEGFR2 showed an increase of VEGFR2 in the 
epithelium and subepithelium of the sigmoid.
In biopsies of stomach and duodenum, six cases of chronic inflammation were found (60%), three 
cases of active inflammation, intestinal metaplasia and angiodysplasia (30%) and two cases of proton 
pump inhibitor effect, reactive gastropathy and infection with helicobacter pylori each (20%). Stainings 
for CMV, D2-40 and CD31 were normal in all patients.
Pati ent Frequency
(per day)
During night Cramps Flatulence Pyrosis
1 4-5 Y N Y N
2 5-6 Y N Y N
3 4 Y Y Y Y
4 5-6 Y Y N Y
5 3-4 N N Y N
6 4 N N N Y
7 2-4 N N N N
8 5-6 Y Y Y Y
9 >7 Y Y Y Y
10 3 Y Y Y Y
Table 9.2 Pati ents’ complaints of diarrhea and other gastrointesti nal adverse events
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ADDITIONAL TESTS
When we found the mucosal abnormalities such as ulcers and erosions, in the duodenum and bulbus 
of four patients, we hypothesized that this might explain the diarrhea and subsequently, three patients 
underwent a video capsule endoscopy (VCE) in order to assess the entire small intestine.
In two patients small angiodysplasias, superficial erosive lesions and microscopic haemorrhages were 
observed in the entire small intestine. In one patient the lesions were mostly localized in the most 
distal part of the small intestine and also in the right-sided colon. No ulcers were observed. In the last 
patient only very few superficial erosions were seen.
discussion
Diarrhea is a frequently occurring adverse event of treatment with VEGFR TKI, which could lead to 
dose interruptions or reductions and diminish quality of life. The endoscopies performed in our study 
showed no definitive evidence for ischemia or inflammation as the cause of the diarrhea. Unexpectedly, 
we found focal mucosal abnormalities such as erosions and ulcers in esophagus, stomach and 
duodenum in the majority of patients.
Despite the high prevalence of the diarrhea in patients with VEGFR TKI and the negative consequences 
on quality of life, research focusing on the cause of this adverse effect is scarce. As far as we know, no 
other cross-sectional studies in which endoscopy was performed had been published before. Thus far, 
only a retrospective case series was published in which colonoscopy was performed in patients treated 
with bevacizumab, which showed bowel mucosa changes consistent with ischemic colitis. However, 
these patients had severe anal pain and bowel perforation(8).
The first hypothesis of ischemia is supported by preclinical research in mice by Kamba et al.(16) which 
showed that capillaries of healthy tissue in adult mice regressed in reaction to anti-VEGF therapy. After 
anti-VEGF therapy for two to three weeks, 20-46% of capillaries in the microvilli in the small intestine 
regressed. In our study, neither endoscopic evaluation showed macroscopic signs of ischemia, nor did 
(immune)histological examination. The results of this study also did not give any indication that 
inflammation is involved in the pathogenesis of diarrhea. Biopsies of the sigmoid were almost 
exclusively normal as well as the macroscopic pictures were. Histology of biopsies of the upper GI tract 
showed signs of focal chronic and acute inflammation. However, the VCE, performed in three patients, 
showed only limited and patchy abnormalities in the small intestine. Since the predominantly 
occurrence of abnormalities in the upper GI tract, this is not a plausible explanation for the diarrhea.
A study performed by Mir et al. did show that the diarrhea and hypophosphatemia which developed 
in eight patients treated with sorafenib was due to a pancreatic exocrine dysfunction(17). Pancreatic 
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exocrine dysfunction leads to malabsorption, as well as other disorders such as celiac disease, lactose 
intolerance and short bowel syndrome. A malabsorption syndrome could explain the macrocytosis, 
vitamin B12 deficit(18, 19) and weight loss despite a normal caloric intake which often develops in 
patients who are treated with VEGFR TKIs. Because of the nature of this study, we were not able to 
investigate non-mucosal diseases such as pancreatic exocrine dysfunction. This should be the scope of 
new studies.
In this study, five out of ten patients showed signs of GERD. In addition, one patient was diagnosed 
with a carcinoma in situ of the esophagus. Three patients used acetylsalicylic acid (ASA), which is a 
known risk factor for the development of gastric and esophageal mucosal injury(20). However, two of 
these patients also used a proton pump inhibitor in combination with ASA to protect their mucosa for 
the detrimental effects. In this study, seven patients had a body mass index (BMI) above 25 (table 1) 
and were thus overweight, which is also a known risk factor for GERD. However, one of the patients 
with a healthy weight suffered from GERD, whereas the patient with very severe obesity did not have 
any abnormalities. Four of the five patients with GERD were symptomatic and complained of pyrosis, 
which started since the initiation of treatment with the VEGFR TKI. Because of the non-prospective 
nature of our study, a causal relationship between the reflux disease and the use of VEGFR TKI could 
not be evaluated.
In conclusion, this study did not support an ischemic or inflammatory cause as the underlying pathop-
hysiological mechanism for diarrhea in patients treated with VEGFR TKIs. However, as an unexpected 
result, we found mucosal abnormalities such as erosions and ulcers in esophagus, stomach and 
duodenum in the majority of patients. Based on these results, we recommend routine gastroduo-
denoscopy in patients treated with VEGFR TKIs who report gastrointestinal symptoms, in order to 
timely diagnose and treat these abnormalities.
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aBstract
INTRODUCTION
To gain greater insight into the biological mechanisms occurring shortly after discontinuation of VEGFR 
TKIs because of progressive disease (PD).
PATIENTS AND METHODS
Sixteen patients with PD during treatment with sorafenib or sunitinib were randomized to either 
directly stop the VEGFR TKI or to continue for another two weeks. At baseline (i.e. at the moment of 
PD) and after two weeks FDG-PET/CT, functional-MRI and blood biomarkers of disease were performed.
RESULTS
A statistically significant difference in median change from baseline to two weeks later in Ktrans and 
LDH levels was observed between patients who directly stopped versus those who continued 
treatment (1.6 s-1 versus -1.1s-1, p=0.03; -73.0 U/L versus 52.0 U/L, p=0.008; respectively). There were 
no further differences between groups.
CONCLUSION
Two weeks after discontinuation of VEGFR TKIs in mRCC because of PD, a rise in Ktrans accompanied by 
a decrease in LDH indicates an increase in tumor vascularization. This implies that at the moment of 
PD the effect of VEGFR TKIs is not completely exhausted.
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introduction
In clear cell renal cell carcinoma (RCC) a loss of function of the Von Hippel-Lindau (VHL) gene product 
leads to accumulation of the hypoxia inducible factor 1α (HIF-1α), with subsequent upregulation of 
HIF target genes, including vascular endothelial growth factor (VEGF)(1-3). These biological insights 
provided the rationale to target the VEGF pathway to treat metastatic RCC (mRCC). A number of VEGF 
receptor tyrosine kinase inhibitors (VEGFR TKIs) has been approved for the treatment of mRCC, such 
as sunitinib, sorafenib, and more recently pazopanib and axitinib.
Treatment with VEGFR TKIs is continued until progressive disease (PD) or intolerable toxicities occur. 
After discontinuation because of PD, a range of clinical sequelae is seen. Most patients will have an 
indolent course with slowly-progressing tumors, but in approximately 10% of all RCC patients 
accelerated tumor growth is described(4, 5). The biological mechanisms of this so-called flare-up 
syndrome are poorly understood.
It has been hypothesized that during therapy with VEGFR TKIs, due to VEGF blockage and tumor 
hypoxia, up-regulation of pro-angiogenic genes and proteins (such as VEGF, PDGF, fibroblast growth 
factor, angiopoietin and interleukin-8) may occur. When treatment is stopped rapid revascularization 
and cell proliferation can occur due to the abundance of angiogenic factors(6). Apart from these 
mechanisms, it is hypothesized that a more malignant tumor phenotype during treatment may 
develop due to selection of hypoxia-tolerant tumor cells and metastatic conditioning(7, 8).
Flare-up syndromes have a negative impact on the quality of life and can preclude the start of a next 
line of therapy due to rapid deteriorating of the clinical condition. Insights in the biological mechanisms 
occurring after discontinuation of VEGFR TKIs due to progressive disease are necessary to be able to 
determine the optimal management strategy for these patients.
To gain greater insight, we performed a randomized study in patients with mRCC at the moment of 
progression during treatment with VEGFR TKIs. We performed functional MR imaging, 
18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and obtained biological markers of 
disease progression.
patients and methods
STUDY DESIGN
Patients with mRCC with PD as assessed by RECIST during either sorafenib or sunitinib treatment were 
eligible for this single centre randomized study. The clinical condition of the patients should permit 
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continuation of the same VEGFR TKI treatment for two more weeks. Baseline measurements (i.e., at 
the moment of PD) were performed during active treatment and consisted of physical examination, 
assessment of adverse events according to the common terminology criteria for adverse events 
(CTCAE) version 3.0(9) and measurement of biomarkers of disease including plasma VEGF, C-reactive 
protein (CRP), D-dimer, lactate dehydrogenase (LDH) and regulatory T-cells (Tregs). In all patients, 
FDG-PET/CT to assess tumor metabolism was mandatory. Functional MR imaging (fMRI) to assess 
changes in tumor perfusion was optional in patients with abdominal RCC lesions with a diameter of at 
least two centimeters and without contra indications for MRI. After baseline measurements, patients 
were randomized in a 1:1 ratio to continue the current VEGFR TKI for two more weeks or discontinue 
immediately. After two weeks, baseline measurements were repeated, including a contrast-enhanced 
CT scan to evaluate changes in tumor size according to RECIST version 1.1(10). The study was approved 
by the medical ethics committee. All patients provided their written informed consent before any 
study procedure.
FDG-PET/CT
Patient preparation and PET/CT acquisition and processing parameters were in strict accordance to 
the Dutch (NEDPAS) and European Association of Nuclear Medicine (EANM) standardization 
guidelines(11, 12). PET scans were acquired on a hybrid PET/CT scanner (Biograph Duo, Siemens 
Medical Solutions Inc., Malvern, Pa., USA). Up to five target lesions per patient were identified and for 
quantitative assessment of these lesions, regions of interest (ROI) around the whole tumor were 
obtained semi-automatically. FDG accumulation for each voxel within the ROI was registered in MBq/
ml. This was corrected for the injected dose of FDG, patients’ body weight and time elapsed between 
injection and scanning to obtain the standardized uptake value (SUV). Volumes of interest (VOIs) were 
delineated using 50% and 70% isocontour thresholds based on a fixed percentage of the maximum 
activity within the lesion. As such, the maximum SUV, SUV50 and SUV70 within the VOI could be 
determined. The total lesion glycolysis (TLG) per patient was calculated by summing the products of 
the mean SUV within the VOI and the volume of that VOI. The fractional change (∆) in the mean SUV 
per patient and TLG between FDG-PET/CT at baseline and after two weeks was calculated and 
expressed in percentage.
FUNCTIONAL MR IMAGING
After conventional T1- and T2-weighted imaging diffusion weighted MRI (DWI), dynamic contrast-en-
hanced MRI (DCE-MRI) and T2* perfusion MRI were acquired. Sequence parameters are listed in 
table 1. Breath-hold DWI was obtained using three gradient factors (b=50, 300 and 600 s/mm2) after 
maximal expiration. After administration of 15 ml 0.5M Gadolinium (Gd)-DTPA the DCE-MRI sequence 
was performed with a temporal resolution of 2 seconds during 5 minutes. A second bolus of 15 ml 
0.5M Gd-DTPA was administered iv followed by dynamic T2* weighted echo-planar measurements 
during 90 sec in order to measure perfusion(13). For quantification, one tumor in the abdomen was 
selected and ROIs were drawn around the whole tumor. Tumor apparent diffusion coefficient (ADC) 
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(s/mm2) maps and Tofts parameters were calculated. (Mevislab, Siemens Syngo VB15). The Tofts 
parameters include Ktrans, a volume transfer constant (s-1), ne which is the volume of the extravascular 
extracellular space (EES) per unit volume of tissue and kep the flux rate constant between EES and 
plasma (s-1) (kep = K
trans /ne). Higher values of kep or K
trans can indicate higher perfusion, higher 
permeability and/or a larger blood vessel surface area, globally denoting an increased tumor vascula-
rization(14). Using T2* images, ROIs were drawn around the tumor and the aorta in order to calculate 
tumor blood volume (tBV)(AU) and tumor blood flow (tBF)(AU/s) (Neuro Perfusion Evaluation, Siemens 
Syngo VB17)(15).
STATISTICS
To analyze the change from baseline to two weeks later in CT, FDG-PET/CT and MRI parameters and in 
blood biomarkers, the Wilcoxon-signed rank test was performed. Differences in change of the 
parameters from baseline to two weeks later between both groups were assessed using the 
Mann-Whitney test. The associations between parameter changes were tested using Spearman’s 
correlation test. All tests performed were two-sided and a p<0.05 was considered significant.
results
PATIENTS
Sixteen patients with mRCC were included in this study in our University Medical Center between 
October 2008 and January 2012. Baseline characteristics are provided in table 2. Nine patients were 
randomized for direct discontinuation of VEGFR TKI, seven patients continued their VEGFR TKI beyond 
progression for another two weeks. The median age of all patients was 61.5 years (range=48-79 years). 
3T ﬁ eldstrength DWI DCE MRI T2* MRI
TR (ms) 1800 39 1000
TE (ms) 62 2.08 23
FoV 360x317 350x263 320x180
Matrix 100x88 256x103
No. of slices 13 8 4
Thickness 10 7 10
α 45 90
Table 10.1 MRI parameters
DWI = Diff usion-weighted MRI  DCE-MRI = Dynamic contrast-enhanced MRI  TR = Repeti ti on ti me  TE = Echo ti me  FoV = Field of view
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Before PD occurred patients were treated for a median of 86 weeks (range=10-219). Of the ten 
patients using sutent, only four patients used sutent intermittently. In the context of this study patients 
restarted their sutent after the CT showed progression, so that at the moment of the first FDG-PET and 
MRI scan, these four patients used sutent for a minimum of one week. There were no significant 
differences in baseline characteristics between the groups. Two patients, both with pulmonary and 
pleural metastases, had a flare-up syndrome, consisting of development of dyspnea, cough and pleural 
effusion starting five to ten days after discontinuation of sorafenib (see figure 1). Both patients had an 
increase in tumor size on CT and one of the patients also developed new subcutaneous metastases. 
FDG-uptake, MRI parameters and biomarkers of these two patients were not different from the 
parameters observed in the other seven patients who directly discontinued treatment.
IMAGING RESULTS
The imaging results are summarized in table 3. Baseline parameter values were not significantly 
different between patients who directly stopped and patients who continued therapy. All patients 
underwent CT and FDG-PET scanning. All but one patient had FDG avid lesions. A total of 56 lesions 
was evaluated with FDG-PET, of which ten were located in bone, eleven in the lungs, thirteen in lymph 
nodes and eight in the liver. There were no significant differences in the change from baseline to two 
weeks later in values between both groups as assessed by RECIST and FDG-PET, indicating that discon-
tinuation of VEGFR TKI did not significantly affect tumor growth or tumor metabolism in the study 
Characteristi cs Disconti nuati on Conti nuati on
No. of pati ents 9 7
Sex Male 7 6
Female 2 1
Age (years) Median 59 68
Range 48-79 51-78
VEGFR TKI Suniti nib 6 4
Sorafenib 3 3
Durati on of therapy (months) Median 24.6 7.9
Range 8.1-49.5 2.3-27.5
Prior nefrectomy 7 6
Prior systemic therapy No 5 2
Yes 4 5
Prior TKI 2 4
Prior (radio)immunotherapy 4 2
Table 10.2 Pati ent characteristi cs
Panels A, B, C Baseline
Panels D, E, F Two weeks aft er disconti nuati on of sorafenib
Figure 10.1 FDG-PET/CT images of a pati ent who disconti nued sorafenib and experienced 
 dyspnea due to an impressive increase in pleural carcinomatosis and pleural 
 eff usions two weeks aft er disconti nuati on
 An enhanced FDG uptake in the bone metastases in the vertebrae and 
 right shoulder is seen.
FDG-PET images
CT images
Combined FDG-PET/CT images
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Female 2 1
Age (years) Median 59 68
Range 48-79 51-78
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Sorafenib 3 3
Durati on of therapy (months) Median 24.6 7.9
Range 8.1-49.5 2.3-27.5
Prior nefrectomy 7 6
Prior systemic therapy No 5 2
Yes 4 5
Prior TKI 2 4
Prior (radio)immunotherapy 4 2
Table 10.2 Pati ent characteristi cs
period. Out of the sixteen patients, eleven underwent two consecutive MRIs as per protocol. Two 
patients had contra-indications for MRI (claustrophobia, pacemaker), two patients did not have an 
abdominal mass larger than 2 cm and one patient experienced tinnitus after the first MRI and refused 
to undergo a second MRI. Of the eleven patients who underwent MRI, six were randomized to stop 
directly and five to continue therapy for two weeks. Patients who stopped therapy directly had a 
median increase from baseline to two weeks later in Ktrans of 1.6 s-1± 1.9, whereas the patients who 
continued had a median decrease of -1.1s-1 ± 15.2 (p=0.03). The median change in kep in the patients 
who stopped versus those who continued was 3.0 s-1 ± 5.1 and -3.3 s-1 ± 20.9 respectively (p=0.08). 
There were no significant differences in changes in ADC, tBV and tBF between the groups.
Panels A, B, C Baseline
Panels D, E, F Two weeks aft er disconti nuati on of sorafenib
Figure 10.1 FDG-PET/CT images of a pati ent who disconti nued sorafenib and experienced 
 dyspnea due to an impressive increase in pleural carcinomatosis and pleural 
 eff usions two weeks aft er disconti nuati on
 An enhanced FDG uptake in the bone metastases in the vertebrae and 
 right shoulder is seen.
FDG-PET images
CT images
Combined FDG-PET/CT images
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Disconti nuati on
median change (range)
Conti nuati on
median change (range)
p-Value
CT
ΔRECIST 7.3 % (-4.1 to 13.0%) 1.4 % (-5 to 19.2%) 0.35
FDG-PET
ΔVGSUV
max
 (%) 1.57 (-14.2 to 44.0) 0.5 (-6.0 to 34.4) 0.7
ΔVGSUV
50
 (%) 3.3 (-13.9 to 46.2) 0.48 (-8.6 to 35.0) 0.78
ΔTLG
max
 (%) 6.8 (-34.7 to 85.2) 6.4 (-17.7 to 33.4) 1.0
ΔTLG
50
 (%) 8.0 (-37.2 to 88.0) 5.8 (-20.0 to 34.0) 1.0
ΔTLG
70
 (%) -0.22 (-59.7 to 102.5) 1.78 (-37.1 to 40.7) 0.61
fMRI
Δ ADC (s/mm2) 15.0 (9-299 to 212) -40.9 (-307 to 300) 0.792
Δ K
trans
 (s-1) 1.56 (-0.9 to 4.25) -1.14 (-34.6 to 0.61) 0.03
Δ K
ep
 (s-1) 3.09 (-3.1 to 11.32) -3.26 (-48.0 to 3.42) 0.082
Δ tBV (AU) 8 (-176 to 410) -54 (-155 to 170) 0.792
Δ tBF (AU/s) -1 (-313 to 28) -28 (-244 to 18) 0.537
Biomarkers
Δ Hb (mmol/L) -0.9 (-1.5 to -0.1) -0.1 (-0.6 to 0.5) 0.003
Δ LDH (U/L) -73 (-372 to 66) 52 (-13 to 186) 0.008
Δ D-dimer (ng/ml) 510 (-4410 to 1670) -10 (-2010 to 1252) 0.351
Δ CRP (mg/L) 5 (-112 to 110) -10 (-7 to 50) 0.606
Δ VEGF (ng/ml) -2.35 (-0.66 to 0.23) 0.11 (-0.38 to 0.88) 0.065
Δ Tregs -0.5 (-1.1 to 10.6) -0.3 (-3.7 to 1.1) 1
Table 10.3 Results of imaging and pharmacodynamics
CT = Computed tomograpghy  Δ = Change  RECIST = Response Evaluati on Criteria In Solid Tumors  FDG-PET = 18F-fl uorodeoxyglucose 
positron emission tomography  VGSUVmax = Volume weighted mean of the maximum standardized uptake value  VGSUV50 = Volume 
weighted mean of the standardized uptake value based on the 50% isocontour treshold  TLGmax = Total lesion glycolysis using SUVmax and 
Vol50, TLG = ∑ (SUVlesion n * volumelesion n)   TLG50 = Total lesion glycolysis using SUV50 and Vol50  TLG70 = Total lesion glycolysis using 
SUV70 and Vol70  fMRI = Functi onal Magneti c Resonance Imaging  ADC = Apparent diff usion coeffi  cient  Ktrans = Volume transfer 
constant  Kep = Flux rate constant between extravascular extracellular space and plasma  tBV = Tumor blood volume  tBF = Tumor 
blood fl ow  Hb = Hemoglobin  LDH = Lactate dehydrogenase  CRP = C-reacti ve protein  VEGF = Vascular endothelial growth 
factor  Tregs = Regulatory T-cells
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PHARMACODYNAMIC RESULTS
Patients who stopped therapy had a median decrease in LDH (-73.0 U/L; range -372 to 66), whereas 
patients who continued therapy had a median increase in LDH (52.0 U/L; range -13 to 86) (p=0.008). 
Interestingly, seven out of nine patients who stopped therapy, showed a decrease in LDH, whereas in 
six out of seven patients who continued therapy the LDH increased. Hemoglobin levels decreased in 
both groups, but mainly in the group who stopped (-0.9 mmol/L; range -1.5 to -0.1 versus -0.1 mmol/L; 
range -0.6 to 0.5, p=0.003). The change in VEGF was -2.35 ng/ml (-0.66 to 0.23) in the group who 
stopped, versus 0.11 ng/ml (-0.38 to 0.88) in the group who continued. This difference just failed to 
reach statistical significance (p=0.065). Moreover, no significant differences were observed for changes 
in Tregs, or the acute phase proteins CRP and D-dimer between both groups.
discussion
In this prospective study, in which VEGFR-TKI-treated mRCC patients were randomized at the moment 
of PD to stop therapy immediately or to continue for two more weeks, we aimed to gain more insight 
in the effects of discontinuing VEGFR TKI. Within two weeks after discontinuation, a rise in Ktrans and a 
decrease in LDH were observed, indicating an increase in tumor vascularization, contrasting to the 
decline in Ktrans and increase in LDH found in patients continuing therapy beyond progression. This 
decrease in LDH is in contrast with the general idea in which a rising LDH is used as a (albeit non-specific) 
marker of progression. However, the production of LDH is stimulated by HIF-1α, that is up-regulated in 
hypoxic conditions. In our study, the decrease in LDH in patients who stopped taking the VEGFR TKI is 
accompanied by an increase in Ktrans and kep. This points to an increased perfusion, a higher permea-
bility and a larger blood vessel surface area, denoting an increased tumor vascularization. Our results 
are in line with the observation that after initiating treatment with sunitinib a temporally increase in 
LDH is observed, which could be explained by the tissue hypoxia induced by the inhibition of VEGFR 
due to sunitinib(16). The change in VEGF is also consistent with other studies, that have shown a rise 
in VEGF during treatment with sunitinib and a decrease after discontinuation(17, 18).
Currently, PD is determined by radiological assessment according to the Response Evaluation Criteria 
In Solid Tumors (RECIST)(10). However, the adequacy of these RECIST guidelines to evaluate treatment 
response of VEGFR TKIs has been questioned, since the anti-angiogenic effect leads to necrosis and 
cavitation with frequently only minimal decrease in tumor size. Using the size-based RECIST criteria 
often underestimates the effect of VEGFR TKIs(6, 19) and therefore a patient can be labeled as PD too 
early.
After discontinuation of VEGFR TKI, CT and FDG-PET/CT suggest no clinical significant difference in 
tumor growth and metabolic activity, respectively. Of course, the period of two weeks is short and the 
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group of patients is small. Nagengast et al. studied mouse xenograft models of tumor after discon-
tinuing treatment with sunitinib for one week and found intratumoral differences, rapid tumor 
revascularization and re-growth of tumors with VEGF-PET, but not with FDG-PET(20). Furthermore, 
the similar tumor metabolism on FDG-PET in our study may be explained by the fact that the larger 
supply of FDG to the tumor due to the increasing tumor vascularization is balanced by a decrease in 
glucose demand due to less hypoxic conditions in the group of patients that discontinued VEGFR TKI.
The mechanisms leading to drug resistance and progressive disease are not fully elucidated. Inadequate 
target inhibition either due to enhanced receptor signaling or decreased plasma levels of VEGFR TKIs 
might play a role in developing resistance. The latter may occur in case of an altered pharmacodynamic 
effect of a TKI due to polymorphisms in specific genes encoding for metabolizing enzymes, efflux 
transporters and drug targets, as is observed for sunitinib(21). It is also hypothesized that, due to VEGF 
blockage and tumor hypoxia, upregulation of pro-angiogenic factors might take place when developing 
resistance to treatment with VEGFR TKIs. When treatment is stopped rapid revascularization and cell 
proliferation occurs due to the abundance of angiogenic factors(6). Griffioen et al. studied tumor 
nephrectomy tissues of patients pre-treated with sunitinib and observed an increase in the number of 
proliferating endothelial which was positively correlated with the time interval between treatment 
stop and cytoreductive surgery(22). In an animal study with two VEGFR inhibitors, complete tumor 
re-vascularization was seen at day seven after cessation of therapy. Endothelial sprouting was already 
observed after one day(23). Another animal study observed an increase in tumor volume nine days 
after discontinuation of sunitinib(24). The observed increase in Ktrans and kep in our patients after 
discontinuation are consistent with these observations. In our study we showed that although all 
patients had PD, only the patients who discontinued showed increased perfusion and permeability, 
implying that at the moment of PD the effect of the VEGFR TKI was not completely exhausted. However, 
there was no difference between the patients with and without a flare-up syndrome, but the number 
of patients was too small to detect such differences.
Apart from these mechanisms, the development of a more malignant tumor phenotype during 
treatment may occur, with accelerated infiltrative growth and dissemination due to selection of 
hypoxia-tolerant tumor cells and metastatic conditioning. Ebos et al. reported that mice receiving 
sunitinib for only seven days either before or after injection of tumor cells suffered from an accelerated 
tumor growth after discontinuation of sunitinib, resulting in a shorter survival(7). The authors 
suggested that short anti-angiogenic treatment resulted in ‘metastatic conditioning’, which might be 
the effect of up-regulation of multiple circulating pro-angiogenic cytokines and growth factors, the 
mobilization of bone marrow derived cells facilitating an enhanced ‘pre-metastatic niche’ including 
circulating endothelial and myeloid progenitors, or the target promiscuity, all together creating a more 
favorable metastatic environment(8).
Flare-up syndromes have a negative impact on the quality of life and can preclude the start of a 
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next-line therapy due to rapid deteriorating of the clinical condition. Insights in the biological 
mechanisms occurring after discontinuation of VEGFR TKIs due to PD are necessary to be able to 
determine the optimal management strategy for these patients. The results of our study imply that at 
the moment of PD the effect of the VEGFR TKI is not completely exhausted. Therefore, a dose-esca-
lation of the VEGFR TKI at the moment of PD, instead of discontinuation, might lead to clinical benefit 
as is shown in a study with sorafenib(25). Alternatively, introducing a VEGF-antibody or switch to 
another VEGFR TKI might prevent rapid revascularization.
Within two weeks after discontinuation of VEGFR TKI in patients with PD, the rise in Ktrans and the 
decrease in LDH indicate a higher tumor perfusion or increased permeability of tumor blood vessels, 
reflecting an increase in tumor vascularization. Although all patients had PD, only the patients who 
stopped showed increased perfusion and permeability, implying that at the moment of PD the vascular 
effects of the VEGFR TKI are not completely exhausted.
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summary
Targeted therapies, in contrast to conventional chemotherapeutics, are directed against specific 
receptors on the cancer cell membrane or pathways within the cancer cell, thereby disrupting several 
crucial processes for cell survival, proliferation and motility. Since the introduction of imatinib for 
bcr-abl positive chronic myeloid leukemia in 2000 and for gastrointestinal stromal cell tumors shortly 
thereafter, an abundance of new drugs has been developed and investigated. To date, almost 40 
targeted therapies have found their way to the daily clinical practice in cancer patients and many more 
are being tested in clinical trials. Although targeted agents were initially introduced as highly tumor-cell 
specific with only minor toxicity towards normal cells, with the expanding use in clinical practice 
limitations were soon observed. Currently, optimism has shifted to realism. The need for strategies to 
optimize treatment outcome of targeted therapies is clear. This thesis focuses on several possibilities 
to improve treatment outcome in targeted therapies.
Chapter 2, 3, 4 and 10 focus on the monitoring of treatment by means of imaging, pharmacokinetics and 
pharmacodynamics. Chapter 3, 5 and 6 describe the possibility to circumvent resistance to therapy by 
combining different agents. Other interventions to improve therapy outcome are described in the other 
chapters and concise of the development of new treatment strategies with better toxicity profiles 
(chapter 7), improving management of symptoms of disease (chapter 8) and adverse events (chapter 9).
The increased knowledge of the development of resistance against these new agents, as well as the 
spectrum of their adverse events, underscores the relevance of early evaluation of effect of treatment. 
Early prediction of progressive disease avoids continuation of a possibly toxic and expensive treatment 
and enables an earlier start of an alternative treatment with possibly favorable anti-tumor effects.
There are several options for monitoring therapy. Conventional assessment uses measurement of 
serological tumor markers, e.g., CEA, CA-125 or PSA, and measurement of tumor size by imaging such 
as ultrasound, conventional radiographs and CT or MRI scans. Classically, volumetric tumor evaluation 
is based on RECIST criteria, which have been developed as uniform strategy in the era of chemotherapy, 
where cytotoxic drugs led to real reductions in size. This has the advantage of global applicability in 
clinical studies, but it has never been developed to measure activity of targeted agents, which have 
mainly cytostatic capabilities. Therefore, for targeted agents, techniques to monitor the metabolism 
or proliferation of tumor cells might be more appropriate than monitoring tumor volume. For this 
reason, there is an increasing interest in positron emission tomography (PET) scans to perform early 
response monitoring. Additionally, pharmacokinetics and pharmacodynamics are exploited to predict 
factors correlated to treatment benefit and the development of toxicity.
Chapter 2 describes a study in 23 patients with metastatic renal cell carcinoma (mRCC) who showed 
progressive disease after treatment with a VEGFR TKI and were treated with the mTOR inhibitor 
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temsirolimus at a dose of 25 mg intravenously once a week. At baseline, after two weeks and after six 
weeks, an 18F-fluorodeoxyglucose (FDG)-PET/CT was performed in order to investigate if early response 
monitoring in this group of patients was feasible. In 20 evaluable patients, we were neither able to 
identify any relation between the fractional decrease in total lesion glycolysis (TLG) or in volume 
weighted standardized uptake value (SUV) after two and six weeks and CT response after six weeks, 
nor with progression free survival or overall survival. In this small, heterogeneous group of patients, 
early response imaging with FDG-PET/CT seems clinically not meaningful. Remarkably, we observed a 
PFS of 7.6 months, which compares favorably to historical controls. We concluded that temsirolimus 
might be effective as second or higher line of therapy. Further research should be performed to 
identify biomarkers for effect, so that patients who might benefit most of treatment with temsirolimus 
could be better selected.
Chapters 3, 5 and 6 address the potential of treatment with combinations of agents to improve 
treatment outcome. In general, monotherapy with a targeted agent results in a limited objective 
response rate and only modest prolongation of progression free survival and overall survival. 
Combination therapy might improve these results by additive and synergistic effects and reduction of 
resistance. When combining targeted agents with conventional cytotoxic chemotherapy, the generally 
non-overlapping toxicity profiles may potentially reduce the risk of severe and potentially life 
threatening toxicities.
In chapter 3 the combination of temsirolimus and pegylated liposomal doxorubicin (PLD) in patients 
with advanced breast, ovarian or endometrial cancer was investigated. The primary endpoint of this 
study was to determine the maximum tolerable dose (MTD) and the recommended phase II dose of 
the combination (RPTD). Twenty patients were included in this study. Dose limiting toxicities were 
grade 3 thrombocytopenia with bleeding, and skin toxicity. The most frequent treatment-related 
adverse events were nausea, fatigue, mucositis and skin toxicity. Three patients (two with ovarian and 
one with endometrial cancer) had confirmed and durable partial responses of 10.1, 12.7 and 13.7 
months, respectively. Ten patients had stable disease, eight of whom (two with ovarian, three with 
endometrial and three with breast cancer) had a prolonged stable disease (>16 weeks) with a median 
duration of 6.4 months. Since the production of PLD was unexpectedly interrupted during the study, 
we were unable to formally establish the MTD of the combination, but we recommended investigating 
temsirolimus 15 mg once a week and PLD 40 mg/m2 once every four weeks in further phase II studies. 
As a secondary endpoint, we performed serial FDG-PET/CTs to early identify those patients who 
benefit from the addition of temsirolimus to PLD. We showed that the FDG-PET/CT after two weeks of 
temsirolimus predicted which patients would have partial response on CT scan after ten weeks of 
therapy, whereas the FDG-PET/CT after six weeks predicted later radiological progressive disease. We 
showed that early response monitoring with serial FDG-PET/CTs is feasible and could lead to optimi-
zation of treatment strategies for patients.
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In the same study, during the first cycle of treatment with temsirolimus and PLD, pharmacokinetic 
sampling was performed. The main objective of this pharmacokinetic and pharmacodynamic study 
was to assess the prognostic and predictive factors for efficacy of PLD, in order to optimize treatment 
with PLD. Results were presented in chapter 4. In 17 patients, venous blood samples were drawn at 
baseline and at several time points during the first cycle. The PLD exposure was calculated. The 
occurrence of rash and mucositis was correlated with a higher PLD exposure compared to those who 
did not have these adverse events. PLD exposure itself was positively related to progression-free 
survival (PFS). This has important clinical implications, since dose reductions or interruptions might 
thus negatively affect treatment outcomes. It was concluded that attention should be paid to 
preventive and supportive measures to ameliorate adverse events of PLD with the aim to keep the 
exposure to PLD as high as possible.
The combination of pazopanib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor 
(VEGFR TKI), and ifosfamide was investigated in the study described in chapter 5. In this study, 
escalating doses of pazopanib were combined with two different infusion schedules of ifosfamide: 
continuously or as a three-hours bolus over three consecutive days. Patients with advanced or 
metastatic solid tumors for whom ifosfamide-based therapy was considered appropriate or for whom 
no standard therapy was available were eligible. The primary objective was to define the RPTD of the 
combination. Pazopanib with continuous ifosfamide infusion appeared to be safe up to 1000mg per 
day, while combination with bolus infusion ifosfamide turned out to be too toxic based on a variety of 
adverse events. The combination of pazopanib and ifosfamide had a clinically important anti-tumor 
effect: 10 out of 45 evaluable patients experienced a partial response in this study. Fourteen patients 
had prolonged stabilization of disease, defined as stable disease for a minimal duration of three 
months. In this study, extended pharmacokinetic sampling was performed of both pazopanib and 
ifosfamide. Pazopanib had neither impact on the plasma half-life or clearance of ifosfamide, nor on 
any of its metabolites. In contrast, ifosfamide, independent of the schedule, appeared to lower 
pazopanib levels, however without effects on its biological activity. The striking difference in the 
tolerability between the continuous and the bolus schedule, could thus not be explained by pharma-
cokinetic phenomena. An obvious explanation for the observed differences was not readily available. 
The recommended phase II dose was pazopanib 800 mg once daily in combination with continuous 
infusion of 9 gram/m2 ifosfamide over three consecutive days.
Chapter 6 describes a phase I study in which sunitinib, a VEGFR TKI, was added to capecitabine and 
irinotecan, a standard combination regimen in the treatment of metastatic colorectal cancer. In the 
first four patients treated with lower-than-normal doses of capecitabine and irinotecan and 25 mg 
sunitinib once daily continuously, two dose limiting toxicities (DLTs) occurred, both hematological. 
According to the protocol we subsequently treated the following patients at a lower dose level with 
sunitinib 12.5 mg once daily continuously. At this dose level both patients experienced neutropenia 
grade 3, which led to dose delays of irinotecan and dose interruptions of sunitinib and capecitabine. 
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In one of these two patients, sunitinib was permanently withdrawn after cycle 4 and thereafter this 
patient did not experience any hematological toxicities anymore, even when the dose of irinotecan 
was escalated. As clinical benefit was not expected with lower doses of sunitinib given the already 
reduced doses of capecitabine and irinotecan, the study was discontinued. We concluded that a 
combination of capecitabine and irinotecan with sunitinib was not feasible.
In the search for the most optimal treatment strategy, new targets are identified and new drugs 
against these targets are developed. A new strategy in the treatment of RCC patients is described in 
chapter 7. Clear cell renal cell cancer cells express carbonic anhydrase IX (CAIX), a tumor-associated 
antigen. Girentuximab, a chimeric monoclonal antibody, specifically targets CAIX-expressing cells and 
can thus serve as a potent carrier for tumor targeted delivery of β-emitting radionuclides, such as 
lutetium-177 (177Lu). The therapeutic efficacy of radioimmunotherapy (RIT) with 177Lu labeled 
girentuximab, was investigated in a phase II study in fourteen patients with clear cell RCC. The mean 
growth rate of the target lesions of all patients decreased from 14% in the three months before start 
of RIT to 5% in the first treatment cycle, although large differences were observed amongst patients. 
In general, RIT was tolerated well with only two grade 3 events (fatigue and anorexia). However, a high 
incidence of grade 3-4 trombocytopenia and leucocytopenia occurred. This myelotoxicity was 
transient, but most patients did not recover to baseline levels. A total of eight patients could not be 
treated with a next cycle of RIT because of the bone marrow suppression. Additionally, three out of six 
patients could not be treated with a full dose of a VEGFR TKI after they progressed on RIT, because of 
a decreased bone marrow reserve. We concluded that the clinical response of this RIT approach is 
encouraging. Because of the high incidence of myelotoxicity, the dose needs to be decreased to allow 
continued treatment until progression in all patients.
Higher response rates or a prolonged progression free survival are not the only objectives to pursue 
when searching for possibilities to improve therapy outcome. Reducing symptoms of disease or 
diminishing adverse events is at least equally important for cancer patients. Chapters 8 and 9 describe 
the management of quality of life in patients with cancer treated with targeted therapy.
Malignant ascites and malignant pleural effusion are challenging clinical problems in cancer patients, 
with a major impact on their quality of life. In 58% of patients ascites-related symptoms exist, such as 
abdominal swelling, abdominal pain, nausea, anorexia, vomiting, fatigue, dyspnea, and early saturation 
with eating. The main complaints of pleural effusion are dyspnea, cough, and chest pain. Drainage of 
ascites and pleural fluids lead to temporarily relieve of symptoms in patients, but repeated procedures 
are not without risks. An effective treatment that provides symptomatic relief of ascites and pleural 
effusion with minimal associated toxicities is urgently needed. Since previous studies have shown that 
levels of VEGF in plasma and in malignant ascites and pleural effusions are high, we hypothesized that 
a VEGFR TKI may exhibit a positive palliative effect on the ascites and pleural effusion related 
complaints (chapter 8). We performed a study in which twelve patients with ascites and pleural 
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effusion were enrolled and randomized between [a] prompt treatment with cediranib 30 mg once 
daily or [b] initiation of treatment after a delay of 28 days or after a clinically required fluid drainage, 
whichever came first. The median puncture free interval in the group that directly started cediranib 
was 45 days, compared to 7 days in the “delayed” group. Cediranib was well tolerated although dose 
reductions were needed. Despite the limited number of patients included in this study, a significantly 
and meaningfully longer puncture free interval was observed in the patients who were promptly 
started on cediranib. As this is most probably a class-effect of all VEGFR TKIs, further exploration of the 
use of VEGFR TKIs is recommended to intervene this major clinical problem.
Diarrhea is a frequent side effect of treatment with VEGFR TKIs, which is often accompanied by 
abdominal cramps, pyrosis or flatulence. These complaints impair quality of life and lead to dose 
reductions and treatment interruptions. The diarrhea is treated symptomatically with loperamide, 
since the pathophysiological mechanism underlying the diarrhea is unknown. It is hypothesized that 
ischemia or inflammation might play a role in the pathogenesis. We performed endoscopy of the 
upper and lower gastrointestinal (GI) tract in ten patients with metastatic renal cell carcinoma who 
developed diarrhea during VEGFR TKI treatment in order to find evidence for any of these hypotheses. 
As described in chapter 9, sigmoidoscopy showed a macroscopically normal aspect of the colon in the 
majority of patients. In particular, there were no signs of ischemic colitis or inflammation. However, 
gastroduodenoscopy revealed gastro-esophageal reflux disease, bulbitis and/or duodenitis with ulcers 
in eight patients. In three selected patients with bulbitis/duodenitis additional video capsule 
endoscopy revealed no additional intestinal abnormalities. Given the predominance of mucosal 
abnormalities in the upper GI tract, there was no evident explanation for the diarrhea. However, it 
provides a possible clue for the frequently occurring GI complaints seen in VEGFR TKI treated patients. 
Based on these results it was suggested to perform upper GI endoscopy in VEGFR TKI treated patients 
with GI complaints.
The first chapters of this thesis discussed treatment monitoring with FDG-PET/CT in the first weeks of 
therapy for early identification of patients who do or do not benefit of treatment. Chapter 10 addresses 
the other side of the spectrum: how can events after discontinuation of VEGFR TKI be monitored in 
order to optimize treatment strategies? Sixteen patients with metastatic RCC, which had progressive 
disease (PD) according to RECIST during treatment with sorafenib or sunitinib were 1:1 randomized to 
either directly stop the VEGFR TKI or to continue for another two weeks. At baseline, i.e. at the 
moment of PD and after two weeks FDG-PET/CT, functional-MRI and blood biomarkers of disease were 
performed in both groups. A statistically significant difference in median change from baseline to two 
weeks later in Ktrans (as determined by dynamic contrast-enhanced MRI), LDH and hemoglobin levels 
were observed between patients who directly stopped versus those who continued treatment (1.6 s-1 
±1.9 versus -1.1s-1 ±15.2, p=0.03; -73.0 U/L ± 131 versus 52.0 U/L ± 62.3, p=0.008; -0.9 mmol/L ± 0.49 
versus -0.1mmol/L ± 0.37, p=0.003, respectively). The change in FDG-uptake, tumor size according to 
RECIST, CRP, D-dimer, VEGF and Tregs did not differ between groups. We concluded that the rise in 
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Ktrans accompanied by a decrease in LDH two weeks after discontinuing the VEGFR TKI because of PD, 
indicates an increase in tumor vascularization. This implies that at the moment of progressive disease 
the anti-tumor effect of VEGFR TKIs is not completely exhausted.
general discussion, future perspectives
IMPROVING OUTCOMES IN TARGETED THERAPY: THE ROAD AHEAD
During the last decade, important progress has been made in unraveling the pathophysiology of 
cancer. The discovery of several regulatory pathways with distinct functions leading to cell growth and 
survival led to the development of drugs specifically targeting these pathways. These targeted agents 
improved progression free survival and overall survival in many patients with several different types of 
cancer. However, after the first era of enthusiasm, in which numerous new targeted agents were 
registered, it is now time for reflection and searching for strategies to optimize targeted therapies. 
Major challenges that need to be addressed in order to improve therapy outcome in targeted therapy 
are 1. optimization of dosing and management of adverse events, 2. early response monitoring and 
treatment evaluation and 3. circumvention of drug resistance.
OPTIMIZATION OF DOSING AND MANAGEMENT OF ADVERSE EVENTS
Although targeted therapies were originally introduced as highly tumor specific leading to only 
minimal toxicity towards normal cells, the use in clinical practice has showed that targeted therapies 
can lead to a wide range of adverse events of which some can be serious. However, also chronic mild 
complaints can have a significant negative impact on the quality of life of patients and as such 
necessitate dose interruptions, withdrawals or dose reductions potentially leading to a less effective 
treatment. Improving the management of the adverse events or, even better, preventing those is of 
utmost importance in improving therapy outcome. In this thesis, we describe our search for the cause 
of diarrhea in patients treated with VEGFR TKIs to identify a treatment based on pathophysiology 
instead of just applying a symptom based approach. In the future, more attention should be paid to 
resolving the pathophysiological mechanisms causing the adverse events of targeted therapies. 
Another way to ameliorate the profile of adverse events is by therapeutic drug monitoring (TDM). 
Targeted therapies are normally prescribed in a fixed dose, regardless of tumor and patient characte-
ristics. However, the anti-tumor effect is dependent on the sensitivity of the tumor for the drug and 
the individual drug concentration, which could be influenced by many factors, e.g., enzyme deficits, 
liver and kidney function or interactions with other drugs. To overcome these pitfalls, TDM aims to 
bring plasma concentrations within a therapeutic range by adjusting the individual drug dose, guided 
by measurement of plasma drug concentrations. In some cases, this will lead to lower doses than the 
fixed dose, thereby diminishing side effects for that individual patient. However, for TDM to become 
an asset in establishing individual drug dosing, certain criteria should be fulfilled. Obviously, it should 
be possible to measure plasma drug concentrations accurately and to have the results available within 
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a reasonable amount of time. Furthermore, it needs to be established which pharmacokinetic 
parameter associates best with therapeutic response, which is currently unknown for most targeted 
agents. In this thesis, we have shown that a higher exposure of PLD (area under the curve) in patients 
treated with the combination of PLD and temsirolimus is predictive for a longer PFS, whereas other PK 
parameters, e.g., the halftime or peak concentration of PLD, were not correlated to treatment 
outcome. Similarly to the use of pharmacokinetic biomarkers for the optimization of the individual 
drug dosing, also many pharmacodynamic biomarkers have been identified. In this thesis, data on the 
positive correlation between hand-foot-syndrome and PFS in patients treated with temsirolimus and 
PLD were presented. Other examples are the development of hypothyroidism and hypertension 
during treatment with VEGFR TKIs. When a predictive pharmacodynamic biomarker for effect is 
identified, this could be used to increase the drug dose until the adverse event develops in order to 
maximize the chances for a beneficial therapeutic effect. However, before applying this “treatment 
until toxicity” principle, one should take into account the nature of the toxicity, the intent of treatment 
(curative or palliative) and the consequences of giving a higher than normal dose on healthy organ 
systems. The challenge for clinical practice is that it demands a lot of resources and money to 
investigate the predictive biomarker in every tumor type in combination with every treatment option. 
However, it is worthwhile to take that challenge, because personalized therapy and individual drug 
dosing, using TDM, are the way to go in the near future in order to diminish side effects of targeted 
therapy.
EARLY RESPONSE MONITORING AND TREATMENT EVALUATION
Targeted therapies often lead to side effects and are expensive. Early selection of patients who do not 
respond to the given treatment, prevents unnecessary adverse events and costs and enables the 
earlier start of a new line of (effective) therapy. Serial positron emission tomography (PET) is extensively 
studied as a modality for (early) therapy response imaging. Fluorodeoxyglucose (FDG) is the most 
frequently used tracer in the oncological application of PET and mimics the transportation of glucose 
into cells in the body that have an increased glucose uptake and metabolism, like tumor cells. However, 
unlike glucose, the metabolite of FDG is trapped in these cells and accumulates. By means of FDG-PET/
CT it is possible to obtain a whole body image and visualize and quantify tumor cell metabolism. 
Besides that, serial FDG-PET/CTs allows repetitive non-invasive visualization of therapy-induced 
changes. In this thesis, we presented two studies of early response imaging with FDG-PET/CT in 
patients treated with the targeted drug temsirolimus. One of these studies was successful in the early 
(i.e. after two and six weeks of treatment) identification of patients who on cross-sectional imaging 
eventually showed partial response and progressive disease respectively. In the other study, we had to 
conclude that early response imaging in that group of patients was not meaningful. It is clear that, 
before treatment decisions whether or not to early discontinue treatment can be made for an 
individual patient based on PET/CT data, more research is needed which confirms these findings and 
explains the differences encountered.
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Although data on early response imaging with PET/CT have not fully matured, PET/CT has become an 
important instrument in the diagnostics of cancer and treatment evaluation next to CT and MRI. 
Developments in recent years will continue and lead to fine-tuning of the technology with more 
accurate results and broader, yet evidence-based applicability. It is important to develop higher 
resolution scans allowing more adequate assessment of smaller lesions, to identify the optimal timing 
for response monitoring and to continue the development of other PET tracers besides FDG depicting 
different phenotypes of the cancer cell like proliferation with 18F-fluoro-l-thymidine (FLT) or hypoxia 
with 18F-fluoromisonidazole (FMISO). Breast cancer is one of the tumor types in which receptor status 
has been evaluated with molecular imaging. 18F-fluoroestradiol (18F-FES) and Zirconium-89(89Zr)-
trastuzumab-PET have been applied to non-invasively obtain information about estrogen-receptor 
status and Her-2 overexpression in primary breast carcinomas and all metastatic sites. This may change 
clinical practice and mean an important benefit for patients and their doctors, as invasive biopsies are 
less frequently or even not at all needed and the more complete information obtained is covering all 
metastatic sites.
Besides PET techniques, different magnetic resonance imaging (MRI) techniques are used for diagnosis 
and treatment evaluation of cancer. Diffusion-weighted MRI (DWI) quantifies diffusion of water 
molecules in tissue. The degree of restriction of water diffusion in tissue is inversely correlated to 
tissue cellularity and the integrity of cell membranes. Therefore, DWI can be used to monitor cellularity, 
edema and necrosis. Dynamic contrast-enhanced (DCE) MRI is the acquisition of serial MRI images 
before, during, and after the administration of an MR contrast agent. It provides information on 
microvessel perfusion, permeability and extracellular leakage space. T2* perfusion MRI measures the 
vascular phase of contrast medium delivery and provides data on tumor blood volume and tumor 
blood flow. With these techniques, a more accurate differentiation is possible between for example 
necrotic tissue and viable cancer cells or a liver metastasis, a hemangioma or a hepatoadenoma and 
could lead to immediate treatment decisions. In recent years, integrated PET/MRI scanners have been 
developed combining the best of the two techniques. In the near future, new technology such as 
integrated PET/MRI, and continuous optimization of already existing imaging techniques should 
provide the rationale for more adequate treatment decisions.
PREVENTING RESISTANCE TO TREATMENT
Another major challenge in the era of targeted therapies is the development of resistance to treatment 
and identification of scenarios to circumvent this. Combination therapy is considered as one of the 
most important options to overcome resistance. In this thesis, three studies were reported in which 
four combinations of a targeted drug with conventional chemotherapy are presented. Two of these 
combinations were successful. However, two of the combinations were too toxic to consider further 
exploration. Improved characterization of drug properties and understanding of the different 
therapeutic effects on cancer cells are the challenges for the future. This should result in a more 
rational design of clinical studies on combination therapies, with higher success rates, more favorable 
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toxicity profiles and lower costs for drug development.
Research on combination studies is not restricted to the combination of targeted therapies with 
conventional chemotherapeutics, but combinations with hormonal therapy, radiotherapy, surgery and 
other targeted agents should also be explored. Especially studies combining targeted therapy with 
immunotherapy yield promising results. Testing of these drugs in a wide range of tumor types will be 
undertaken in the near future. Besides combination studies, alternative treatment schedules should 
be assessed. Of special interest is metronomic therapy, which implies therapy with a continuously 
low-dosed chemotherapeutic agent. In contrast to the conventional intermittent high dosing, 
metronomic therapy does exert its anti-tumor effect not so much directly on the tumor cells, but 
rather on the surrounding endothelial cells, for example by inducing sustained apoptosis of endothelial 
cells within the vascular tumor bed. The addition of metronomic chemotherapy to a VEGFR TKI might 
enhance its anti-tumor effect without causing additional toxicities.
Another way to circumvent resistance is to better select the candidates for any given therapy. In the 
past, drugs were developed for patients with the same anatomical or histological tumor subtypes. 
Since we are able to better characterize tumor biology and the somatic mutations resulting in tumor 
progression, development of targeted therapy is more and more based upon tumor subtypes harboring 
specific somatic mutations rather than the “one size fits all” approach. For example, a drug, i.e., a PARP 
inhibitor, can be registered for all patients harboring a BRCA mutation, regardless of the origin of the 
cancer cells. Because target expression is usually a prerequisite for response to a targeted agent, the 
use of this “tumorgenomics” might lead to a better, more individualized selection of patients and 
thereby to more effective therapies and less tumor resistance.
The development of targeted therapies has led to exciting results in the treatment of patients with 
cancer. Now, the challenge lies in the optimization of therapy for each individual patient, using imaging 
techniques, pharmacokinetics, pharmacodynamics and oncogenomics, to be able to deliver 
high-quality personalized targeted therapy to every patient with cancer.
149
summary - general discussion - future perspectives
11

CHAPTER 12
nederlandse
samenvatting
152
nederlandse samenvatting
Lange tijd bestond de systemische behandeling van kanker vooral uit chemotherapie en in mindere 
mate uit hormonale therapie en immunotherapie. Het anti-tumor effect van chemotherapie berust op 
het feit dat het de groei van sneldelende cellen in het lichaam kan remmen. Het nadeel hiervan is dat 
het niet kankercel-specifiek is, maar de groei remt van alle sneldelende cellen. Door de schadelijke 
effecten op de gezonde lichaamscellen, geeft chemotherapie veel bijwerkingen. Er bestond dus een 
grote behoefte aan een behandeling die effectief zou zijn tegen kankercellen, maar geen of veel 
minder bijwerkingen zou veroorzaken.
De laatste jaren is onze kennis over het ontstaan van kanker en de mogelijkheid van kankercellen om 
uit te groeien enorm toegenomen. Deze toegenomen kennis van de cel biologie heeft geleid tot de 
ontwikkeling van de zogeheten doelgerichte behandelingen (Engels: targeted therapies). Een 
behandeling met doelgerichte therapie is, in tegenstelling tot chemotherapie, gericht tegen specifieke 
eigenschappen van de kankercel of tegen processen die cruciaal zijn voor de overleving, groei en 
motiliteit van de kankercel. Eén van die processen is bijvoorbeeld het vermogen van de kankercel om 
nieuwe bloedvaten te laten groeien naar de tumor toe, waardoor er meer zuurstof en bouwstoffen 
aangevoerd kunnen worden. Dit proces wordt aangestuurd door de productie van vasculaire 
endotheliale groeifactor (VEGF) door de kankercel en de binding van VEGF aan de specifieke receptor 
(de VEGF receptor, of VEGFR). In de afgelopen jaren zijn er meerdere doelgerichte therapieën op de 
markt gekomen die danwel de werking van VEGF, danwel de VEGF receptor blokkeren. Deze middelen 
worden bloedvatremmers of VEGFR tyrosine kinase inhibitors (TKIs) genoemd. In dit proefschrift 
komen vier verschillende VEGFR TKIS aan bod in verschillende onderzoeken: sunitinib, pazopanib, 
cediranib en sorafenib. Een andere vorm van doelgerichte behandeling die in dit proefschrift wordt 
beschreven is de mTOR remmer temsirolimus. mTOR is een eiwit in de kankercel dat deel uitmaakt van 
een hele keten eiwitten die signalen aan elkaar doorgeven. Uiteindelijk leidt dat signaal tot een 
toename van de groei en deling van de cel. Een mTOR remmer blokkeert het signaal op het niveau van 
mTOR en remt daarmee de groei en deling van de kankercel.
Sinds de introductie van de eerste doelgerichte therapie in 2001 zijn er al bijna veertig doelgerichte 
therapieën geregistreerd voor de behandeling van patiënten met kanker en worden er nog veel meer 
getest in klinische onderzoeken. Met het toenemende gebruik van deze nieuwe middelen, kwamen de 
beperkingen echter al snel aan het licht. Alhoewel doelgerichte therapieën werden geïntroduceerd als 
uiterst tumor-specifiek, blijken de specifieke doelen die ze blokkeren of remmen helaas niet alleen 
aanwezig te zijn op de kankercellen. Daarmee hebben ook doelgerichte therapieën ongewenste 
bijwerkingen. Daarnaast bleek er vaak resistentie op te treden, waardoor de tumoren ongevoelig 
worden voor het remmende of blokkerende effect van de doelgerichte behandeling.
Tegenwoordig is het optimisme verandert in realisme en zijn we ons er van bewust dat er nog heel veel 
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verbeteringen mogelijk en nodig zijn. Dit proefschrift focust op verschillende mogelijkheden om de 
uitkomst van de behandeling en de kwaliteit van leven van patiënten met doelgerichte therapie te 
verbeteren. Hoofdstukken 2, 3, 4 en 10 focussen op het monitoren van de behandeling door middel 
van beeldvormende technieken, farmacokinetiek en farmacodynamiek. Hoofdstukken 3, 5 en 6 
beschrijven de mogelijkheid om resistentie tegen de behandeling te voorkomen door verschillende 
medicijnen te combineren. In de overige hoofdstukken worden interventies beschreven die er op 
gericht zijn de kwaliteit van leven van patiënten te verbeteren zoals door het ontwikkelen van nieuwe 
behandelingsstrategieën met een gunstiger bijwerkingenprofiel (hoofdstuk 7), het verbeteren van de 
behandeling van klachten van de kanker (hoofdstuk 8) en het verbeteren van de bijwerkingen van de 
behandeling (hoofdstuk 9).
Naarmate de kennis over de beperkingen van doelgerichte behandelingen toenam, werd de noodzaak 
om al vroeg in de behandeling het effect te kunnen evalueren steeds duidelijker. Het vroeg voorspellen 
van groei van ziekte voorkomt namelijk dat een potentieel toxische en dure behandeling wordt 
voortgezet en zorgt ervoor dat er sneller gestart kan worden met een alternatieve behandeling die 
mogelijk wel een gunstig anti-tumor effect heeft. Er zijn verschillende mogelijkheden om het effect van 
de behandeling te evalueren. Conventionele methodes zijn bijvoorbeeld het meten van tumor markers 
zoals CEA, CA-125 en PSA in het bloed en het meten van de grootte van de tumoren met behulp van 
beeldvormende technieken zoals echo, röntgenfoto’s, CT en MRI scans. Tot op heden wordt er voor 
het vaststellen van al of niet progressie van kanker gebruik gemaakt van de RECIST criteria (Engels: 
response evaluation criteria for solid tumors). De RECIST criteria zijn ontwikkeld als een instrument om 
uniforme metingen van de grootte van tumoren te kunnen doen in de tijd dat er alleen chemotherapie 
gegeven werd. Chemotherapie zorgt ervoor dat kankercellen afsterven en kan zo de tumoren duidelijk 
doen krimpen. Doelgerichte behandelingen zorgen er in eerste instantie voor dat de kankercellen niet 
verder groeien of delen en leiden daarom niet altijd tot afname van de grootte van tumoren, maar 
vaker tot stabilisatie of necrose en holtevorming. Het is de vraag of de RECIST criteria daarom wel een 
juiste inschatting geven van het effect van doelgerichte therapieën. Technieken die het metabolisme 
of de deling van de tumorcellen meten, zijn wellicht meer geschikt voor het evalueren van doelge-
richte behandelingen dan het meten van tumorgrootte. Om die reden is er een toenemende interesse 
in positron emissie tomografie (PET) scans voor het vaststellen van de vroege effecten van therapie. 
Daarnaast worden ook farmacokinetiek en farmacodynamiek ingezet om de behandeling te monitoren, 
bijvoorbeeld door het bepalen van spiegels (concentratie in het bloed) van het medicijn of door het 
identificeren van factoren die samenhangen met een goede respons op de behandeling of met de 
ontwikkeling van bijwerkingen.
Hoofdstuk 2 beschrijft een studie waarin 23 patiënten met uitgezaaide nierkanker, die progressief 
waren na behandeling met een VEGFR TKI, behandeld werden met de mTOR remmer temsirolimus in 
een dosis van 25 mg intraveneus eenmaal per week. Aan het begin, na twee weken en na zes weken 
werd er een 18F-fluorodeoxyglucose (FDG)-PET/CT gemaakt om te onderzoeken of het mogelijk was 
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om in deze groep patiënten al vroeg het effect van therapie te evalueren. In twintig evalueerbare 
patiënten konden wij geen relatie aantonen tussen de fractionele verlaging van de total lesion 
glycolysis (TLG) of van de volume gewogen standardized uptake value (SUV) na twee en na zes weken 
enerzijds en de respons op CT na zes weken, de progressie vrije overleving (PFS) of de totale overleving 
(OS) anderzijds. We concludeerden dat, in deze kleine, heterogene groep patiënten vroege effect 
metingen middels FDG-PET/CT de respons op de langere termijn niet konden voorspellen. Een 
opvallende nevenbevinding in deze studie was een PFS van 7.6 maanden, wat lang is in vergelijking 
met historische controles. Daaruit concludeerden we dat temsirolimus wel effectief kan zijn als tweede 
of hogere lijn behandeling bij patiënten met uitgezaaide nierkanker. Vervolgonderzoeken zouden 
gericht moeten zijn op het identificeren van biomarkers voor effect, zodat de patiënten die het meeste 
baat bij een behandeling met temsirolimus kunnen hebben, beter geselecteerd kunnen worden.
Hoofdstukken 3, 5 en 6 beschrijven de mogelijkheden om de uitkomst van de behandeling te 
verbeteren door combinaties van middelen te gebruiken. Over het algemeen leidt behandeling met 
alleen een doelgerichte therapie tot een beperkt aantal patiënten waarbij de grootte van de tumoren 
met meer da 30% afneemt en geeft het slechts een beperkte verlenging van de PFS en OS van een 
aantal maanden. Combinatie therapie kan tot een verbetering van deze resultaten leiden doordat de 
middelen elkaars werking versterken en door vermindering van de kans op resistentie. Doordat 
doelgerichte therapie en conventionele chemotherapie over het algemeen niet-overlappende bijwer-
kingenprofielen hebben, is er een laag risico op ernstige en potentieel dodelijke bijwerkingen.
In hoofdstuk 3 werd de combinatie van temsirolimus met chemotherapie in de vorm van gepegyleerd 
liposomaal doxorubicine (PLD) onderzocht bij patiënten met uitgezaaide borst-, baarmoeder- of 
eierstokkanker. Het primaire doel van deze studie was om de maximale tolereerbare dosis (MTD) en 
de aanbevolen dosis voor fase II studies (Engels: recommended phase two dose, RPTD) vast te stellen. 
Er werden twintig patiënten geïncludeerd. Bijwerkingen die verdere ophoging van de dosis onmogelijk 
maakten waren huidafwijkingen en een ernstige trombocytopenie met bloedingen. De meest frequent 
voorkomende behandeling-gerelateerde bijwerkingen waren misselijkheid, moeheid, mucositis en 
huidafwijkingen. Vanwege de onverwachte productiestop van PLD tijdens de studie, kon er geen 
formele MTD van de combinatie vastgesteld worden. De RPTD werd vastgesteld op de combinatie van 
temsirolimus 15 mg per week en PLD 40 mg/m2 eens per vier weken. In deze studie werden er ook 
opeenvolgende FDG-PET/CTs verricht voor het monitoren van vroege respons. De FDG-PET/CTs na 
twee giften temsirolimus voorspelden welke patiënten een partiële respons op de CT na tien weken 
behandeling hadden, terwijl de FDG-PET/CT na zes weken latere radiologische progressieve ziekte 
voorspelden. In deze groep patiënten, behandeld met de combinatie van temsirolimus en PLD, is 
vroege respons monitoring door middel van FDG-PET/CTs mogelijk en kan het leiden tot de optima-
lisatie van behandelstrategieën voor patiënten.
Tevens werd in deze studie, tijdens de eerste cyclus van temsirolimus en PLD, bloed afgenomen voor 
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farmacokinetiek en dynamiek. Het belangrijkste doel was om de prognostische en voorspellende 
factoren voor effectiviteit van PLD vast te stellen, om zo de behandeling met PLD te kunnen verbeteren. 
De resultaten zijn beschreven in hoofdstuk 4. Van zeventien patiënten werd er bloed afgenomen voor 
start van de behandeling en op verschillende tijdstippen tijdens de eerste cyclus. Hiermee werd de 
blootstelling aan PLD berekend. Het optreden van huiduitslag en mucositis was gecorreleerd aan een 
hogere blootstelling aan PLD. De blootstelling aan PLD zelf was positief gecorreleerd aan de PFS, wat 
betekent dat hoe hoger de blootstelling aan PLD, hoe langer de PFS was. Dit heeft belangrijke klinische 
implicaties, omdat dosisverlagingen of -pauzes dus de uitkomst van de behandeling negatief kunnen 
beïnvloeden. We concludeerden dat er aandacht besteedt moet worden aan preventieve en 
ondersteunende maatregelen met als doel de bijwerkingen van PLD te verminderen, zodat de 
blootstelling aan PLD zo hoog mogelijk gehouden kan worden.
De combinatie van de VEGFR TKI pazopanib met chemotherapie in de vorm van ifosfamide werd 
onderzocht in de studie die beschreven wordt in hoofdstuk 5. In deze studie werden steeds hogere 
doses van pazopanib gecombineerd met twee verschillende toedieningsschema’s van ifosfamide: een 
continu schema of een bolus- infusie gedurende drie uur gedurende drie opeenvolgende dagen. 
Patiënten met lokaal uigebreide of uitgezaaide solide tumoren voor wie ifosfamide behandeling 
passend werd geacht of voor wie geen standaard behandeling voorhanden was, konden meedoen met 
de studie. Het primaire doel was het definiëren van de RPTD van de combinatie. De behandeling met 
continue infusie van ifosfamide in combinatie met pazopanib bleek veilig tot een dosis van de 
pazopanib van 1000 mg per dag, terwijl de combinatie met bolus infusie ifosfamide te veel bijwer-
kingen gaf om veilig toegediend te kunnen worden, zelfs met hele lage doseringen van de pazopanib. 
De combinatie van pazopanib en ifosfamide had een klinisch belangrijk anti-tumor effect: tien van de 
45 evalueerbare patiënten had een partiële respons in deze studie. Veertien patiënten hadden een 
langdurige stabilisatie van ziekte, gedefinieerd als stabiele ziekte gedurende minimaal drie maanden. 
Tevens werden er in deze studie bloedmonsters afgenomen voor farmacokinetiek van zowel pazopanib 
als ifosfamide. Pazopanib had geen invloed op de plasma halfwaardetijd of klaring van ifosfamide noch 
op een van zijn afbraakproducten. Daarentegen bleek ifosfamide, ongeacht het toedieningschema, de 
pazopanib concentratie iets te verlagen, echter zonder effect op de biologische activiteit van pazopanib. 
Het opvallende verschil in de verdraagbaarheid van het continue en het bolus schema kon dus niet 
verklaard worden door farmacokinetische fenomenen. De RPTD werd vastgesteld op pazopanib 800 
mg één keer per dag in combinatie met continue infusie van ifosfamide 9 gram/m2 gedurende drie 
opeenvolgende dagen.
Hoofdstuk 6 beschrijft een fase I studie waarbij sunitinib, een VEGFR TKI, werd toegevoegd aan capeci-
tabine en irinotecan, een standaard combinatie regime in de behandeling van uitgezaaide darmkanker. 
De eerste vier patiënten werden behandeld met lager dan normale dosis van capecitabine en 
irinotecan en 25 mg sunitinib één keer per dag continu. Daarbij traden twee dosis beperkende bijwer-
kingen (Engels: dose limiting toxicities, DLTs) op, beiden hematologisch van aard. Volgens het protocol 
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behandelden we de volgende twee patiënten met een lagere dosis sunitinib van 12,5 mg per dag. 
Beide patiënten kregen echter ernstig verlaagde witte bloedcellen, wat leidde tot dosis uitstel van 
irinotecan en onderbrekingen van de behandeling met capecitabine en sunitinib. In één van de twee 
patiënten werd sunitinib definitief gestaakt na cyclus vier, waarna deze patiënt geen hematologische 
toxiciteit meer ondervond, zelfs niet toen de dosis van irinotecan weer werd opgehoogd. Omdat we 
geen gunstig klinisch effect verwachtten van een nog lagere dosis sunitinib bij de reeds verlaagde dosis 
van capecitabine en irnotecan, werd de studie gesloten. We concludeerden dat een combinatie van 
capecitabine, irinotecan en sunitinib niet haalbaar was.
In de zoektocht naar de optimale strategie voor het behandelen van kanker, worden er steeds nieuwe 
aangrijpingspunten voor behandeling gezocht en gevonden. Deze nieuwe aangrijpingspunten kunnen 
vervolgens geremd of geblokkeerd worden door nieuwe doelgerichte therapieën. Een voorbeeld van 
een nieuwe strategie in de behandeling van nierkanker wordt beschreven in hoofdstuk 7. Heldercellige 
nierkankercellen brengen vaak een bepaalde eiwit, carbon anhydrase IX (CAIX), tot expressie op hun 
oppervlak. Dit eiwit kan gebonden worden door girentuximab, een eiwit dat in het laboratorium 
gemaakt wordt. Als aan de girentuximab een radioactief deeltje, bijvoorbeeld 177-lutetium, wordt 
gekoppeld, kan er heel specifiek radioactieve straling afgegeven worden aan de cellen die CAIX tot 
expressie brengen (zie figuur 1). De cellen worden dan door de radioactieve straling beschadigd en 
sterven af. Of deze vorm van radioimmunotherapie (RIT) therapeutisch effect heeft werd onderzocht 
in een fase II studie met veertien patiënten met heldercellige nierkanker. In negen van de veertien 
patiënten trad stabilisatie van de ziekte op na de eerste cyclus. De gemiddelde groeisnelheid van alle 
gemeten laesies van alle patiënten in de studie verminderde van 14% in de drie maanden voorafgaand 
aan de behandeling tot 5% in de eerste cyclus van behandeling, alhoewel er hele grote verschillen 
werden gezien tussen patiënten. In het algemeen werd de RIT goed verdragen met slechts twee 
ernstige bijwerkingen (moeheid en verminderde eetlust). Echter bij veel patiënten daalden de 
bloedplaatjes en de witte bloedcellen sterk. Dit nadelige effect op het beenmerg was tijdelijk, maar 
niet alle patiënten herstelden tot de beginwaarden. Vanwege de verlaagde bloedwaarden, konden in 
totaal acht patiënten niet behandeld worden met een volgende cyclus. Bovendien konden drie van de 
zes patiënten niet met de volledige dosis van een VEGFR TKI behandeld worden toen de tumoren weer 
begonnen te groeien, vanwege de lage bloedcellen. Wij concludeerden dat het klinisch effect van deze 
radioimmunotherapie zeer bemoedigend is, maar dat vanwege het frequente voorkomen van 
beenmergschade, de dosis verlaagd zal moeten worden zodat alle patiënten hun behandeling kunnen 
voortzetten tot aan progressie.
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Hogere respons percentages of een langere PFS zijn niet de enige doelen die men moet nastreven als 
men zoekt naar mogelijkheden om de uitkomst van de therapie te verbeteren. Het verminderen van 
symptomen van de ziekte en het verminderen van bijwerkingen is op zijn minst even belangrijk voor 
kankerpatiënten. Hoofdstukken 8 en 9 beschrijven manieren om de kwaliteit van leven van patiënten 
met kanker die behandeld worden met doelgerichte therapie te verbeteren.
Bij patiënten met kanker, kunnen kankercellen uitzaaien naar de buikholte of naar de longvliezen en 
daar vocht produceren. Vocht in de buikholte wordt ascites genoemd en kan leiden tot klachten als 
toegenomen buikomvang, buikpijn, misselijkheid, verminderde eetlust, braken, vermoeidheid, 
kortademigheid en snel vol gevoel. Vocht tussen de longvliezen wordt pleuravocht genoemd en geeft 
belangrijke klachten als kortademigheid, hoesten en pijn. Deze problemen hebben vaak een grote 
impact op de kwaliteit van leven van de patiënten. Het aftappen van het vocht door middel van een 
punctie kan tot een tijdelijke vermindering van klachten leiden, maar puncties zijn vaak ook vervelend 
voor patiënten en geven kans op complicaties, zoals bloedingen of infecties. Daarom is er veel behoefte 
aan een effectieve behandeling van ascites en pleuravocht, die zorgt voor vermindering van klachten 
zonder veel bijkomende bijwerkingen. Omdat eerdere studies hebben laten zien dat er hoge waarden 
van VEGF voorkomen in ascites en pleuravocht, was de hypothese dat het remmen van VEGF met een 
VEGFR TKI een positief palliatief effect op de aan ascites en pleuravocht gerelateerde klachten zou 
Figure 12.1 Principe van radioimmunotherapie
CAIX
Nierkankercel
Girentuximab
Girentuximab bindt 
zich aan CAIX.
radioactieve lading
De nierkankercel wordt door 
de radioactieve lading van de 
antistof bestraald.
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kunnen hebben. In hoofdstuk 8 wordt de studie beschreven waaraan twaalf patiënten met ascites en/
of pleuravocht meededen en waarbij geloot werd tussen a)directe behandeling met cediranib 30 mg 
één keer per dag of b)starten van de behandeling op dag 29 of eerder als er klachten waren die een 
punctie van het vocht noodzakelijk maakten (uitgestelde start). Het mediane punctie vrije interval in 
de groep patiënten die direct startte met cediranib was 45 dagen, vergeleken met zeven dagen in de 
uitgestelde start groep. Cediranib werd goed verdragen, alhoewel er wel dosisverlagingen moesten 
worden toegepast in sommige patiënten. Concluderend werd er, ondanks het beperkte aantal 
patiënten dat meedeed in deze studie, een significant en klinisch belangrijk verlengd punctie vrij 
interval gevonden in de patiënten die direct startten met cediranib. Omdat de verwachting is dat alle 
VEGFR TKIs dit positieve effect zouden kunnen geven, zou de toepassing van VEGFR TKIs als palliatieve 
behandeling van ascites en pleuravocht verder onderzocht moeten worden.
Diarree is een vaak voorkomende bijwerking van de behandeling met VEGFR TKIs en gaat vaak samen 
met buikkrampen, winderigheid of zuurbranden. Deze klachten verminderen de kwaliteit van leven 
van patiënten en leiden tot verlaging van de dosis of tot het onderbreken van de behandeling, 
waardoor de behandeling minder effectief wordt. Alhoewel het duidelijk is dat diarree een bijwerking 
is van de VEGFR TKIs, is het onbekend wat het mechanisme achter de diarree is. Daarom kan de 
diarree alleen symptomatisch bestreden worden met diarreeremmers zoals loperamide. Dit werkt 
echter onvoldoende in het merendeel van de patiënten. Met het achterhalen van de oorzaak van de 
diarree, is het wellicht ook mogelijk om de behandeling te verbeteren en daarmee de kwaliteit van 
leven van de patiënten die behandeld worden met VEGFR TKIs. Hoofdstuk 9 beschrijft de resultaten 
van een kleine exploratieve studie bij tien patiënten met nierkanker die tijdens de behandeling met 
een VEGFR TKI diarree ontwikkelden. Bij alle patiënten werd een kijkonderzoek van de maag en de 
twaalfvingerige darm (gastroduodenoscopie) en van een deel van de dikke darm (sigmoidoscopie) 
verricht. Daarbij werden ook biopten afgenomen. De sigmoidoscopie en de biopten van de dikke darm 
lieten in het merendeel van de patiënten geen afwijkingen zien, met name geen ontsteking of zuurstof-
tekort. Het onderzoek van de maag en twaalfvingerige darm echter, was in acht patiënten afwijkend 
met ontstekingen, zweertjes en aantastingen van het slijmvlies. Drie van deze patiënten ondergingen 
een aanvullend onderzoek van de dunne darm, wat geen verdere afwijkingen liet zien. Omdat de 
gevonden afwijkingen alleen in de maag en de twaalfvingerige darm voorkwamen, kan het geen 
verklaring zijn voor de diarree. Deze afwijkingen kunnen echter wel een verklaring zijn voor de boven- 
buiksklachten die veel patiënten ook hebben en we zouden dan ook willen adviseren om bij iedere 
patiënt met bovenbuiksklachten en een behandeling met VEGFR TKIs een gastroduodenoscopie te 
verrichten, zodat afwijkingen snel kunnen worden opgespoord en behandeld.
De eerste hoofdstukken van dit proefschrift beschreven de mogelijkheden om de FDG-PET/CT te 
gebruiken om al vroeg (in de eerste paar weken) het effect van de behandeling te kunnen voorspellen. 
Hoofdstuk 10 beschrijft het andere eind van het spectrum: monitoring van de veranderingen na het 
beëindigen van een behandeling met een VEGFR TKI om zo de behandel strategieën te optimaliseren. 
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Zestien patiënten met uitgezaaide nierkanker, wiens ziekte progressief was tijdens behandeling met 
een VEGFR TKI, werden verdeeld in twee groepen. De ene groep stopte direct met inname van de 
VEGFR TKI, de andere groep ging nog twee weken door. Op het moment van het vaststellen van groei 
van de ziekte en na ongeveer twee weken werd er een FDG-PET/CT en een functionele MRI gemaakt 
en werd er bloed geprikt. De resultaten van deze studie lieten zien dat in de groep patiënten die direct 
stopten met de VEGFR TKI er een aanwijzing was voor een toename in de vaatvoorziening naar de 
tumor, in tegenstelling tot de patiënten die nog doorgingen met de behandeling. Het lijkt dus zo te zijn 
dat op het moment van groei van ziekte (en dus een verwachtte resistentie van de tumor tegen de 
behandeling) er nog wel degelijk een anti-tumor effect van de VEGFR TKIs aanwezig is.
Concluderend heeft de ontwikkeling van doelgerichte therapieën tot opzienbare resultaten geleid in 
de behandeling van patiënten met kanker. De uitdaging ligt nu in de optimalisatie van de behandeling 
voor iedere individuele patiënt, gebruik makend van beeldvormende technieken, farmacokinetica, 
farmacodynamica en oncogenomics, zodat hoog-kwalitatieve gepersonaliseerde zorg geleverd kan 
worden aan iedere patiënt met kanker.
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Bedankt!
De cover van dit proefschrift wordt gesierd door een deel van een schilderij, dat voor mij een bijzondere 
betekenis heeft. Ik kreeg het doek bijna tien jaar geleden van de schilder zelf, die toen pas ziek was 
geweest, onder de voorwaarde dat ik, iedere keer als ik ernaar zou kijken, stil zou staan bij de impact 
die een dokter kan hebben op zijn of haar patiënten en aan hoe belangrijk het is om naar hen te 
luisteren en er voor hen te zijn. De symboliek achter dit schilderij past heel goed bij het doel van dit 
proefschrift: manieren onderzoeken om tot betere uitkomsten en kwaliteit van leven voor patiënten 
te komen. Bedankt, Theo.
In de afgelopen jaren heb ik naar veel patiënten en hun families geluisterd. Zij vertelden mij hoe de 
diagnose kanker alles op zijn kop zet, maar ook hoe je desondanks toch kunt blijven genieten van het 
leven. Dit waren hele waardevolle ontmoetingen waarvan sommigen me altijd bij zullen blijven. 
Verschillende patiënten kozen ervoor om deel te nemen aan één van de studies beschreven in dit 
proefschrift. Ik heb enorm veel respect voor die patiënten en hun families die, in een onzekere en 
moeilijke periode in hun leven, deze stap durfden te nemen. Dank jullie wel!
Prof. van der Graaf, beste Winette, dank je wel dat je me de kans hebt gegeven om te promoveren op 
dit fantastische onderwerp. Jouw hulp, je kritische opmerkingen die altijd precies de vinger op de zere 
plek legden en je scherpe inzicht in discussies waren daarbij onmisbaar.
Prof. Oyen, beste Wim, bedankt voor je begeleiding bij en kritische evaluatie van de PET-studies. Jij 
wist altijd snel en eenvoudig overzicht aan te brengen in die enorme brij aan data die al die ROI’s 
opleverden en haalde er steeds die resultaten uit die voor de kliniek belangrijk zijn.
Mijn copromotor dr. van Herpen, beste Carla, dank je wel voor alles. Ik vind je ontzettend goed in je vak, 
zowel in de spreekkamer als in het onderzoek en ik ben heel blij dat ik zo veel van je heb kunnen leren.
Wat maakt je sterk? Teamwerk! Het voelde goed om deel uit te maken van het fase I team. Carla, Anja, 
Ingrid, Rafke, Annelieke, Maartje, Mirjam, Michiel, Marlies, Annette en Maaike, bedankt voor de 
samenwerking en het gezamenlijke doel om de beste zorg te leveren aan de patiënten in de fase I- 
studies. Ingrid, jij bracht me de fijne kneepjes van het fase I-vak bij. Ik heb enorm veel van je geleerd 
en doe dat nu nog steeds! Dank je wel daarvoor en voor de gezellige tijd waarin we samen een kamer 
deelden. Lieve researchverpleegkundigen, ik kan maar een ding zeggen: M’s zijn de beste!
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Alle villa bewoners wil ik bedanken voor de lunches, de afleiding, de borrels, etentjes en feestjes, het 
lenen van jullie statistiekboeken, de opbeurende woorden na een computercrash, het lezen van eerste 
versies, het vertrouwen dat het goed komt en al het andere. Lieve Chan, Siem, Janneke en Annelieke, 
wat ben ik blij dat we naast al het werk ook ons sociale leven kunnen delen. Ik hoop dat nog heel lang 
te kunnen doen!
Sasja Mulder, onze levens hebben er de afgelopen jaren vergelijkbaar uitgezien. Ook jij combineerde 
een drukke baan met vele uitdagingen, het krijgen van twee kinderen en de verbouwing van jullie huis 
met het doen van onderzoek naar VEGFR TKI’s en niercelcarcinoom. Ik vond het heel erg fijn over al 
deze zaken met je te sparren, dank je wel voor alle gezelligheid, tips en trics!
Alle mede-auteurs, dank voor jullie bijdragen aan de manuscripten. Dr. Stijn Muselaers, het was 
gezellig om met je samen te werken op het radio-immunotherapie project. Prof. Peter Mulders en 
dr. Hans Langenhuijsen, door de wekelijkse nierkankerbespreking waren de lijntjes kort en de samen- 
werking prettig. Dr. Geert Wanten, dr. Frank Hoentjen en prof. Iris Nagtegaal, jullie enthousiaste 
adviezen en kritische commentaren op het ontwerp en de uitvoering van de studie naar diarree was 
van grote waarde. Prof. Lioe-Fee de Geus-Oei, zonder jouw duidelijke uitleg en hulp bij het analyseren 
van de PET-data was ik nooit zo ver gekomen. Dank voor je interesse in mij en in het onderzoek. 
Dr. Nielka van Erp, jouw passie voor je vak werkt zeer aanstekelijk! Dank je wel voor je begeleiding bij 
het PK-stuk.
 
Oncologen, fellows, onderzoekers, verpleegkundigen, poli-assistentes, secretaresses, planners, coördi-
natoren en leidinggevenden van de afdeling Medische Oncologie in het Radboudumc: voor mij heeft 
het onderzoek en de kliniek de afgelopen zes jaar door elkaar heen gelopen en op beide gebieden kon 
ik rekenen op jullie adviezen en ondersteuning en op een gezellig praatje! Ook de dames van het 
trialcentrum IKNL die betrokken waren bij het datamanagement en de monitoring van de studies zijn 
een enorme hulp geweest.
De medewerkers van de afdeling Nucleaire Geneeskunde hebben met hun flexibele planning van de 
vele PET- en G250-scans, hun hulp bij het analyseren van de PET-scans en alle zaken die zij voor de 
RIT-patiënten regelden een belangrijke bijdrage geleverd aan de onderzoeken.
Prof. Jacqueline de Graaf, opleider van de Interne Geneeskunde, dank je wel voor je vertrouwen in mij. 
De manuscriptcommissie bestaande uit prof. Burger, prof. de Vries en prof. Verheul wil ik bedanken 
voor hun kritische beschouwing en goedkeuring van dit manuscript.
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Lieve familie en vrienden, de afgelopen jaren waren tropenjaren met het krijgen van twee kindjes, de 
verbouwingen van ons huis, het tuinproject en ook nog promoveren. Bedankt voor jullie belang-
stelling, praktische hulp en geestelijke steun bij al deze projecten!
Lieve Johanneke, ik kan me niet voorstellen te promoveren zonder dat jij naast me staat. We zijn 
samen begonnen met het doen van onderzoek en hebben alle hoogte- en dieptepunten gedurende 
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